Клинические рекомендации Российского медицинского общества по артериальной гипертонии (РМОАГ) и Евразийской Ассоциации Кардиологов (ЕАК) по диагностике и лечению артериальной гипертонии (2024)

В клинических рекомендациях представлены основные подходы к ведению пациентов с артериальной гипертонией (АГ) с использованием принципов доказательной медицины. Рекомендации включают разделы, содержащие расширенную и обновленную информацию по основным аспектам диагностики, лечения, методам профилактики и диспансерного наблюдения при гипертонической болезни с учетом фенотипов заболевания и различных клинических ситуаций, а также при вторичных формах АГ различного генеза.

1. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal association (ERa). J Hypertens. 2023;41(12):1874-2071. https://doi.org/10.1097/HJH.0000000000003480

2. Zhou B., Carrillo-Larco R.M., Danaei G. et al. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957-980. https://doi.org/10.1016/S0140-6736(21)01330-1

3. Бадин Ю.В., Фомин И.В., Беленков Ю.Н. и др. ЭПОХА-АГ 1998-2017 гг.: динамика распространенности, информированности об артериальной гипертонии, охвате терапией и эффективного контроля артериального давления в Европейской части РФ. Кардиология. 2019;59(1S):34-42. https://doi.org/10.18087/cardio.2445

4. Rana J, Oldroyd J, Islam MM, et al. Prevalence of hypertension and controlled hypertension among United States adults: Evidence from NHaNES 2017-18 survey. Int J Cardiol. Hypertens. 2020;7:100061. https://doi.org/10.1016/J.IJCHY.2020.100061

5. Шальнова С.А., Деев А.Д., Вихирева О.В. и др. Распространенность артериальной гипертонии в России. Информированность, лечение, контроль. Профилактика заболеваний и укрепление здоровья. 2001;2:3-7.

6. Kearney P. M., Whelton K.R., Reynolds K. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-223. https://doi.org/10.1016/S0140-6736(05)17741-1

7. STEPS: Распространенность факторов риска неинфекционных заболеваний в Республике Беларусь, 2020 г. Копенгаген: Европейское региональное бюро ВОЗ; 2022 г.

8. Health statistics, azerbaijan, https://data.who.int/countries/031

9. Health statistics, armenia, https://data.who.int/countries/051

10. Health statistics, Kazakhstan https://data.who.int/countries/398

11. Health statistics, Turkmenistan https://data.who.int/countries/795

12. https://www.who.int/publications/m/item/2016-2017-steps-country-report-tajikistan

13. Robitaille C., Dai S., Waters C. et al. Diagnosed hypertension in Canada: Incidence, prevalence and associated mortality. CMaJ. 2012. https://doi.org/10.1503/cmaj.101863

14. Ikeda N, Sapienza D, Guerrero R, и др. Control of hypertension with medication: a comparative analysis of national surveys in 20 countries. Bull World Health Organ. 2014;92(1):10-19C. https://doi.org/10.2471/BLT.13.121954

15. Баланова Ю.А., Шальнова С.А., Куценко В.А. и др. Вклад артериальной гипертонии и других факторов риска в выживаемость и смертность в российской популяции. Кардиоваскулярная терапия и профилактика. 2021;20(5):3003. (In Russ.) https://doi.org/10.15829/1728-8800-2021-3003

16. Баланова Ю.А., Концевая А.В., Мырзаматова А.О. и др. Экономический ущерб от артериальной гипертонии, обусловленный ее вкладом в заболеваемость и смертность от основных хронических неинфекционных заболеваний в Российской Федерации. Рациональная фармакотерапия в кардиологии. 2020;16(3):415-423. https://doi.org/10.20996/1819-6446-2020-05-03

17. Zhou B., Danaei G., Stevens G.a. et al. Long-term and recent trends in hypertension awareness, treatment, and control in 12 high-income countries: an analysis of 123 nationally representative surveys. Lancet. 2019;394(10199):639-651. https://doi.org/10.1016/s0140-6736(19)31145-6

18. Шальнова С.А., Баланова Ю.А., Константинов В.В. и др. Артериальная гипертония: распространенность, осведомленность, прием антигипертензивных препаратов и эффективность лечения среди населения Российской Федерации. Российский кардиологический журнал. 2006;4:45-50.

19. Баланова Ю.А., Шальнова С.А., Имаева А.Э. и др. от имени участников исследования ЭССЕ-РФ2. Распространенность артериальной гипертонии, охват лечением и его эффективность в Российской Федерации (данные наблюдательного исследования ЭССЕ-РФ-2). Рациональная фармакотерапия в кардиологии. 2019;15(4):450-466. https://doi.org/10.20996/1819-6446-2019-15-4-450-466

20. Бойцов С.А., Баланова Ю.А., Шальнова С.А. и др. Артериальная гипертония среди лиц 25-64 лет: распространенность, осведомленность, лечение и контроль. По материалам исследования ЭССЕ. Кардиоваскулярная терапия и профилактика. 2014;14(4):4-14. https://doi.org/10.15829/1728-8800-2014-4-4-14

21. Баланова Ю.А., Драпкина О.М., Куценко В.А. и др. Артериальная гипертония в российской популяции в период пандемии COVID-19: гендерные различия в распространённости, лечении и его эффективности. Данные исследования ЭССЕ-РФ3. Кардиоваскулярная терапия и профилактика. 2023;22(8S):3785. https://doi.org/10.15829/1728-8800-2023-3785

22. Баланова Ю.А., Шальнова С.А., Куценко В.А. и др. Особенности антигипертензивной терапии в российской популяции: данные исследования ЭССЕ-РФ3. Рациональная Фармакотерапия в Кардиологии. 2024;20(1):4-12. https://doi.org/10.20996/1819-6446-2024-3010

23. Blood Pressure Lowering Treatment Trialists' Collaboration. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet.2021;397(10285):1625-1636. https://doi.org/10.1016/S0140-6736(21)00590-0

24. Долгалёв И.В., Иванова А.Ю., Шипхинеева А.Ю. Артериальная гипертензия как фактор риска смерти мужчин и женщин 20-59 лет: 34-летнее когортное проспективное исследование. Кардиоваскулярная терапия и профилактика. 2023;22(8):3602. https://doi.org/10.15829/1728-8800-2023-3602

25. anari R, amani R, Latifi SM, Veissi M, Shahbazian H. association of obesity with hypertension and dyslipidemia in type 2 diabetes mellitus subjects. Diabetes Metab Syndr. 2017;11(1):37-41. https://doi.org/10.1016/j.dsx.2016.07.004

26. Ehret GB, Caulfield MJ. Genes for blood pressure: an opportunity to understand hypertension. Eur Heart J. 2013;34(13):951-961. https://doi.org/10.1093/eurheartj/ehs455

27. He fJ, Tan M, Ma Y, MacGregor Ga. Salt Reduction to Prevent Hypertension and Cardiovascular Disease: JaCC State-of-the-art Review. J am Coll Cardiol. 2020;75(6):632-647. https://doi.org/10.1016/j

28. Чазов Е. И. Руководство по кардиологии в четырех томах Т: Методы диагностики сердечно-сосудистых заболеваний/ Е.И. Чазов. М.: Практика, 2014. – 776 c. ISBN 9785898161293

29. Чазова И.Е., Ощепкова Е.В., Жернакова Ю.В. Диагностика и лечение артериальной гипертонии. Евразийский Кардиологический Журнал. 2015;(2):3-30. https://doi.org/10.38109/2225-1685-2015-2-3-30

30. Padwal R, Campbell NRC, Schutte aE, et al. Optimizing observer performance of clinic blood pressure measurement: a position statement from the Lancet. Commission on Hypertension Group. J Hypertens. 2019;37(9):1737-1745. https://doi.org/10.1097/HJH.0000000000002112

31. Рогоза А.Н., Ощепкова Е.В., Цагареишвили Е.В., Гориева Ш.Б. Современные неинвазивные методы измерения артериального давления для диагностики артериальной гипертонии и оценки эффективности антигипертензивной терапии. Пособие для врачей. М.: Медика, 2007.

32. Горбунов В. М., Смирнова М. И., Курехян А. С., Драпкина О. М. Оценка клинического и амбулаторного артериального давления в практической работе врача первичного звена здравоохранения. Методические рекомендации. Кардиоваскулярная терапия и профилактика. 2023;22(7):3666. https://doi.org/10.15829/1728-8800-2023-3666

33. Функциональная диагностика: национальное руководство/ под ред. Н.Ф. Берестень, В.А. Сандрикова, С.И. Федоровой – Москва: ГЭОТАР-Медиа, 2019. – 784 с. (Серия «Национальные руководства») ISBN 978-5-9704-4242-5

34. Чазова И.Е., Жернакова Ю.В. от имени экспертов. Клинические рекомендации. Диагностика и лечение артериальной гипертонии. Системные гипертензии. 2019;16(1):6-31. https://doi.org/10.26442/2075082X.2019.1.190179

35. Котовская Ю.В., Кобалава Ж.Д. Амбулаторные методы регистрации артериального давления в клинической практике. Евразийский Кардиологический Журнал. 2015;(3):38-44. https://doi.org/10.38109/2225-1685-2015-3-38-44

36. Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal association (ERa). J Hypertens. 2024 Jan 1;42(1):194. https://doi.org/10.1097/HJH.0000000000003621

37. Myers MG. a Short History of automated Office Blood Pressure – 15 Years to SPRINT. J Clin Hypertens (Greenwich). 2016;18(8):721-724. https://doi.org/10.1111/jch.12820

38. Roerecke M, Kaczorowski J, Myers MG. Comparing automated Office Blood Pressure Readings With Other Methods of Blood Pressure Measurement for Identifying Patients With Possible Hypertension: a Systematic Review and Meta-analysis. JaMa. Intern Med 2019; 179:351-362. https://doi.org/10.1001/jamainternmed.2018.6551

39. Seo J, Lee CJ, Oh J, Lee SH, Kang SM, Park S. Large discrepancy between unobserved automated office blood pressure and ambulatory blood pressure in a high cardiovascular risk cohort. J Hypertens. 2019;37(1):42-49. https://doi.org/10.1097/HJH.0000000000001868

40. SPRINT Research Group, Wright JT Jr, Williamson JD, et al. a Randomized Trial of Intensive versus Standard Blood-Pressure Control [published correction appears in N Engl J Med. 2017 Dec 21;377(25):2506. https://doi. org/10.1056/NEJMx170008]. N Engl J Med. 2015;373(22):2103-2116. https://doi.org/10.1056/NEJMoa1511939

41. Myers MG, Kaczorowski J, Paterson JM, Dolovich L, Tu K. Thresholds for Diagnosing Hypertension Based on automated Office Blood Pressure Measurements and Cardiovascular Risk. Hypertension. 2015;66(3):489-495. https://doi.org/10.1161/HYPERTENSIONaHa.115.05782

42. Le VV, Mitiku T, Sungar G, Myers J, froelicher V. The blood pressure response to dynamic exercise testing: a systematic review. Prog Cardiovasc Dis. 2008;51(2):135-160. https://doi.org/10.1016/j.pcad.2008.07.001

43. Niebauer J, B?rjesson M, Carre f, et al. Recommendations for participation in competitive sports of athletes with arterial hypertension: a position statement from the sports cardiology section of the European association of Preventive Cardiology (EaPC). Eur Heart J. 2018;39(40):3664-3671. https://doi.org/10.1093/eurheartj/ehy511

44. Schultz MG, La Gerche a, Sharman JE. Blood Pressure Response to Exercise and Cardiovascular Disease. Curr Hypertens Rep. 2017 Oct 18;19(11):89. https://doi.org/10.1007/s11906-017-0787-1

45. Palatini P, Rosei Ea, avolio a, et al. Isolated systolic hypertension in the young: a position paper endorsed by the European Society of Hypertension [published correction appears in J Hypertens. 2018 Oct;36(10):2120. https:// doi.org/10.1097/HJH.0000000000001910]. J Hypertens. 2018;36(6):1222-1236. https://doi.org/10.1097/HJH.0000000000001726

46. Sharman JE, avolio aP, Baulmann J, et al. Validation of non-invasive central blood pressure devices: aRTERY Society task force consensus statement on protocol standardization. Eur Heart J. 2017;38(37):2805-2812. https://doi.org/10.1093/eurheartj/ehw632

47. Cheng YB, Thijs L, aparicio LS, et al. Risk Stratification by Cross-Classification of Central and Brachial Systolic Blood Pressure. Hypertension. 2022;79(5):1101-1111. https://doi.org/10.1161/HYPERTENSIONaHa.121.18773

48. Herbert a, Cruickshank JK, Laurent S, Boutouyrie P; Reference Values for arterial Measurements Collaboration. Establishing reference values for central blood pressure and its amplification in a general healthy population and according to cardiovascular risk factors. Eur Heart J. 2014;35(44):3122-3133. https://doi.org/10.1093/eurheartj/ehu293

49. McEniery CM, Cockcroft JR, Roman MJ, franklin SS, Wilkinson IB. Central blood pressure: current evidence and clinical importance. Eur Heart J. 2014;35(26):1719-1725. https://doi.org/10.1093/eurheartj/eht565

50. Boutouyrie P, achouba a, Trunet P, Laurent S; EXPLOR Trialist Group. amlodipine-valsartan combination decreases central systolic blood pressure more effectively than the amlodipine-atenolol combination: the EXPLOR study. Hypertension. 2010;55(6):1314-1322. https://doi.org/10.1161/HYPERTENSIONaHa.109.148999

51. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension [published correction appears in J Hypertens. 2019 Jan;37(1):226. https://doi.org/10.1097/HJH.0000000000002017]. J Hypertens. 2018;36(10):1953-2041. https://doi.org/10.1097/HJH.0000000000001940

52. Stergiou GS, Palatini P, Parati G, et al. 2021 European Society of Hypertension practice guidelines for office and out-of-office blood pressure measurement. J Hypertens. 2021;39(7):1293-1302. https://doi.org/10.1097/HJH.0000000000002843

53. Stergiou GS, Kyriakoulis KG, Kollias a. Office blood pressure measurement types: Different methodology- Different clinical conclusions. J Clin Hypertens (Greenwich). 2018;20(12):1683-1685. https://doi.org/10.1111/jch.13420

54. International Consensus on Standardized Clinic Blood Pressure Measurement – a Call to action Cheung, alfred K. et al. The american Journal of Medicine. 2023 May;136(5):438-445.e1. https://doi.org/10.1016/j.amjmed.2022.12.015

55. Plumettaz C, Viswanathan B, Bovet P. Hypertension Prevalence Based on Blood Pressure Measurements on Two vs. One Visits: a Community-Based Screening Programme and a Narrative Review. Int J Environ Res Public Health. 2020 Dec 15;17(24):9395. https://doi.org/10.3390/ijerph17249395

56. Kronish IM, Edmondson D, Shimbo D, Shaffer Ja, Krakoff LR, Schwartz JE. a Comparison of the Diagnostic accuracy of Common Office Blood Pressure Measurement Protocols. am J Hypertens. 2018;31(7):827-834. https://doi.org/10.1093/ajh/hpy053

57. Jose aP, awasthi a, Kondal D, Kapoor M, Roy a, Prabhakaran D. Impact of repeated blood pressure measurement on blood pressure categorization in a population-based study from India. J Hum Hypertens. 2019;33(8):594- 601. https://doi.org/10.1038/s41371-019-0200-4

58. Handler J, Zhao Y, Egan BM. Impact of the number of blood pressure measurements on blood pressure classification in US adults: NHaNES 1999-2008. J Clin Hypertens (Greenwich). 2012;14(11):751-759. https://doi.org/10.1111/jch.12009

59. Sakhuja S, Jaeger BC, akinyelure OP, et al. Potential impact of systematic and random errors in blood pressure measurement on the prevalence of high office blood pressure in the United States. J Clin Hypertens (Greenwich). 2022;24(3):263-270. https://doi.org/10.1111/jch.14418

60. Clark CE, Warren fC, Boddy K, et al. Higher arm Versus Lower arm Systolic Blood Pressure and Cardiovascular Outcomes: a Meta-analysis of Individual Participant Data from the INTERPRESS-IPD Collaboration. Hypertension. 2022;79(10):2328-2335. https://doi.org/10.1161/HYPERTENSIONaHa.121.18921

61. Griendling KK, Camargo LL, Rios fJ, alves-Lopes R, Montezano aC, Touyz RM. Oxidative Stress and Hypertension. Circ Res. 2021;128(7):993-1020. https://doi.org/10.1161/CIRCRESaHa.121.318063

62. avery EG, Bartolomaeus H, Maifeld a, et al. The Gut Microbiome in Hypertension: Recent advances and future Perspectives. Circ Res. 2021;128(7):934-950. https://doi.org/10.1161/CIRCRESaHa.121.3180652021;128:934-950

63. Stergiou GS, alpert B, Mieke S, et al. a universal standard for the validation of blood pressure measuring devices: association for the advancement of Medical Instrumentation/European Society of Hypertension/ International Organization for Standardization (aaMI/ESH/ISO) Collaboration Statement. J Hypertens. 2018;36(3):472-478. https://doi.org/10.1097/HJH.0000000000001634

64. Arnold AC, Raj SR. Orthostatic Hypotension: a Practical approach to Investigation and Management. Can J Cardiol. 2017;33(12):1725-1728. https://doi.org/10.1016/j.cjca.2017.05.007

65. Brignole M, Moya a, de Lange fJ et al. 2018 ESC Guidelines for the diagnosis and management of syncope. Eur Heart J 2018. https://doi.org/10.1093/eurheartj/ehy037

66. Panel on Prevention of falls in Older Persons, american Geriatrics Society and British Geriatrics Society. Summary of the Updated american Geriatrics Society/British Geriatrics Society clinical practice guideline for prevention of falls in older persons. J am Geriatr Soc. 2011;59(1):148-157. https://doi.org/10.1111/j.1532-5415.2010.03234.x

67. Juraschek SP, Miller ER 3rd, appel LJ. Orthostatic Hypotension and Symptoms in the aaSK Trial. am J Hypertens. 2018;31(6):665-671. https://doi.org/10.1093/ajh/hpy010

68. Juraschek SP, Daya N, Rawlings aM, et al. association of History of Dizziness and Long-term adverse Outcomes With Early vs Later Orthostatic Hypotension assessment Times in Middle-aged adults. JaMa. Intern Med. 2017;177(9):1316-1323. https://doi.org/10.1001/jamainternmed.2017.2937

69. Maurer MS, Cohen S, Cheng H. The degree and timing of orthostatic blood pressure changes in relation to falls in nursing home residents. J am Med Dir assoc. 2004;5(4):233-238. https://doi.org/10.1097/01.JaM.0000129837.51514.93

70. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the merican autonomic Society and the american academy of Neurology. Neurology. 1996;46(5):1470. https://doi.org/10.1212/wnl.46.5.1470

71. freeman R, Wieling W, axelrod fB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin auton Res. 2011;21(2):69-72. https://doi.org/10.1007/s10286-011-0119-5

72. Аксенова А.В., Гориева Ш.Б., Рогоза А.Н. и др. Современные представления о диагностике и лечении ортостатической гипотензии. Системные гипертензии.2018;15(2):32-42. https://doi.org/10.26442/2075-082X_2018.2.32-42

73. Irving G, Holden J, Stevens R, McManus RJ. Which cuff should I use? Indirect blood pressure measurement for the diagnosis of hypertension in patients with obesity: a diagnostic accuracy review. BMJ. Open. 2016 Nov 3;6(11):e012429. https://doi.org/10.1136/bmjopen-2016-012429

74. Рогоза А.Н., Гориева Ш.Б. Возможности автоматических осциллометрических приборов при измерении артериального давления у пациентов с фибрилляцией предсердий. Системные гипертензии. 2012;9(4):40-43. https://doi.org/10.26442/SG28938

75. Гориева Ш. Б., Рогоза А. Н. Точность измерения артериального давления при постоянной форме фибрилляции предсердий. РМЖ. 2013;21(12):629-33.

76. Pagonas N, Schmidt S, Eysel J, et al. Impact of atrial fibrillation on the accuracy of oscillometric blood pressure monitoring. Hypertension. 2013;62(3):579-584. https://doi.org/10.1161/HYPERTENSIONaHa.113.01426

77. Dom?nech M, Berruezo a, Molina I, Mont L, Coca a. Nighttime ambulatory blood pressure is associated with atrial remodelling and neurohormonal activation in patients with idiopathic atrial fibrillation. Rev Esp Cardiol (Engl Ed). 2013;66(6):458-463. https://doi.org/10.1016/j.rec.2012.11.011

78. Lakhal K, Ehrmann S, Martin M, et al. Blood pressure monitoring during arrhythmia: agreement between automated brachial cuff and intra-arterial measurements. Br J anaesth. 2015;115(4):540-549. https://doi.org/10.1093/bja/aev304

79. Sykes D, Dewar R, Mohanaruban K, et al. Measuring blood pressure in the elderly: does atrial fibrillation increase observer variability? BMJ. 1990;300(6718):162-163. https://doi.org/10.1136/bmj.300.6718.162

80. Giantin V, Perissinotto E, franchin a, et al. ambulatory blood pressure monitoring in elderly patients with chronic atrial fibrillation: is it absolutely contraindicated or a useful tool in clinical practice and research? Hypertens Res. 2013;36(10):889-894. https://doi.org/10.1038/hr.2013.65

81. Stergiou GS, Kollias a, Destounis a, Tzamouranis D. automated blood pressure measurement in atrial fibrillation: a systematic review and meta-analysis. J Hypertens. 2012;30(11):2074-2082. https://doi.org/10.1097/HJH.0b013e32835850d7

82. Penny Ja, Halligan aW, Shennan aH, et al. automated, ambulatory, or conventional blood pressure measurement in pregnancy: which is the better predictor of severe hypertension? am J Obstet Gynecol. 1998;178(3):521-526. https://doi.org/10.1016/s0002-9378(98)70432-6

83. Magee La, Ramsay G, von Dadelszen P. What is the role of out-of-office BP measurement in hypertensive pregnancy? Hypertens Pregnancy. 2008;27(2):95-101. https://doi.org/10.1080/10641950801950197

84. Vera Regitz-Zagrosek, Jolien W Roos-Hesselink, Johann Bauersachs, Carina Blomstr?m-Lundqvist, et al., ESC Scientific Document Group, 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy: The Task force for the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). European Heart Journal. 07 September 2018;39(34):3165-3241. https://doi.org/10.1093/eurheartj/ehy340

85. dablVR Educational Trust. www.dableducation.org

86. Li Y, Wang JG. Isolated nocturnal hypertension: a disease masked in the dark. Hypertension. 2013;61(2):278- 283. https://doi.org/10.1161/HYPERTENSIONaHa.111.00217

87. Mancia G, Verdecchia P. Clinical value of ambulatory blood pressure: evidence and limits. Circ Res. 2015;116(6):1034-1045. https://doi.org/10.1161/CIRCRESaHa.116.303755

88. Машин В.В., Грищук Д.В., Альберт М.А. Факторы и маркеры риска развития различных подтипов ишемического инсульта. Ульяновский медико-биологический журнал. 2013;(1):8-14.

89. Bj?rklund K, Lind L, Zethelius B, et al. Prognostic significance of 24-h ambulatory blood pressure characteristics for cardiovascular morbidity in a population of elderly men. J Hypertens. 2004;22(9):1691-7. https://doi.org/10.1097/00004872-200409000-00012

90. Conen D, Ridker PM, Buring JE, et al. Risk of cardiovascular events among women with high normal blood pressure or blood pressure progression: prospective cohort study. BMJ. 2007;335(7617):432. https://doi.org/10.1136/bmj.39269.672188.aE

91. O'Brien E, Parati G, Stergiou G, et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring [published correction appears in J Hypertens. 2013 Dec;31(12):2467]. J Hypertens. 2013;31(9):1731-1768. https://doi.org/10.1097/HJH.0b013e328363e964

92. Kollias a, Stergiou GS, Dolan E, O'Brien E. ambulatory arterial stiffness index: a systematic review and meta-analysis. atherosclerosis. 2012;224(2):291-301. https://doi.org/10.1016/j.atherosclerosis.2012.03.039

93. Kips JG, Vermeersch SJ, Reymond P, et al. ambulatory arterial stiffness index does not accurately assess arterial stiffness. J Hypertens. 2012;30(3):574-580. https://doi.org/10.1097/HJH.0b013e32834fca18

94. Mancia G. Evidence in favour of ambulatory blood pressure grows but gaps in knowledge remain. Lancet. 2023;401(10393):2014-2015. https://doi.org/10.1016/S0140-6736(23)00442-7

95. Рогоза А.Н., Гориева Ш.Б., Мордвинова Е.В. Возможности тонометров высокого класса точности в обеспечении дистанционного самоконтроля артериального давления. РМЖ. 2014;23:1707.

96. Parati G, Stergiou GS, Bilo G, et al. Home blood pressure monitoring: methodology, clinical relevance and practical application: a 2021 position paper by the Working Group on Blood Pressure Monitoring and Cardiovascular Variability of the European Society of Hypertension. J Hypertens. 2021;39(9):1742-1767. https://doi.org/10.1097/HJH.0000000000002922

97. Stergiou GS, Baibas NM, Gantzarou aP, et al. Reproducibility of home, ambulatory, and clinic blood pressure: implications for the design of trials for the assessment of antihypertensive drug efficacy. am J Hypertens. 2002;15(2 Pt 1):101-104. https://doi.org/10.1016/s0895-7061(01)02324-x

98. Guo QH, Cheng YB, Zhang DY, et al. Comparison Between Home and ambulatory Morning Blood Pressure and Morning Hypertension in Their Reproducibility and associations With Vascular Injury. Hypertension. 2019;74(1):137-144. https://doi.org/10.1161/HYPERTENSIONaHa.119.12955

99. Niiranen TJ, asayama K, Thijs L, et al. Outcome-driven thresholds for home blood pressure measurement: international database of home blood pressure in relation to cardiovascular outcome [published correction appears in Hypertension. 2014 apr;63(4):e91. H?nninen, M R [removed]]. Hypertension. 2013;61(1):27-34. https://doi.org/10.1161/HYPERTENSIONaHa.111.00100

100. Ward aM, Takahashi O, Stevens R, Heneghan C. Home measurement of blood pressure and cardiovascular disease: systematic review and meta-analysis of prospective studies. J Hypertens. 2012;30(3):449-456. https://doi.org/10.1097/HJH.0b013e32834e4aed

101. Ntineri a, Niiranen TJ, McManus RJ, et al. ambulatory versus home blood pressure monitoring: frequency and determinants of blood pressure difference and diagnostic disagreement. J Hypertens. 2019;37(10):1974-1981. https://doi.org/10.1097/HJH.0000000000002148

102. Kyriakoulis KG, Ntineri a, Niiranen TJ, et al. Home blood pressure monitoring schedule: optimal and minimum based on 2122 individual participants' data. J Hypertens. 2022;40(7):1380-1387. https://doi.org/10.1097/HJH.0000000000003157

103. Hodgkinson Ja, Stevens R, Grant S, et al. Schedules for Self-monitoring Blood Pressure: a Systematic Review. am J Hypertens. 2019;32(4):350-364. https://doi.org/10.1093/ajh/hpy185

104. Whelton PK, Carey RM, aronow WS, et al. 2017 aCC/aHa/aaPa/aBC/aCPM/aGS/aPha/aSH/aSPC/NMa/PCNa Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in adults: Executive Summary: a Report of the american College of Cardiology/american Heart association Task force on Clinical Practice Guidelines [published correction appears in Hypertension. 2018 Jun;71(6):e136-e139. https://doi.org/10.1161/HYP.0000000000000075] [published correction appears in Hypertension. 2018 Sep;72(3):e33. https://doi.org/10.1161/HYP.0000000000000080]. Hypertension. 2018;71(6):1269-1324. https://doi.org/10.1161/HYP.0000000000000066

105. Sega R, Cesana G, Milesi C, Grassi G, Zanchetti a, Mancia G. ambulatory and home blood pressure normality in the elderly: data from the PaMELa population. Hypertension. 1997;30(1 Pt 1):1-6. https://doi.org/10.1161/01.hyp.30.1.1

106. Mancia G, Sega R, Bravi C, et al. ambulatory blood pressure normality: results from the PaMELa study. J Hypertens. 1995;13(12 Pt 1):1377-1390. PMID: 8866899

107. Thomopoulos C. Target blood pressure in isolated systolic hypertension: a meta-analysis of randomized outcome trials. J Hypertens. 2023;41(12):2113-2114. https://doi.org/10.1097/HJH.0000000000003476

108. Wang JG, Staessen Ja, Gong L, Liu L. Chinese trial on isolated systolic hypertension in the elderly. Systolic Hypertension in China (Syst-China) Collaborative Group. arch Intern Med. 2000;160(2):211-220. https://doi.org/10.1001/archinte.160.2.211

109. Mancia G, Parati G, Bilo G, et al. Blood pressure control by the nifedipine GITS-telmisartan combination in patients at high cardiovascular risk: the TaLENT study [published correction appears in J Hypertens. 2011 May;29(5):1022]. J Hypertens. 2011;29(3):600-609. https://doi.org/10.1097/HJH.0b013e328342ef04

110. Межгосударственный стандарт ГОСТ ISO 81060-2-2021. Сфигмоманометры (измерители артериального давления) неинвазивные. Часть 2. Клинические испытания моделей с автоматическим типом измерения.

111. Turner MJ, Speechly C, Bignell N. Sphygmomanometer calibration--why, how and how often? aust fam Physician. 2007;36(10):834-838. PMID: 17925905

112. Чазова И.Е., Чихладзе Н.М., Блинова Н.В. и соавт. Евразийские клинические рекомендации по диагностике и лечению вторичных (симптоматических) форм артериальной гипертонии (2022). Евразийский Кардиологический Журнал. 2023;(1):6-65. https://doi.org/10.38109/2225-1685-2023-1-6-65 https://doi.org/10.38109/2225-1685-2023-1-6-65]

113. Rimoldi Sf, Scherrer U, Messerli fH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J. 2014;35(19):1245-1254. https://doi.org/10.1093/eurheartj/eht534

114. Ramachandran a, Snehalatha C. Rising burden of obesity in asia. J Obes. 2010;2010:868573. Epub 2010 aug 30. PMID: 20871654; PMCID: PMC2939400. https://doi.org/10.1155/2010/868573

115. Ежов М.В., Сергиенко И.В., Кухарчук В.В. Клинические рекомендации по нарушениям липидного обмена 2023. Что нового? Атеросклероз и Дислипидемии. 2023;3(52):5-9. https://doi.org/10.34687/2219-8202.JaD.2023.03.0001

116. Borghi C, Rosei Ea, Bardin T, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens. 2015;33(9):1729-1741. https://doi.org/10.1097/HJH.0000000000000701

117. Levey aS, Stevens La, Schmid CH, et al. a new equation to estimate glomerular filtration rate [published correction appears in ann Intern Med. 2011 Sep 20;155(6):408]. ann Intern Med. 2009;150(9):604-612. https://doi.org/10.7326/0003-4819-150-9-200905050-00006

118. Matsushita K, Mahmoodi BK, Woodward M, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JaMa. 2012;307(18):1941-1951. https://doi.org/10.1001/jama.2012.3954

119. Gerstein HC, Mann Jf, Yi Q, et al. albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JaMa. 2001;286(4):421-426. https://doi.org/10.1001/jama.286.4.421

120. andrassy KM. Comments on 'KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease'. Kidney Int. 2013;84(3):622-623. https://doi.org/10.1038/ki.2013.243

121. Mach f, Baigent C, Catapano aL, et al. 2019 ESC/EaS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk [published correction appears in Eur Heart J. 2020 Nov 21;41(44):4255. https://doi.org/10.1093/eurheartj/ehz826]. Eur Heart J. 2020;41(1):111-188. https://doi.org/10.1093/eurheartj/ehz455

122. Okin PM, Oikarinen L, Viitasalo M, et al. Prognostic value of changes in the electrocardiographic strain pattern during antihypertensive treatment: the Losartan Intervention for End-Point Reduction in Hypertension Study (LIfE). Circulation. 2009;119(14):1883-1891. https://doi.org/10.1161/CIRCULaTIONaHa.108.812313

123. Devereux RB, Wachtell K, Gerdts E, et al. Prognostic significance of left ventricular mass change during treatment of hypertension. JaMa. 2004;292(19):2350-2356. https://doi.org/10.1001/jama.292.19.2350

124. de Simone G, Izzo R, Chinali M, et al. Does information on systolic and diastolic function improve prediction of a cardiovascular event by left ventricular hypertrophy in arterial hypertension? Hypertension. 2010;56(1):99- 104. https://doi.org/10.1161/HYPERTENSIONaHa.110.150128

125. Willeit P, Tschiderer L, allara E, et al. Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-analysis of 119 Clinical Trials Involving 100 667 Patients. Circulation. 2020;142(7):621-642. https://doi.org/10.1161/CIRCULaTIONaHa.120.046361

126. Touboul PJ, Hennerici MG, Meairs S, et al. Mannheim carotid intima-media thickness and plaque consensus (2004-2006-2011). an update on behalf of the advisory board of the 3rd, 4th and 5th watching the risk symposia, at the 13th, 15th and 20th European Stroke Conferences, Mannheim, Germany, 2004, Brussels, Belgium, 2006, and Hamburg, Germany, 2011. Cerebrovasc Dis. 2012;34(4):290-296. https://doi.org/10.1159/000343145

127. Бойцов С.А., Погосова Н.В., Аншелес А.А. и соавт. Кардиоваскулярная профилактика 2022. Российские национальные рекомендации. Российский кардиологический журнал. 2023;28(5):5452. https://doi.org/10.15829/1560-4071-2023-5452

128. Inaba Y, Chen Ja, Bergmann SR. Carotid plaque, compared with carotid intima-media thickness, more accurately predicts coronary artery disease events: a meta-analysis. atherosclerosis. 2012;220(1):128-133. https://doi.org/10.1016/j.atherosclerosis.2011.06.044

129. Балахонова Т.В., Ершова А.И., Ежов М.В., и соавт. Фокусированное ультразвуковое исследование сосудов. Консенсус российских экспертов. Кардиоваскулярная терапия и профилактика. 2022;21(7):3333. https://doi.org/10.15829/1728-8800-2022-3333

130. Рогоза А.Н., Балахонова Т.В., Чихладзе Н.М. и др. Современные методы оценки состояния сосудов у больных артериальной гипертонией. Пособие для практикующих врачей. Москва: Атмосфера, 2009. – 72 с. – ISBN 978-5-902123-31-6.

131. Laurent S, Cockcroft J, Van Bortel L, et al. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. 2006;27(21):2588-2605. https://doi.org/10.1093/eurheartj/ehl254

132. Van Bortel LM, Laurent S, Boutouyrie P, et al. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012;30(3):445-448. https://doi.org/10.1097/HJH.0b013e32834fa8b0

133. Ben-Shlomo Y, Spears M, Boustred C, et al. aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J am Coll Cardiol. 2014;63(7):636-646. https://doi.org/10.1016/j.jacc.2013.09.063

134. Cardoso CRL, Salles Gf. Prognostic Value of Changes in aortic Stiffness for Cardiovascular Outcomes and Mortality in Resistant Hypertension: a Cohort Study. Hypertension. 2022;79(2):447-456. https://doi.org/10.1161/HYPERTENSIONaHa.121.18498

135. Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 aHa/aCC Guideline on the Management of Patients With Lower Extremity Peripheral artery Disease: Executive Summary: a Report of the american College of Cardiology/american Heart association Task force on Clinical Practice Guidelines [published correction appears in Circulation. 2017 Mar 21;135(12):e790. https://doi.org/10.1161/CIR.0000000000000501]. Circulation. 2017;135(12):e686-e725. https://doi.org/10.1161/CIR.0000000000000470

136. Национальные рекомендации по диагностике и лечению заболеваний артерий нижних конечностей. Москва 2019 г).

137. Andrikou I, Tsioufis C, Konstantinidis D, Kasiakogias a, Dimitriadis K, Leontsinis I, et al. Renal resistive index in hypertensive patients. J Clin Hypertens (Greenwich) 2018;20:1739-1744. https://doi.org/10.1111/jch.13410

138. Saydam CD. Subclinical cardiovascular disease and utility of coronary artery calcium score [published correction appears in Int J Cardiol. Heart Vasc. 2023 apr 21;46:101208. https://doi.org/10.1016/j.ijcha.2023.101208]. Int J Cardiol. Heart Vasc. 2021 Nov 17;37:100909. https://doi.org/10.1016/j.ijcha.2021.100909

139. Maniar Y, Blumenthal RS, alfaddagh a. The role of coronary artery calcium in allocating pharmacotherapy for primary prevention of cardiovascular disease: The aBCs of CaC. Clin Cardiol. 2022;45(11):1107-1113. https://doi.org/10.1002/clc.23918

140. Chaowu Y, Li L. Histopathological basis of myocardial late gadolinium enhancement in patients with systemic hypertension. Circulation. 2014;130(24):2210-2212. https://doi.org/10.1161/CIRCULaTIONaHa.114.012960

141. Bellenger NG, Davies LC, francis JM, et al. Reduction in sample size for studies of remodeling in heart failure by the use of cardiovascular magnetic resonance. J Cardiovasc Magn Reson. 2000;2(4):271-278. https://doi.org/10.3109/10976640009148691

142. Vermeer SE, Longstreth WT Jr, Koudstaal PJ. Silent brain infarcts: a systematic review. Lancet. Neurol. 2007;6(7):611-619. https://doi.org/10.1016/S1474-4422(07)70170-9

143. Scuteri a, Benetos a, Sierra C, et al. Routine assessment of cognitive function in older patients with hypertension seen by primary care physicians: why and how-a decision-making support from the working group on 'hypertension and the brain' of the European Society of Hypertension and from the European Geriatric Medicine Society. J Hypertens. 2021;39(1):90-100. https://doi.org/10.1097/HJH.0000000000002621

144. Iadecola C, Duering M, Hachinski V, et al. Vascular Cognitive Impairment and Dementia: JaCC Scientific Expert Panel. J am Coll Cardiol. 2019;73(25):3326-3344. https://doi.org/10.1016/j.jacc.2019.04.034

145. Клинические рекомендации – Ишемический инсульт и транзиторная ишемическая атака у взрослых – 2021-2022-2023 (01.09.2021) – Утверждены Минздравом РФ.

146. Wong TY, Rosamond W, Chang PP, et al. Retinopathy and risk of congestive heart failure. JaMa. 2005;293(1):63- 69. https://doi.org/10.1001/jama.293.1.63

147. aronov M, allon R, Stave D, et al. Retinal Vascular Signs as Screening and Prognostic factors for Chronic Kidney Disease: a Systematic Review and Meta-analysis of Current Evidence. J Pers Med. 2021 Jul 15;11(7):665. https://doi.org/10.3390/jpm11070665

148. Sairenchi T, Iso H, Yamagishi K, et al. Mild retinopathy is a risk factor for cardiovascular mortality in Japanese with and without hypertension: the Ibaraki Prefectural Health Study. Circulation. 2011;124(23):2502-2511. https://doi.org/10.1161/CIRCULaTIONaHa.111.049965

149. Клинические рекомендации – Сахарный диабет: ретинопатия диабетическая, макулярный отек диабетический – 2023-2024-2025 (16.02.2023) – Утверждены Минздравом РФ.

150. Berry JD, Dyer a, Cai X, et al. Lifetime risks of cardiovascular disease. N Engl J Med. 2012;366(4):321-329. https://doi.org/10.1056/NEJMoa1012848

151. Conroy RM, Py?r?l? K, fitzgerald aP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J. 2003;24(11):987-1003. https://doi.org/10.1016/s0195-668x(03)00114-3

152. Visseren fLJ, Mach f, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice [published correction appears in Eur Heart J. 2022 Nov 7;43(42):4468. https://doi.org/10.1093/eurheartj/ehac458]. Eur Heart J. 2021;42(34):3227-3337. https://doi.org/10.1093/eurheartj/ehab484

153. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42(25):2439-2454. https://doi.org/10.1093/eurheartj/ehab309

154. Ежов М. В., Кухарчук В. В., Сергиенко И. В. и соавт. Нарушения липидного обмена. Клинические рекомендации 2023. Российский кардиологический журнал. 2023;28(5):5471. https://doi.org/10.15829/1560-4071-2023-5471

155. Kathariya G, aggarwal J, Garg P, et al. Is evaluation of non-HDL-C better than calculated LDL-C in CaD patients? MMIMSR experiences. Indian Heart J. 2020;72(3):189-191. https://doi.org/10.1016/j.ihj.2020.05.008

156. Шальнова С.А., Метельская В.А., Куценко В.А., и соавт. Холестерин, не входящий в состав липопротеинов высокой плотности: современный ориентир оценки нарушений липидного обмена. Рациональная Фармакотерапия в Кардиологии 2022;18(4):366-375. https://doi.org/10.20996/1819-6446-2022-07-01

157. Cingolani OH. Cardiovascular Risks and Organ Damage in Secondary Hypertension. Endocrinol Metab Clin North am. 2019;48(4):657-666. https://doi.org/10.1016/j.ecl.2019.08.015

158. Kivim?ki M, Steptoe a. Effects of stress on the development and progression of cardiovascular disease. Nat Rev Cardiol. 2018;15(4):215-229. https://doi.org/10.1038/nrcardio.2017.189

159. Higueras-fresnillo S, Cabanas-S?nchez V, Lopez-Garcia E, et al. Physical activity and association Between frailty and all-Cause and Cardiovascular Mortality in Older adults: Population-Based Prospective Cohort Study. J am Geriatr Soc. 2018;66(11):2097-2103. https://doi.org/10.1111/jgs.15542

160. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension [published correction appears in J Hypertens. 2003 Nov;21(11):2203-4] [published correction appears in J Hypertens. 2004 feb;22(2):435]. J Hypertens. 2003;21(6):1011-1053. https://doi.org/10.1097/00004872-200306000-00001

161. Sehestedt T, Jeppesen J, Hansen TW, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE [published correction appears in Eur Heart J. 2010 Jul;31(13):1662. Torp-Petersen, Christian [corrected to Torp-Pedersen, Christian]]. Eur Heart J. 2010;31(7):883-891. https://doi.org/10.1093/eurheartj/ehp546

162. Жернакова Ю.В., Шарипова Г.Х., Чазова И.Е. Риск поражения органов-мишеней у больных артериальной гипертонией с разным числом компонентов метаболического синдрома. Системные гипертензии. 2014;11(1):40-44. https://doi.org/10.26442/SG29006

163. Небиеридзе Д.В., Камышова Т.В., Сарычева А.А., Сафарян А.С. Структура сердечно-сосудистого риска у пациентов с артериальной гипертонией впервые обратившихся к врачу. Кардиоваскулярная терапия и профилактика. 2018;17(5):5-10. https://doi.org/10.15829/1728-8800-2018-5-5-10

164. Volpe M, Battistoni a, Tocci G, et al. Cardiovascular risk assessment beyond Systemic Coronary Risk Estimation: a role for organ damage markers. J Hypertens. 2012;30(6):1056-1064. https://doi.org/10.1097/HJH.0b013e3283525715

165. Yeboah J, Young R, McClelland RL, et al. Utility of Nontraditional Risk Markers in atherosclerotic Cardiovascular Disease Risk assessment. J am Coll Cardiol. 2016;67(2):139-147. https://doi.org/10.1016/j.jacc.2015.10.058

166. Peters Sa, den Ruijter HM, Bots ML, Moons KG. Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review. Heart. 2012;98(3):177-184. https://doi.org/10.1136/heartjnl-2011-300747

167. McEvoy JW, Martin SS, Dardari Za, et al. Coronary artery Calcium to Guide a Personalized Risk-Based approach to Initiation and Intensification of antihypertensive Therapy. Circulation. 2017;135(2):153-165. https://doi.org/10.1161/CIRCULaTIONaHa.116.025471

168. Nicolaides aN, Panayiotou aG, Griffin M, et al. arterial Ultrasound Testing to Predict atherosclerotic Cardiovascular Events. J am Coll Cardiol. 2022;79(20):1969-1982. https://doi.org/10.1016/j.jacc.2022.03.352

169. an DW, Hansen TW, aparicio LS, et al. Derivation of an Outcome-Driven Threshold for aortic Pulse Wave Velocity: an Individual-Participant Meta-analysis. Hypertension. 2023;80(9):1949-1959. https://doi.org/10.1161/HYPERTENSIONaHa.123.21318

170. Hussain a, Sun W, Deswal a, et al. association of NT-ProBNP, Blood Pressure, and Cardiovascular Events: The aRIC Study. J am Coll Cardiol. 2021;77(5):559-571. https://doi.org/10.1016/j.jacc.2020.11.063

171. Viera aJ, Neutze DM. Diagnosis of secondary hypertension: an age-based approach. am fam Physician. 2010;82(12):1471-1478. PMID: 21166367

172. Чихладзе Н.М. Симптоматические (вторичные) артериальные гипертонии: диагностика и лечение. М.: Медицинское информационное агентство, 2018. — 168 с. ISBN 978-5-907098-01-5

173. Rossi G.P., Bisogni V., Rossitto G. et al. Practice Recommendations for Diagnosis and Treatment of the Most Common forms of Secondary Hypertension. High Blood Press Cardiovasc Prev. 2020;27(6):547-560. https://doi.org/10.1007/s40292-020-00415-9

174. Шилов Е.М., Смирнов А.В., Козловская Н.Л., ред. Нефрология. Клинические Рекомендации. ГЭОТАР-Медиа; 2016.

175. Ikizler T.a., Burrowes J.D., Byham-Gray L.D., et al. KDOQI Clinical Practice Guideline for Nutrition in CKD: 2020 Update. am J Kidney Dis. 2020;76(3):S1-S107. https://doi.org/10.1053/J.aJKD.2020.05.006

176. Boutari C, Georgianou E, Sachinidis a, Katsimardou a, Christou K, Piperidou a, Karagiannis a. Renovascular Hypertension: Novel Insights. Curr Hypertens Rev. 2020;16(1):24-29. https://doi.org/10.2174/1573402115666190416153321

177. Покровский А.В., Богатов Ю.П. Вазоренальная гипертония. Гл. в кн.: Руководство по артериальной гипертонии. Под ред. Е.И.Чазова, И.Е.Чазовой. М.: МедиаМедика, 2005;95-117.

178. Шилов Е.М., Батюшкин М.М. Реноваскулярная артериальная гипертензия и ишемическая болезнь почек. В кн.: Нефрология. Клинические рекомендации. Под ред. Е.М.Шилова, А.В.Смирнова, Н.Л. Козловской. M.: ГЭОТАР-Медиа, 2016; 449-460.

179. Мухин Н.А., Фомин В.В. Атеросклеротический стеноз почечных артерий. В кн.: Руководство по атеросклерозу и ишемической болезни сердца. Под ред. Е.И Чазова, В.В. Кухарчука, С.А. Бойцова. Media Medica, 2007; 248-273.

180. de Mast Q, Beutler JJ. The prevalence of atherosclerotic renal artery stenosis in risk groups: a systematic literature review. J Hypertens. 2009;27:1333-40. https://doi.org/10.1097/hjh.0b013e328329bbf4

181. Фомин В.В., Кутырина И.М., Швецов М.Ю. Ишемическая болезнь почек. В кн.: Нефрология. Национальное руководство. Краткое издание. Гл. ред. Н.А Мухин. – М.: «ГЭОТaР-Медиа», 2014. – C. 377-386.

182. Aboyans V., Ricco J.B., Bartelink M.E.L. et al. ESC Scientific Document Group. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task force for the Diagnosis and Treatment of Peripheral arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J. 2018 Mar 1;39(9):763-816. https://doi.org/10.1093/eurheartj/ehx095

183. Weber-Mzell D. Coronary anatomy predicts presence or absence of renal artery stenosis. a prospective study in patients undergoing cardiac catheterization for suspected coronary artery disease. European Heart Journal, 2002;23(21):1684–1691. https://doi.org/:10.1053/euhj.2002.3314

184. Safian R.D. Renal artery stenosis. Prog Cardiovasc Dis. 2021 Mar-apr;65:60-70. https://doi.org/10.1016/j.pcad.2021.03.003

185. Balafa O., Kalaitzidis R., Siamopoulos K.C. Optimal medical management in patients with renovascular hypertension. am J Cardiovasc Drugs. 2013 apr;13(2):71-8. https://doi.org/10.1007/s40256-013-0011-x

186. Hackam D.G., Spence J.D., Garg a.X. et al. Role of renin-angiotensin system blockade in atherosclerotic renal artery stenosis and renovascular hypertension. Hypertension. 2007 Dec;50(6):998-1003. https://doi.org/10.1161/HYPERTENSIONaHa.107.097345

187. Manaktala R., Tafur-Soto J.D., White C.J. Renal artery Stenosis in the Patient with Hypertension: Prevalence, Impact and Management. Integr Blood Press Control. 2020 Jun 2;13:71-82. https://doi.org/10.2147/IBPC.S248579

188. Hackam DG, Duong-Hua ML, Mamdani M et al. angiotensin inhibition in renovascular disease: a population- based cohort study. am Heart J. 2008;156:549-55. https://doi.org/10.1016/j.ahj.2008.05.013

189. Chrysochou C, foley RN, Young Jf et al. Dispelling the myth: the use of renin-angiotensin blockade in atheromatous renovascular disease. Nephrol Dial Transplant. 2012;27:1403-9. https://doi.org/10.1093/ndt/gfr496

190. Sarafidis Pa, Theodorakopoulou M, Ortiz a, et atherosclerotic renovascular disease: a clinical practice document by the European Renal Best Practice (ERBP) board of the European Renal association (ERa) and the Working Group Hypertension and the Kidney of the European Society of Hypertension (ESH). Nephrol Dial Transplant. 2023 Nov 30;38(12):2835-2850. PMID: 37202218; PMCID: PMC10689166. https://doi.org/10.1093/ndt/gfad095

191. Pappaccogli M, Robberechts T, Lengele JP, Van der Niepen P, Sarafidis P, Rabbia f, et al. Endovascular versus medical management of atherosclerotic renovascular disease: update and emerging concepts. Hypertension (Dallas, Tex: 1979) 2023; 80:1150-1161. https://doi.org/10.1161/hypertensionaha.122.17965

192. Theodorakopoulou MP, Karagiannidis aG, ferro CJ, Ortiz a, Sarafidis Pa. Renal artery stenting in the correct patients with atherosclerotic renovascular disease: time for a proper renal and cardiovascular outcome study? Clinical Kidney Journal. 2022 May 12;16(2):201-204. https://doi.org/10.1093/ckj/sfac140

193. Klein a.J., Jaff M.R., Gray B.H. et al. SCaI appropriate use criteria for peripheral arterial interventions: an update. Catheter Cardiovasc Interv. 2017 Oct 1;90(4):E90-E110. https://doi.org/10.1002/ccd.27141

194. Reinhard M, Schousboe K, andersen UB, Buus NH, Rantanen JM, Bech JN, et al. Renal artery Stenting in Consecutive High-Risk Patients With atherosclerotic Renovascular Disease: a Prospective 2-Center Cohort Study. Journal of the american Heart association 2022;11:e024421. https://doi.org/10.1161/jaha.121.024421

195. Prince M, Tafur JD, White CJ. When and How Should We Revascularize Patients With atherosclerotic Renal artery Stenosis? JaCC Cardiovasc Interv. 2019 Mar 25;12(6):505-517. https://doi.org/10.1016/j.jcin.2018.10.023

196. Щелкова Г.В., Данилов Н.М., Эркенова А.М., и др. Консенсус по диагностике и лечению реноваскулярной артериальной гипертонии. Системные гипертензии. 2023;20(2):5-20. https://doi.org/10.38109/2075-082X-2023-2-5-20

197. Young W.f. Primary aldosteronism: renaissance of a syndrome. Clin Endocrinol (Oxf). 2007;66(5):607-18. https://doi.org/10.1111/j.1365-2265.2007.02775.x

198. Funder J.W., Carey R.M., Mantero f. et al. The Management of Primary aldosteronism: Case Detection, Diagnosis, and Treatment: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2016;101(5):1889-1916. https://doi.org/10.1210/jc.2015-4061

199. Rossi G.P., Bisogni V., Bacca a.V. et al. The 2020 Italian Society of arterial Hypertension (SIIa) practical guidelines for the management of primary aldosteronism. Int J Cardiol. Hypertens. 2020;5. https://doi.org/10.1016/j.ijchy.2020.100029

200. Mosso L., Carvajal C., Gonz?lez a. et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003;42(2):161-5. https://doi.org/10.1161/01.HYP.0000079505.25750.11

201. Douma S., Petidis K., Doumas M. et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet. 2008 Jun 7;371(9628):1921-6. https://doi.org/10.1016/S0140-6736(08)60834-X. Erratum in: Lancet. 2008 Dec 13;372(9655):2022

202. Чихладзе Н.М. Первичный гиперальдостеронизм как возможная причина резистентного течения артериальной гипертонии. Системные гипертензии. 2020;17(4):20-23. https://doi.org/10.26442/2075082X.2020.4.200338

203. Monticone S., D'ascenzo f., Moretti C. et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet. Diabetes Endocrinol. 2018;6(1):41-50. https://doi.org/10.1016/S2213-8587(17)30319-4

204. Schmiemann G., Gebhardt K., Hummers-Pradier E. et al. Prevalence of hyperaldosteronism in primary care patients with resistant hypertension. J am Board fam Med. 2012 Jan-feb;25(1):98-103. https://doi.org/10.3122/jabfm.2012.01.110099

205. Чихладзе Н.М. Первичный гиперальдостеронизм: показания для скрининга. Терапевтический архив. 2022;94(1):107-113. https://doi.org/10.26442/00403660.2022.01.201324

206. Young W.f. Jr. Diagnosis and treatment of primary aldosteronism: practical clinical perspectives. J Intern Med. 2019;285(2):126-148. https://doi.org/10.1111/joim.12831

207. Zennaro M.C., Jeunemaitre X. SfE/SfHTa/afCE consensus on primary aldosteronism, part 5: Genetic diagnosis of primary aldosteronism. ann Endocrinol (Paris). 2016;77(3):214-9. https://doi.org/10.1016/ando.2016.02.00

208. Williams T.a., Lenders J.W.M., Mulatero P. et al. Outcomes after adrenalectomy for unilateral primary aldosteronism: an international consensus on outcome measures and analysis of remission rates in an international cohort. Lancet. Diabetes Endocrinol. 2017;5(9):689-699. https://doi.org/10.1016/S2213-8587(17)30135-3

209. Mulatero P., Sechi L.a., Williams T.a. et al. Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020;38(10):1929- 1936. https://doi.org/10.1097/HJH.0000000000002520

210. Чихладзе Н.М., Фаворова О.О., Чазова И.Е. Семейная форма гиперальдостеронизма I типа: клиническое наблюдение и обзор литературы. Терапевтический архив. 2018;90(9):115-22. https://doi.org/10.26442/terarkh2018909115-122

211. Feelders R., Sharma S., Nieman L. Cushing’s syndrome: epidemiology and developments in disease management. Clin Epidemiol. 2015 apr 17:7:281-93. https://doi.org/10.2147/CLEP.S44336

212. Мельниченко Г.А., Дедов И.И., Белая Ж.Е. и соавт. Болезнь Иценко-Кушинга: клиника, диагностика, диф- ференциальная диагностика, методы лечения. Проблемы Эндокринологии. 2015;61(2):55-77. https://doi.org/10.14341/proderalbl201561255-77

213. Trifanescu R., Carsote M., Caragheorgheopol a. et al. Screening for secondary endocrine hypertension in young patients. Maedica (Bucur). 2013;8(2):108-115. PMID: 24371473 PMCID: PMC3865118

214. Omura M., Saito J., Yamaguchi K. et al. Prospective study on the prevalence of secondary hypertension among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res. 2004;27(3):193-202. https://doi.org/10.1291/hypres.27.193

215. Nieman L.K., Biller B.M.K., findling J.W. et al. The diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2008;93(5):1526-1540. https://doi.org/10.1210/jc.2008-0125

216. Марова Е.И., Белая Ж.Е., Малыгина А.А. и соавт. Болезнь Иценко-Кушинга (учебное пособие). – М.: ФГБУ «НМИЦ эндокринологии» Минздрава России, 2021. – 40 с.

217. Lindholm J., Juul S., J?rgensen J.O.L. et al. Incidence and Late Prognosis of Cushing’s Syndrome: a Population- Based Study 1. The Journal of Clinical Endocrinology & Metabolism 2001;86(1):117-123. https://doi.org/10.1210/jcem.86.1.7093

218. Biller B.M., Grossman a.B., Stewart P.M., et al. Treatment of adrenocorticotropin – dependent Cushing's syndrome: a consensus statement. J Clin Endocrinol Metab. 2008 Jul;93(7):2454-62. https://doi.org/10.1210/jc.2007-2734

219. Дедов И.И., Мельниченко Г.А. Эндокринология. Национальное Руководство. 2-е изд. – М.: ГЭОТАР-Ме- диа; 2018.

220. Barbot M., Ceccato f., Scaroni C. The Pathophysiology and Treatment of Hypertension in Patients With Cushing's Syndrome. front Endocrinol (Lausanne). 2019 May 21;10:321. https://doi.org/10.3389/fendo.2019.00321

221. Блинова Н.В., Иловайская И.А., Чихладзе Н.М., Луговская А.Ю., и соавт. Диагностика и ведение пациентов с феохромоцитомой/параганглиомой. Консенсус экспертов Российского медицинского общества по артериальной гипертонии и междисциплинарной группы по диагностике и лечению нейроэндокринных опухолей. Терапевтический архив. 2024;96(7):645-658. https://doi.org/10.26442/00403660.2024.07.202779

222. Lenders J.W.M., Kerstens M.N., amar L., et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J Hypertens. 2020;38(8):1443- 1456. https://doi.org/10.1097/HJH.0000000000002438

223. Calissendorff J., Juhlin C.C., Bancos I. et al. Pheochromocytomas and abdominal Paragangliomas: a Practical Guidance. Cancers (Basel). 2022 feb 12;14(4):917. https://doi.org/10.3390/cancers14040917

224. Mete O., asa S.L., Gill a.J. et al. Overview of the 2022 WHO Classification of Paragangliomas and Pheochromocytomas. Endocr Pathol. 2022 Mar;33(1):90-114. https://doi.org/10.1007/s12022-022-09704-6

225. Calhoun D.a., Jones D., Textor S. et al.; american Heart association Professional Education Committee. Resistant hypertension: diagnosis, evaluation, and treatment: a scientific statement from the american Heart association Professional Education Committee of the Council for High Blood Pressure Research. Circulation. 2008 Jun 24;117(25):e510-26. https://doi.org/10.1161/CIRCULaTIONaHa.108.189141

226. Zelinka T., Pac?k K., Widimsk? J. Jr. Characteristics of blood pressure in pheochromocytoma. ann N Y acad Sci. 2006 aug;1073:86-93. https://doi.org/10.1196/annals.1353.009

227. Ebbehoj a., Stochholm K., Jacobsen S.f. et al. Incidence and Clinical Presentation of Pheochromocytoma and Sympathetic Paraganglioma: a Population-based Study. J. Clin. Endocrinol. Metab. 2021;106:e2251-e2261. https://doi.org/10.1210/clinem/dgaa965

228. Y-Hassan S., falhammar H. Cardiovascular Manifestations and Complications of Pheochromocytomas and Paragangliomas. J Clin Med. 2020 Jul 30;9(8):2435. https://doi.org/10.3390/jcm9082435

229. antonio K., Valdez M.M.N., Mercado-asis L., et al. Pheochromocytoma/paraganglioma: recent updates in genetics, biochemistry, immunohistochemistry, metabolomics, imaging and therapeutic options. Gland Surg. 2020 feb;9(1):105-123. https://doi.org/10.21037/gs.2019.10.25

230. Lenders J.W.M., Duh Q.-Y., Eisenhofer G. et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915-1942. https://doi.org/10.1210/jc.2014-1498

231. Мельниченко Г.А., Трошина Е.А., Бельцевич Д.Г. и соавт. Клинические рекомендации Российской Ассоциации эндокринологов по диагностике и лечению феохромоцитомы/параганглиомы. Эндокринная хирургия. 2015;9(3):15-33. https://doi.org/10.14341/serg2015315-33

232. Zuber S.M., Kantorovich V., Pacak K. Hypertension in pheochromocytoma: characteristics and treatment. Endocrinol Metab Clin North am. 2011 Jun;40(2):295-311, vii. https://doi.org/10.1016/j.ecl.2011.02.002

233. Bravo E.L., Tagle R. Pheochromocytoma: state-of-the-art and future prospects. Endocr Rev. 2003;24(4):539- 553. https://doi.org/10.1210/er.2002-0013

234. Garcia-Carbonero R., Matute Teresa f., Mercader-Cidoncha E. et al. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. Clin Transl Oncol. 2021 Oct;23(10):1995-2019. https://doi.org/10.1007/s12094-021-02622-9

235. Fishbein L., Del Rivero J., Else T. et al. The North american Neuroendocrine Tumor Society Consensus Guidelines for Surveillance and Management of Metastatic and/or Unresectable Pheochromocytoma and Paraganglioma. Pancreas. 2021;50(4):469-493. https://doi.org/10.1097/MPa.0000000000001792

236. Falhammar H., Kjellman M., Calissendorff J. Treatment and outcomes in pheochromocytomas and paragangliomas: a study of 110 cases from a single center. Endocrine. 2018;62(3):566-575. https://doi.org/10.1007/s12020-018-1734-x

237. Thomopoulos C, Parati G, Zanchetti a. Effects of blood pressure lowering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels--overview and meta-analyses of randomized trials. J Hypertens. 2014;32(12):2296-2304. https://doi.org/10.1097/HJH.0000000000000379

238. Sundstr?m J, arima H, Jackson R, et al. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. ann Intern Med. 2015;162(3):184-191. https://doi.org/10.7326/M14-0773

239. Lonn EM, Bosch J, L?pez-Jaramillo P, et al. Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016;374(21):2009-2020. https://doi.org/10.1056/NEJMoa1600175

240. Beckett NS, Peters R, fletcher aE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-1898. https://doi.org/10.1056/NEJMoa0801369

241. Williamson JD, Supiano Ma, applegate WB, et al. Intensive vs Standard Blood Pressure Control and Cardiovascular Disease Outcomes in adults aged ?75 Years: a Randomized Clinical Trial. JaMa. 2016;315(24):2673-2682. https://doi.org/10.1001/jama.2016.7050

242. Perry HM Jr, Davis BR, Price TR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JaMa. 2000;284(4):465-471. https://doi.org/10.1001/jama.284.4.465

243. Staessen Ja, fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet. 1997;350(9080):757-764. https://doi.org/10.1016/s0140-6736(97)05381-6

244. Kremer KM, Braisch U, Rothenbacher D, Denkinger M, Dallmeier D; actifE Study Group. Systolic Blood Pressure and Mortality in Community-Dwelling Older adults: frailty as an Effect Modifier. Hypertension. 2022;79(1):24- 32. https://doi.org/10.1161/HYPERTENSIONaHa.121.17530

245. Odden MC, anderson TS. How Low Should You Go in the Presence of frailty? Hypertension. 2022;79(1):33-35. https://doi.org/10.1161/HYPERTENSIONaHa.121.18373

246. Rea f, Cantarutti a, Merlino L, Ungar a, Corrao G, Mancia G. antihypertensive treatment in elderly frail patients: evidence from a large Italian database. Hypertension (Dallas, Tex: 1979) 2020; 76:442-449. https://doi.org/10.1161/hypertensionaha.120.14683

247. Zhang W, Zhang S, Deng Y, et al. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N Engl J Med. 2021;385(14):1268-1279. https://doi.org/10.1056/NEJMoa2111437

248. Ettehad D, Emdin Ca, Kiran a, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387(10022):957-967. https://doi.org/10.1016/S0140-6736(15)01225-8

249. Thomopoulos C, Parati G, Zanchetti a. Effects of blood pressure lowering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels – updated overview and meta-analyses of randomized trials. J Hypertens. 2016;34(4):613-622. https://doi.org/10.1097/HJH.0000000000000881

250. Thomopoulos C, Parati G, Zanchetti a. Effects of blood pressure-lowering treatment on cardiovascular outcomes and mortality: 13 – benefits and adverse events in older and younger patients with hypertension: overview, meta-analyses and meta-regression analyses of randomized trials. J Hypertens. 2018;36(8):1622- 1636. https://doi.org/10.1097/HJH.0000000000001787

251. arguedas Ja, Leiva V, Wright JM. Blood pressure targets in adults with hypertension. Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD004349. https://doi.org/10.1002/14651858.CD004349.pub3

252. Saiz LC, Gorricho J, Garj?n J, Celaya MC, Erviti J, Leache L. Blood pressure targets for the treatment of people with hypertension and cardiovascular disease. Cochrane Database Syst Rev. 2020 Sep 9;9(9):CD010315. https://doi.org/10.1002/14651858.CD010315.pub4

253. Kreutz R, Brunstr?m M, Thomopoulos C, Carlberg B, Mancia G. Do recent meta-analyses truly prove that treatment with blood pressure-lowering drugs is beneficial at any blood pressure value, no matter how low? a critical review. J Hypertens. 2022;40(5):839-846. https://doi.org/10.1097/HJH.0000000000003056

254. andersson OK, almgren T, Persson B, Samuelsson O, Hedner T, Wilhelmsen L. Survival in treated hypertension: follow up study after two decades. BMJ. 1998;317(7152):167-171. https://doi.org/10.1136/bmj.317.7152.167

255. Blacher J, Evans a, arveiler D, et al. Residual cardiovascular risk in treated hypertension and hyperlipidaemia: the PRIME Study. J Hum Hypertens. 2010;24(1):19-26. https://doi.org/10.1038/jhh.2009.34

256. Zhou D, Xi B, Zhao M, Wang L, Veeranki SP. Uncontrolled hypertension increases risk of all-cause and cardiovascular disease mortality in US adults: the NHaNES III Linked Mortality Study. Sci Rep. 2018 Jun 20;8(1):9418. https://doi.org/10.1038/s41598-018-27377-2

257. Zanchetti a. Bottom blood pressure or bottom cardiovascular risk? How far can cardiovascular risk be reduced? J Hypertens. 2009;27(8):1509-1520. https://doi.org/10.1097/HJH.0b013e32832e9500

258. Thomopoulos C, Parati G, Zanchetti a. Effects of blood pressure lowering on outcome incidence in hypertension: 3. Effects in patients at different levels of cardiovascular risk--overview and meta-analyses of randomizedtrials. J Hypertens. 2014;32(12):2305-2314. https://doi.org/10.1097/HJH.0000000000000380

259. Rothwell PM, Howard SC, Dolan E, et al. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet. 2010;375(9718):895-905. https://doi.org/10.1016/S0140-6736(10)60308-X

260. Mancia G, Schumacher H, B?hm M, et al. Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTaRGET and TRaNSCEND Patients. Hypertension. 2017;70(5):938-948. https://doi.org/10.1161/HYPERTENSIONaHa.117.09714

261. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VaLUE randomised trial. Lancet. 2004;363(9426):2022-2031. https://doi.org/10.1016/S0140-6736(04)16451-9

262. Weber Ma, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VaLUE Trial. Lancet. 2004;363(9426):2049-2051. https://doi.org/10.1016/S0140-6736(04)16456-8

263. Mancia G, Kjeldsen SE, Zappe DH, Holzhauer B, Hua Ta, Zanchetti a, et al. Cardiovascular outcomes at different on-treatment blood pressures in the hypertensive patients of the VaLUE trial. Eur Heart J 2016; 37:955-964. https://doi.org/10.1093/eurheartj/ehv633

264. Mancia G, Messerli f, Bakris G, Zhou Q, Champion a, Pepine CJ. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension (Dallas, Tex: 1979) 2007; 50:299-305. https://doi.org/10.1161/hypertensionaha.107.090290

265. Doumas M, Tsioufis C, fletcher R, amdur R, faselis C, Papademetriou V. Time in therapeutic range, as a determinant of all-cause mortality in patients with hypertension. J am Heart assoc. 2017 Nov 3;6(11):e007131. https://doi.org/10.1161/jaha.117.007131

266. Mahfoud f, Mancia G, Schmieder RE, Ruilope L, Narkiewicz K, Schlaich M, et al. Cardiovascular Risk Reduction after Renal Denervation according to Time in Therapeutic Systolic Blood Pressure Range. J am Coll Cardiol. 2022; 80:1871-1880. https://doi.org/10.1016/j.jacc.2022.08.802

267. Wang N, Harris K, Hamet P, Harrap S, Mancia G, Poulter N, et al. Cumulative Systolic Blood Pressure Load and Cardiovascular Risk in Patients With Diabetes. J am Coll Cardiol. 2022; 80:1147-1155. https://doi.org/10.1016/j.jacc.2022.06.039

268. Piper Ma, Evans CV, Burda BU, Margolis KL, O'Connor E, Whitlock EP. Diagnostic and predictive accuracy of blood pressure screening methods with consideration of rescreening intervals: a systematic review for the U.S. Preventive Services Task force. ann Intern Med. 2015;162(3):192-204. https://doi.org/10.7326/M14-1539

269. Mortensen RN, Gerds Ta, Jeppesen JL, Torp-Pedersen C. Office blood pressure or ambulatory blood pressure for the prediction of cardiovascular events. Eur Heart J. 2017;38(44):3296-3304. https://doi.org/10.1093/eurheartj/ehx464

270. Mancia G, Parati G, Bilo G, et al. ambulatory blood pressure values in the Ongoing Telmisartan alone and in Combination with Ramipril Global Endpoint Trial (ONTaRGET). Hypertension. 2012;60(6):1400-1406. https://doi.org/10.1161/HYPERTENSIONaHa.112.199562

271. Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, et al. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTaRGET (ONgoing Telmisartan alone and in combination with Ramipril Global Endpoint Trial). J am Coll Cardiol. 2012;59:74-83. https://doi.org/10.1016/j.jacc.2011.09.040

272. Хачатрян Н. Т., Жернакова Ю. В., Блинова Н. В., Чазова И. Е. Изучение различных диетических вмешательств у пациентов с артериальной гипертонией и метаболическим синдромом. Системные гипертензии. 2024; 21(1):29-35. https://doi.org/10.38109/2075-082X-2024-1-29-35

273. Методические рекомендации MP 2.3.1.0253-21. «Нормы физиологических потребностей в энергии и пищевых веществах для различных групп населения Российской Федерации» (утв. Федеральной службой по надзору в сфере защиты прав потребителей и благополучия человека 22 июля 2021 г.)

274. Ma Y, He fJ, Sun Q, Yuan C, Kieneker LM, Curhan GC, et al. 24-Hour urinary sodium and potassium excretion and cardiovascular risk. N Engl J Med. 2022;386:252-63. https://doi.org/10.1056/NEJMoa2109794

275. O’Donnell M, Yusuf S, Vogt L, Mente a, Messerli fH. Potassium intake: the Cinderella electrolyte. Eur Heart J 2023;44:4925-34. https://doi.org/10.1093/eurheartj/ehad628

276. Yuan Y, Jin a, Neal B, feng X, Qiao Q, Wang H, et al. Salt substitution and salt-supply restriction for lowering blood pressure in elderly care facilities: a cluster-randomized trial. Nat Med 2023;29:973-81. https://doi.org/10.1038/s41591-023-02286-8

277. filippini T, Naska a, Kasdagli MI, Torres D, Lopes C, Carvalho C, et al. Potassium Intake and Blood Pressure: a Dose-Response Meta-analysis of Randomized Controlled Trials. J am Heart assoc. 2020; 9:e015719. https://doi.org/10.1161/jaha.119.015719

278. Filippou CD, Thomopoulos CG, Kouremeti MM, Sotiropoulou LI, Nihoyannopoulos PI, Tousoulis DM, et al. Mediterranean diet and blood pressure reduction in adults with and without hypertension: a systematic review and meta-analysis of randomized controlled trials. Clin Nutr 2021;40:3191-200. https://doi.org/10.1016/j.clnu.2021.01.030

279. Cowell OR, Mistry N, Deighton K, Matu J, Griffiths a, Minihane aM, et al. Effects of a Mediterranean diet on blood pressure: a systematic review and meta-analysis of randomized controlled trials and observational studies. J Hypertens. 2021;39:729-39. https://doi.org/10.1097/hjh.0000000000002667

280. Chandra a, Neeland IJ, Berry JD, ayers CR, Rohatgi a, Das SR, et al. The relationship of body mass and fat distribution with incident hypertension: observations from the Dallas heart study. J am Coll Cardiol. 2014;64:997-1002. https://doi.org/10.1016/j.jacc.2014.05.057

281. Semlitsch T, Krenn C, Jeitler K, Berghold a, Horvath K, Siebenhofer a. Long-term effects of weightreducing diets in people with hypertension. Cochrane Database Syst Rev. 2021;2:CD008274. https://doi.org/10.1002/14651858.CD008274.pub4

282. Кисляк О.А., Леонтьева И.В., Стародубова А.В., Александров А.А., и соавт. Евразийские клинические рекомендации по профилактике сердечно-сосудистых заболеваний в детском и подростковом возрасте (2023). Евразийский кардиологический журнал. 2023;(3):6-35. https://doi.org/10.38109/2225-1685-2023-3-6-35

283. Farhangi Ma, Nikniaz L, Khodarahmi M. Sugar-sweetened beverages increases the risk of hypertension among children and adolescence: a systematic review and dose–response meta-analysis. J Transl Med 2020;18:344. https://doi.org/10.1186/s12967-020-02511-9

284. Mullee a, Romaguera D, Pearson-Stuttard J, Viallon V, Stepien M, freisling H, et al. association between soft drink consumption and mortality in 10 European countries. JaMa. Intern Med 2019;179:1479-90. https://doi.org/10.1001/jamainternmed.2019.2478

285. Tasnim S, Tang C, Musini VM, Wright JM. Effect of alcohol on blood pressure. Cochrane Database Syst Rev. 2020;7:CD012787. https://doi.org/10.1002/14651858.CD012787.pub2

286. Liu f, Liu Y, Sun X, Yin Z, Li H, Deng K, et al. Raceand sex-specific association between alcohol consumption and hypertension in 22 cohort studies: a systereview and meta-analysis. Nutr Metab Cardiovasc Dis 2020;30:1249- 59. https://doi.org/10.1016/j.numecd.2020.03.018

287. Hanssen H, Boardman H, Deiseroth a, Moholdt T, Simonenko M, Kr?nkel N, et al. Personalized exercise prescription in the prevention and treatment of arterial hypertension: a consensus document from the European association of Preventive Cardiology (EaPC) and the ESC Council on Hypertension. Eur J Prev Cardiol 2022; 29:205-15. https://doi.org/10.1093/eurjpc/zwaa141

288. Kim SY, Jeong SH, Joo HJ, Park M, Park E-C, Kim JH, et al. High prevalence of hypertension among smokers of conventional and e-cigarette: using the nationally representative community dwelling survey. front Public Health 2022;10:919585. https://doi.org/10.3389/fpubh.2022.919585

289. Hahad O, Rajagopalan S, Lelieveld J, Sorensen M, Kuntic M, Daiber a, etal. Noise and air Pollution as Risk factors for Hypertension: Part II-Pathophysiologic Insight. Hypertension (Dallas, Tex: 1979). 2023 Jul;80(7):1384-1392. https://doi.org/10.1161/hypertensionaha.123.20617

290. Wojciechowska W, Januszewicz a, Dro?d? T, Rojek M, B?czalska J, Terlecki M, et al. Blood pressure and arterial stiffness in association with aircraft noise exposure: long-term observation and potential effect of COVID-19 lockdown. Hypertension (Dallas, Tex: 1979) 2022; 79:325-334. https://doi.org/10.1161/hypertensionaha.121.17704

291. Thomopoulos C, Parati G, Zanchetti a. Effects of blood pressure-lowering on outcome incidence in hypertension: 5. Head-to-head comparisons of various classes of antihypertensive drugs – overview and meta-analyses. J Hypertens. 2015;33:1321-1341. https://doi.org/10.1097/hjh.0000000000000614

292. Wei J, Galaviz KI, Kowalski aJ, Magee MJ, Haw JS, Narayan KMV, et al. Comparison of Cardiovascular Events among Users of Different Classes of antihypertension Medications: a Systematic Review and Network Metaanalysis. JaMa. Netw Open 2020;3:e1921618. https://doi.org/10.1001/jamanetworkopen.2019.21618

293. van Vark LC, Bertrand M, akkerhuis KM, Brugts JJ, fox K, Mourad JJ, et al. angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin-angiotensinaldosterone system inhibitors involving 158,998 patients. Eur Heart J 2012;33:2088-2097. https://doi.org/10.1093/eurheartj/ehs075

294. Gallo G, Volpe M, Rubattu S. angiotensin Receptor Blockers in the Management of Hypertension: a Real- World Perspective and Current Recommendations. Vasc Health Risk Manag 2022;18:507-515. https://doi.org/10.2147/vhrm.s337640

295. Reboldi G, angeli f, Cavallini C, Gentile G, Mancia G, Verdecchia P. Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta-analysis. J Hypertens. 2008;26:1282-1289. https://doi.org/10.1097/hjh.0b013e328306ebe2

296. Corrao G, Zambon a, Parodi a, Poluzzi E, Baldi I, Merlino L, et al. Discontinuation of and changes in drug therapy for hypertension among newlytreated patients: a population-based study in Italy. J Hypertens. 2008; 26:819- 824. https://doi.org/10.1097/hjh.0b013e3282f4edd7

297. Burnier M. Telmisartan: a different angiotensin II receptor blocker protecting a different population? J Int Med Res. 2009 Nov-Dec;37(6):1662-79. https://doi.org/10.1177/147323000903700602

298. Wang YC, Hsieh TC, Chou CL, Wu JL, fang TC. Risks of adverse Events following Coprescription of Statins and Calcium Channel Blockers: a Nationwide Population-Based Study. Medicine (Baltimore) 2016;95:e2487. https://doi.org/10.1097/md.0000000000002487

299. Xu Y, Chang aR, Inker La, Mcadams-DeMarco M, Grams ME, Shin JI. Concomitant use of diltiazem with direct oral anticoagulants and bleeding risk in atrial fibrillation. J am Heart assoc. 2022; 11:e025723. https://doi.org/10.1161/jaha.122.025723

300. Roush GC, Ernst ME, Kostis JB, Tandon S, Sica Da. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension (Dallas, Tex: 1979). 2015;65:1041-1046. https://doi.org/10.1161/hypertensionaha.114.05021

301. do Vale GT, Ceron CS, Gonzaga Na, Simplicio Ja, Padovan JC. Three Generations of b-blockers: History, Class Differences and Clinical applicability. Current hypertension reviews 2019;15:22-31. https://doi.org/10.2174/1573402114666180918102735

302. Mancia G, Kjeldsen SE, Kreutz R, et al. Individualized Beta-Blocker Treatment for High Blood Pressure Dictated by Medical Comorbidities: Indications Beyond the 2018 European Society of Cardiology/European Society of Hypertension Guidelines. Hypertension. 2022;79(6):1153-1166. https://doi.org/10.1161/HYPERTENSIONaHa.122.19020

303. Agarwal R, Kolkhof P, Bakris G, Bauersachs J, Haller H, Wada T, et al. Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine. Eur Heart J 2021; 42:152-161. https://doi.org/10.1093/eurheartj/ehaa736

304. Кисляк О.А., Жернакова Ю.В., Аксенова А.В., Чазова И.Е. Консенсус экспертов Российского медицинского общества по артериальной гипертонии: применение фиксированных комбинаций в лечении больных артериальной гипертонией. Системные гипертензии. 2024;21(1):5-13. https://doi.org/10.38109/2075-082X-2024-1-5-13

305. Ontarget Investigators. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008; 358:1547-1559. https://doi.org/10.1056/nejmoa0801317

306. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEaRT study): case-control study. Lancet. 2004;364(9438):937-952. https://doi.org/10.1016/S0140-6736(04)17018-9

307. Sever PS, Dahl?f B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering arm (aSCOT-LLa): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149-1158. https://doi.org/10.1016/S0140-6736(03)12948-0

308. Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy [published correction appears in Lancet. 2017 feb 11;389(10069):602. https://doi.org/10.1016/S0140-6736(16)31468-4]. Lancet. 2016;388(10059):2532-2561. https://doi.org/10.1016/S0140-6736(16)31357-5

309. Silverman MG, ference Ba, Im K, et al. association Between Lowering LDL-C and Cardiovascular Risk Reduction among Different Therapeutic Interventions: a Systematic Review and Meta-analysis. JaMa. 2016;316(12):1289-1297. https://doi.org/10.1001/jama.2016.13985

310. Yusuf S, Bosch J, Dagenais G, et al. Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. N Engl J Med. 2016;374(21):2021-2031. https://doi.org/10.1056/NEJMoa1600176

311. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients [published correction appears in BMJ. 2002 Jan 19;324(7330):141]. BMJ. 2002;324(7329):71-86. https://doi.org/10.1136/bmj.324.7329.71

312. Shantsila E, Kozie?-Sio?kowska M, Lip GY. antiplatelet agents and anticoagulants for hypertension. Cochrane Database Syst Rev. 2022 Jul 28;7:CD003186. https://doi.org/10.1002/14651858.CD003186.pub4

313. Dibona Gf. Sympathetic nervous system and the kidney in hypertension. Curr Opin Nephrol Hypertens. 2002 Mar;11(2):197-200. https://doi.org/10.1097/00041552-200203000-00011

314. Stella a, Zanchetti a. functional role of renal afferents. Physiol Rev 1991; 71:659–682.

315. Dibona Gf, Esler M. Translational medicine: the antihypertensive effect of renal denervation. am JPhysiol Regul Integr Comp Physiol 2010;298:R245-53. https://doi.org/10.1152/ajpregu.00647.2009

316. Esler M, Guo L. The future of renal denervation. auton Neurosci. 2017 May;204:131-138. https://doi.org/10.1016/j.autneu.2016.08.004

317. Grassi G, Seravalle G, Brambilla G, Trabattoni D, Cuspidi C, Corso R, et al. Blood pressure responses to renal denervation precede and are independent of the sympathetic and baroreflex effects. Hypertension (Dallas, Tex: 1979) 2015;65:1209-1216. https://doi.org/10.1161/hypertensionaha.114.04823

318. Esler M. Illusions of truths in the Symplicity HTN-3 trial: generic design strengths but neuroscience failings. J am Soc Hypertens. 2014; 8:593-598. https://doi.org/10.1016/j.jash.2014.06.001

319. Biffi a, Dell’Oro R, Quarti-Trevano f, Cuspidi C, Corrao G, Mancia G, et al. Effects of renal denervation on sympathetic nerve traffic and correlates in drug-resistant and uncontrolled hypertension: a systematic review and meta-analysis. Hypertension (Dallas, Tex: 1979) 2023; 80:659-667. https://doi.org/10.1161/hypertensionaha.122.20503

320. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: durability of blood pressure reduction out to 24 months. Hypertension 2011; 57: 911-7. https://doi.org/10.1161/hypertensionaha.110.163014

321. Elser MD, Krum H, Schlaich M, Schmieder RE, Bohm M, Sobotka Pa; Symplicity HTN-2 Investigators. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-years results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012;126 (25): 2976-2982. https://doi.org/10.1161/circulationaha.112.130880

322. Kandzari DE, Bhatt DL, Brar S et al. Predictors of blood pressure response in the SYMPLICITY HTN-3trial. Eur Heart J 2015;36:219-27. https://doi.org/10.1093/eurheartj/ehu441

323. Bakris GL, Townsend RR, flack JM et al. 12-month blood pressure results of catheter-based renal ar-tery denervation for resistant hypertension: the symplicity HTN-3 trial. J am Coll Cardiol. 2015;65:1314-1321. https://doi.org/10.1016/j.jacc.2015.01.037

324. Mahfoud f, Schmieder RE, azizi M, Pathak a, Sievert H, Tsioufis C, et al. Proceedings from the 2nd European Clinical Consensus Conference for device-based therapies for hypertension: state of the art and considerations for the future. Eur Heart J 2017;38:3272-3281. https://doi.org/10.1093/eurheartj/ehx215

325. Kandzari DE, Bohm M, Mahfoud f et al. Effect of renal denervation on blood pressure in the presenceof antihypertensive drugs: 6-month efficacy and safety results from the SPYRaL HTN-ON MED proof-of-concept randomised trial. Lancet. 2018;391:2346-2355. https://doi.org/10.1016/s0140-6736(18)30951-6

326. Townsend RR, Mahfoud f, Kandzari DE et al. Catheter-based renal denervation in patients with un-controlled hypertension in the absence of antihypertensive medications (SPYRaL HTN-Off MED): arandomised, sham-controlled, proof-of-concept trial. Lancet. 2017;390:2160-2170. https://doi.org/10.1016/s0140-6736(17)32281-x

327. Mahfoud f, Bohm M, Schmieder R, Narkiewicz K, Ewen S, Ruilope L, et al. Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J 2019;40:3474-3482. https://doi.org/10.1093/eurheartj/ehz118

328. Pekarskiy SE, Baev aE, Mordovin Vf et al. Denervation of the distal renal arterial branches vs. conven-tional main renal artery treatment: a randomized controlled trial for treatment of resistant hyperten-sion. J Hypertens. 2017;35:369-75. https://doi.org/10.1097/hjh.0000000000001160

329. Данилов Н.М., Агаева Р.А., Матчин Ю.Г. и др. Консенсус экспертов Российского медицинского общества по артериальной гипертонии (РМОАГ) по применению радиочастотной денервации почечных артерий у пациентов с артериальной гипертонией. Системные гипертензии. 2020;17(4):7-18. https://doi.org/10.26442/2075082X.2020.4.200398

330. Azizi M, Schmieder RE, Mahfoud f et al. Endovascular ultrasound renal denervation to treat hypertension (RaDIaNCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-cont-rolled trial. Lancet. 2018;391:2335-2345. https://doi.org/10.1016/s0140-6736(18)31082-1

331. F. Mahfoud, J.Renkin, H. Sievert et al. alcohol-Mediated Renal Denervation Using the Peregrine System Infusion Catheter for Treatment of Hypertension. JaCC Cardiovasc Interv. 2020 feb 24;13(4):471-484. https://doi.org/10.1016/j.jcin.2019.10.048

332. Heusser K, Tank J, Engeli S, Diedrich a, Menne J, Eckert S, et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension (Dallas, Tex: 1979) 2010;55:619-626. https://doi.org/10.1161/hypertensionaha.109.140665

333. Monique E.a.M. van Kleef, Chandan M. Devireddy, Jan van der Heyden. Treatment of Resistant Hypertension With Endovascular Baroreflex amplification: 3-Year Results from the CaLM-fIM Study. JaCC: Cardiovascular Interventions. 2022 feb 14;15(3):321-332. https://doi.org/10.1016/j.jcin.2021.12.015

334. Аксенова А.В., Сивакова О.А., Блинова Н.В. и соавт. Консенсус экспертов Российского медицинского об- щества по артериальной гипертонии по диагностике и лечению резистентной артериальной гиперто- нии. Терапевтический архив. 2021;93(9):1018-1029. https://doi.org/10.26442/00403660.2021.09.201007

335. Dudenbostel T, Siddiqui M, Oparil S, et al. Refractory Hypertension: a Novel Phenotype of antihypertensive Treatment failure. Hypertension. 2016;67(6):1085-1092. https://doi.org/10.1161/HYPERTENSIONaHa.116.06587

336. Matanes f, Khan MB, Siddiqui M, et al. an Update on Refractory Hypertension. Curr Hypertens Rep. 2022;24(7):225-234. https://doi.org/10.1007/s11906-022-01185-6

337. Resistant or refractory hypertension: it is not just the of number of drugs Veglio, franco; Mulatero, Paolo at al. Journal of Hypertension. 2021 Mar 1;39(3):589-591. https://doi.org/10.1097/HJH.0000000000002814

338. Gupta aK, Nasothimiou EG, Chang CL, et al. Baseline predictors of resistant hypertension in the anglo- Scandinavian Cardiac Outcome Trial (aSCOT): a risk score to identify those at high-risk. J Hypertens. 2011;29(10):2004-2013. https://doi.org/10.1097/HJH.0b013e32834a8a42

339. Jafari E, Cooper-DeHoff RM, Effron MB, et al. Characteristics and Predictors of apparent Treatment-Resistant Hypertension in Real-World Populations Using Electronic Health Record-Based Data. am J Hypertens. 2024;37(1):60-68. https://doi.org/10.1093/ajh/hpad084

340. Armario P, Calhoun Da, Oliveras a, et al. Prevalence and Clinical Characteristics of Refractory Hypertension. J am Heart assoc. 2017 Dec 7;6(12):e007365. https://doi.org/10.1161/JaHa.117.007365

341. Velasco a, Siddiqui M, Kreps E, et al. Refractory Hypertension Is not attributable to Intravascular fluid Retention as Determined by Intracardiac Volumes. Hypertension. 2018;72(2):343-349. https://doi.org/10.1161/HYPERTENSIONaHa.118.10965

342. Dudenbostel T, acelajado MC, Pisoni R, Li P, Oparil S, Calhoun Da. Refractory Hypertension: Evidence of Heightened Sympathetic activity as a Cause of antihypertensive Treatment failure. Hypertension. 2015 Jul;66(1):126-33. Epub 2015 May 18. PMID: 25987662; PMCID: PMC4465856. https://doi.org/10.1161/HYPERTENSIONaHa.115.05449

343. Cuspidi C, Macca G, Sampieri L, Michev I, Salerno M, fusi V, et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertens. 2001;19:2063-2070. https://doi.org/10.1097/00004872-200111000-00018

344. Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi fa, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125:1635-1642. https://doi.org/10.1161/circulationaha.111.068064

345. Choudhry NK, Kronish IM, Vongpatanasin W, ferdinand KC, Pavlik VN, Egan BM, et al. Medication adherence and Blood Pressure Control: a Scientific Statement from the american Heart association. Hypertension (Dallas, Tex: 1979) 2022;79:e1-e14. https://doi.org/10.1161/hyp.0000000000000203

346. Grossman a, Messerli fH, Grossman E. Drug induced hypertension – an unappreciated cause of secondary hypertension. Eur J Pharmacol 2015;763:15-22. https://doi.org/10.1016/j.ejphar.2015.06.027

347. Carey RM, Calhoun Da, Bakris GL, Brook RD, et al.; american Heart association Professional/Public Education and Publications Committee of the Council on Hypertension; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Genomic and Precision Medicine; Council on Peripheral Vascular Disease; Council on Quality of Care and Outcomes Research; and Stroke Council. Resistant Hypertension: Detection, Evaluation, and Management: a Scientific Statement from the american Heart association. Hypertension. 2018 Nov;72(5):e53-e90. PMID: 30354828; PMCID: PMC6530990. https://doi.org/10.1161/HYP.0000000000000084

348. Parati G, Kjeldsen S, Coca a, Cushman W C, Wang J. adherence to single-pill versus free-equivalent combination therapy in hypertension: a systematic review and meta-analysis. Hypertension (Dallas, Tex: 1979). 2021;77:692-705. https://doi.org/10.1161/hypertensionaha.120.15781

349. agarwal R, Sinha aD, Cramer aE, Balmes-fenwick M, Dickinson JH, Ouyang f, et al. Chlorthalidone for Hypertension in advanced Chronic Kidney Disease. N Engl J Med. 2021; 385:2507-2519. https://doi.org/10.1056/nejmoa2110730

350. agarwal R, Sinha aD, Tu W. Chlorthalidone for Resistant Hypertension in advanced Chronic Kidney Disease. Circulation. 2022;146:718-720. https://doi.org/10.1161/circulationaha.122.060167

351. Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. Expert opinion on pharmacotherapy. 2014;15:605-621. https://doi.org/10.1517/14656566.2014.879117

352. Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine theoptimal treatment for drug-resistant hypertension (PaTHWaY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059-2068. https://doi.org/10.1016/s0140-6736(15)00257-3

353. Bolignano D, Palmer SC, Navaneethan SD, Strippoli Gf. aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev. 2014;4:CD007004. https://doi.org/10.1002/14651858.cd007004.pub3

354. Williams B, MacDonald TM, Morant SV, Webb DJ, Sever P, McInnes GT, et al. Endocrine and haemodynamic changes in resistant hypertension, and blood pressure responses to spironolactone or amiloride: the PaTHWaY-2 mechanisms substudies. Lancet. Diabetes Endocrinol 2018;6:464-475. https://doi.org/10.1016/s2213-8587(18)30071-8

355. Agarwal R, Rossignol P, Romero a, Garza D, Mayo MR, Warren S, et al. Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (aMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet. 2019;394:1540-1550. https://doi.org/10.1016/S0140-6736(19)32135-X

356. Jami O, Tijani Y, Et-Tahir a. Device-Based Therapy for Resistant Hypertension: an Up-to-Date Review. High Blood Press Cardiovasc Prev. 2022 Nov;29(6):537-546. Epub 2022 Sep 30. PMID: 36178479; PMCID: PMC9523625. https://doi.org/10.1007/s40292-022-00539-0

357. Azizi M, Sanghvi K, Saxena M, et al; RaDIaNCE-HTN investigators. Ultrasound renal denervation for hypertension resistant to a triple medication pill (RaDIaNCE-HTN TRIO): a randomised, multicentre, single- blind, sham-controlled trial. Lancet. 2021 Jun 26;397(10293):2476-2486. Epub 2021 May 16. PMID: 34010611. https://doi.org/10.1016/S0140-6736(21)00788-1

358. Pio-abreu a, Drager Lf. Resistant hypertension: time to consider the best fifth anti-hypertensive treatment. Curr Hypertens Rep. 2018;20:67. https://doi.org/10.1007/s11906-018-0866-y

359. Barbato E, azizi M, Schmieder RE, et al. Renal Denervation in the Management of Hypertension in adults. a Clinical Consensus Statement of the ESC Council on Hypertension and the European association of Cardiovascular Interventions (EaPCI). Eur Heart J. 2023 apr 17;44(15):1313-1330. https://doi.org/10.1093/eurheartj/ehad054. Erratum in: Eur Heart J. 2023 Jul 14;44(27):2439. PMID: 36790101. https://doi.org/10.1093/eurheartj/ehad321

360. Martinez-Garcia Ma, Pengo Mf. Clinical phenotype of resistant hypertension responders to continuous positive airway pressure treatment: results from the HIPaRCO randomized clinical trial. Hypertension (Dallas, Tex: 1979). 2021;78:559-561. https://doi.org/10.1161/HYPERTENSIONaHa.121.17364

361. 25. Giugliano D, Scappaticcio L, Longo M, Caruso P, Maiorino MI, Bellastella G, et al. GLP-1 receptor agonists and cardiorenal outcomes in type 2 diabetes: an updated meta-analysis of eight CVOTs. Cardiovasc Diabetol. 2021;20:189. https://doi.org/10.1186/s12933-021-01366-8

362. 26. Schiavon Ca, Ikeoka D, Santucci EV, Santos RN, Damiani LP, Bueno PT, et al. Effects of bariatric surgery versus medical therapy on the 24-hour ambulatory blood pressure and the prevalence of resistant hypertension. Hypertension (Dallas, Tex: 1979). 2019;73:571-577. https://doi.org/10.1161/HYPERTENSIONaHa.118.12290

363. 27. Georgianos PI, agarwal R. ambulatory blood pressure reduction with SGLT-2 inhibitors: dose-response meta-analysis and comparative evaluation with low-dose hydrochlorothiazide. Diabetes Care. 2019;42:693- 700. https://doi.org/10.2337/dc18-2207

364. Mancia G, Bertinieri G, Grassi G, Parati G, Pomidossi G, ferrari a, et al. Effects of blood-pressure measurement by the doctor on patient’s blood pressure and heart rate. Lancet. 1983;2:695-698. https://doi.org/10.1016/s0140-6736(83)92244-4

365. Mancia G, Parati G, Pomidossi G, Grassi G, Casadei R, Zanchetti a. alerting reaction and rise in blood pressure during measurement by physician and nurse. Hypertension (Dallas, Tex: 1979). 1987;9:209-215. https://doi.org/10.1161/01.hyp.9.2.209

366. Palatini P, Palomba D, Bertolo O, Minghetti R, Longo D, Sarlo M, et al. The white-coat effect is unrelated to the difference between clinic and daytimeblood pressure and is associated with greater reactivity to public speaking. J Hypertens. 2003;21:545-553. https://doi.org/10.1097/00004872-200303000-00020

367. Grassi G, Pisano a, Bolignano D, Seravalle G, D’arrigo G, Quarti-Trevano f, et al. Sympathetic nerve traffic activation in essential hypertension and its correlates: systematic reviews and meta-analyses. Hypertension (Dallas, Tex: 1979). 2018; 72:483-491. https://doi.org/10.1161/hypertensionaha.118.11038

368. Sega R, Trocino G, Lanzarotti a, Carugo S, Cesana G, Schiavina R, et al. alterations of cardiac structure in patients with isolated office, ambulatory, or home hypertension: Data from the general population (Pressione arteriose Monitorate E Loro associazioni [PaMELa] Study). Circulation. 2001;104:1385-1392. https://doi.org/10.1161/hc3701.096100

369. Briasoulis a, androulakis E, Palla M, Papageorgiou N, Tousoulis D. White-coat hypertension and cardiovascular events: a meta-analysis. J Hypertens. 2016;34:593-599. https://doi.org/10.1097/hjh.0000000000000832

370. Huang Y, Huang W, Mai W, Cai X, an D, Liu Z, et al. White-coat hypertension is a risk factor for cardiovascular diseases and total mortality. J Hypertens. 2017;35:677-688. https://doi.org/10.1097/hjh.0000000000001226

371. anstey DE, Pugliese D, abdalla M, Bello Na, Givens R, Shimbo D. an update on masked hypertension. Curr Hypertens Rep. 2017;19:94. https://doi.org/10.1007/s11906-017-0792-4

372. Hung MH, Shih LC, Wang YC, Leu HB, Huang PH, Wu TC, et al. Prediction of masked hypertension and masked uncontrolled hypertension using machine learning. front Cardiovasc Med 2021;8:778306. https://doi.org/10.3389/fcvm.2021.778306

373. Shimbo D, abdalla M, falzon L, Townsend RR, Muntner P. Studies comparing ambulatory blood pressure and home blood pressure on cardiovascular disease and mortality outcomes: a systematic review. J am Soc Hypertens. 2016;10:224-234;e17. https://doi.org/10.1016/j.jash.2015.12.013

374. Palatini P, Winnicki M, Santonastaso M, Mos L, Longo D, Zaetta V, et al. Prevalence and clinical significance of isolated ambulatory hypertension in young subjects screened for stage 1 hypertension. Hypertension (Dallas, Tex: 1979). 2004;44:170-174. https://doi.org/10.1161/01.hyp.0000135250.57004.19

375. Antza C, Vazakidis P, Doundoulakis I, Bouras E, Haidich aB, Stabouli S, et al. Masked and white coat hypertension, the double trouble of large arteries: a systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2020;22:802-811. https://doi.org/10.1111/jch.13876

376. Cuspidi C, Sala C, Tadic M, Rescaldani M, Grassi G, Mancia G. Untreated masked hypertension and subclinical cardiac damage: a systematic review and meta-analysis. am J Hypertens. 2015;28:806-813. https://doi.org/10.1093/ajh/hpu231

377. Paiva aMG, Gomes M, Campana E ? MG, feitosa aDM, Sposito aC, Mota-Gomes Ma, et al. Impact of hypertension phenotypes on the office and 24-h pulse wave velocity and augmentation index in individuals with or without antihypertensive medication use. Hypertens Res 2019;42:1989-1995. https://doi.org/10.1038/s41440-019-0323-6

378. Kim HJ, Shin JH, Lee Y, Kim JH, Hwang SH, Kim WS, et al. Clinical features and predictors of masked uncontrolled hypertension from the Korean ambulatory Blood Pressure Monitoring Registry. Korean J Intern Med 2021;36:1102-1114. https://doi.org/10.3904/kjim.2020.650

379. Egan BM, Li J, Hutchison fN, ferdinand KC. Hypertension in the United States, 1999 to 2012: progress toward Healthy People 2020 goals. Circulation. 2014;130(19):1692-1699. https://doi.org/10.1161/circulationaha.114.010676

380. Liu X, Rodriguez CJ, Wang K. Prevalence and trends of isolated systolic hypertension among untreated adults in the United States. J am Soc Hypertens. 2015;9(3):197-205. https://doi.org/10.1016/j.jash.2015.01.002

381. Saladini f, Santonastaso M, Mos L, Benetti E, Zanatta N, Maraglino G, Palatini P. HaRVEST Study Group. Isolated systolic hypertension of young-to-middle-age individuals implies a relatively low risk of developing hypertension needing treatment when central blood pressure is low. J Hypertens. 2011;29:1311-1319. https://doi.org/10.1097/hjh.0b013e3283481a32

382. Ekundayo OJ, allman RM, Sanders PW, et al. Isolated systolic hypertension and incident heart failure in older adults: a propensity-matched study. Hypertension. 2009;53(3):458-465. https://doi.org/10.1161/hypertensionaha.108.119792

383. Li Y, Wei ff, Thijs L et al. ambulatory hypertension subtypes and 24-hour systolic and diastolic blood pressure as distinct outcome predictors in 8341 untreated people recruited from 12 populations. Circulation. 2014;130(6):466-474. https://doi.org/10.1161/circulationaha.113.004876

384. Kostis WJ, Sargsyan D, Mekkaoui C, Moreyra aE, Cabrera J, Cosgrove NM, et al. association of orthostatic hypertension with mortality in the Systolic Hypertension in the Elderly Program. J Hum Hypertens. 2019;33:735-740. https://doi.org/10.1038/s41371-019-0180-4

385. Mancia G, Giannattasio C. Diagnostic and therapeutic problems of isolated systolic hypertension. J Hypertens. 2015;33:33-43. https://doi.org/10.1097/hjh.0000000000000424

386. Bavishi C, Goel S, Messerli fH. Isolated systolic hypertension: an update after SPRINT. am J Med 2016;129:1251- 1258. https://doi.org/10.1016/j.amjmed.2016.08.032

387. Mahajan S, Zhang D, He S, Lu Y, Gupta a, Spatz ES, et al. Prevalence, awareness, and Treatment of Isolated Diastolic Hypertension: Insights from the China PEaCE Million Persons Project. J am Heart assoc. 2019; 8:e012954. https://doi.org/10.1161/jaha.119.012954

388. Li fR, He Y, Yang HL, Liu HM, Zhou R, Chen GC, et al. Isolated systolic and diastolic hypertension by the 2017 american College of Cardiology/ american Heart association guidelines and risk of cardiovascular disease: a large prospective cohort study. J Hypertens. 2021;39:1594-1601. https://doi.org/10.1097/hjh.0000000000002805

389. McGrath BP, Kundu P, Daya N, Coresh J, Selvin E, McEvoy JW, et al. Isolated diastolic hypertension in the UK Biobank: comparison of aCC/aHa and ESC/NICE guideline definitions. Hypertension (Dallas, Tex: 1979). 2020;76:699-706. https://doi.org/10.1161/hypertensionaha.120.15286

390. Yue L, Chen H, Sun Q, Shi L, Sun J, Li G, et al. Prevalence of isolated diastolic hypertension and the risk of cardiovascular mortality among adults aged 40 years and older in northeast China: a prospective cohort study. BMJ. Open 2022;12:e061762. https://doi.org/10.1136/bmjopen-2022-061762

391. Rosner B, Cook NR, Daniels S, falkner B. Childhood blood pressure trends and risk factors for high blood pressure: the NHaNES experience 1988-2008. Hypertension. 2013;62(2):247-54. https://doi.org/10.1161/hypertensionaha.111.00831

392. Flynn JT, Kaelber DC, Baker-Smith CM, Blowey D, Carroll aE, Daniels SR, de ferranti SD, Dionne JM, falkner B, flinn SK, Gidding SS, Goodwin C, Leu MG, Powers ME, Rea C, Samuels J, Simasek M, Thaker VV, Urbina EM. Clinical Practice Guideline for Screening and Management of High Blood Pressure in Children and adolescents. Pediatrics. 2017;140(3):e20171904. https://doi.org/10.1542/peds.2017-1904

393. Flechtner-Mors M, Neuhauser H, Reinehr T, Roost HP, Wiegand S, Siegfried W, et al., aPV initiative and the BMBf Competence Network Obesity. Blood pressure in 57,915 pediatric patients who are overweight or obese based on five reference systems. am J Cardiol. 2015;115:1587-1594. https://doi.org/10.1016/j.amjcard.2015.02.063

394. Александров А.А., Кисляк О.А., Леонтьева И.В. от имени экспертов. Клинические рекомендации. Диа- гностика, лечение и профилактика артериальной гипертензии у детей и подростков. Системные гипер- тензии. 2020;17(2):7-35. https://doi.org/10.26442/2075082X.2020.2.200126

395. Lurbe E., agabiti-Roseic E., Cruickshankd J.K, Dominiczake a., Erdinef S., Hirthg a., et.al. 2016 European Society of Hypertension guidelines for the management of high blood pressure in children and adolescents. J Hypertens. 2016 Oct;34(10):1887-920. https://doi.org/10.1097/HJH.0000000000001039

396. Lurbe E, Mancia G, Calpe J, Droz?dz? D, Erdine S, fernandez-aranda f, et al. Joint statement for assessing and managing high blood pressure in children and adolescents: Chapter 1. How to correctly measure blood pressure in children and adolescents. front Pediatr 2023;11:1140357. https://doi.org/10.3389/fped.2023.1140357

397. W?hl E, Witte K, Soergel M, Mehls O, Schaefer f, German Working Group on Pediatric Hypertension. Distribution of 24-h ambulatory blood pressure in children: normalized reference values and role of body dimensions. J Hypertens. 2002;20:1995-2007. https://doi.org/10.1097/00004872-200210000-00019

398. Gidding SS, Rana J, Prendergast C, et al. Pathobiological Determinants of atherosclerosis in Youth (PDaY) Risk Score in Young adults Predicts Coronary artery and abdominal aorta Calcium in Middle age. The CaRDIa Study. Circulation. 2016;133(2):2139-146. https://doi.org/10.1161/circulationaha.115.018042

399. Berenson G., Srinivasan S.R, Bao W et al. for the Bogalusa Heart Study. association between Multiple Cardiovascular Risk factors and atherosclerosis in Children and Young adults. N Engl J Med. 1998 Jun 4;338(23):1650-1656. https://doi.org/10.1056/nejm199806043382302

400. Son JS, Choi S, Kim K, Kim SM, Choi D, Lee G, et al. association of Blood Pressure Classification in Korean Young adults according to the 2017 american College of Cardiology/american Heart association Guidelines With Subsequent Cardiovascular Disease Events. JaMa. 2018;320:1783-1792. https://doi.org/10.1001/jama.2018.16501

401. Luo D, Cheng Y, Zhang H, Ba M, Chen P, Li H, et al. association between high blood pressure and long term cardiovascular events in young adults:systematic review and meta-analysis. BMJ. 2020;370:m3222. https://doi.org/10.1136/bmj.m3222

402. Розанов В Б, Александров А А, Перова Н В и др. Первичная профилактика сердечно-сосудистых заболеваний, отдаленные результаты пятилетнего профилактического вмешательства у мальчиков 12-летнего возраста (десятилетнее проспективное исследование). Кардиология. 2007;47(8):60-68.

403. Derington CG, King JB, Bryant KB, McGee BT, Moran aE, Weintraub WS, et al. Cost-effectiveness and challenges of implementing intensive blood pressure goals and team-based care. Curr Hypertens Rep. 2019;21:91. https://doi.org/10.1007/s11906-019-0996-x

404. Lee H, Yano Y, Cho SMJ, Park JH, Park S, Lloyd-Jones DM, et al. Cardiovascular risk of isolated systolic or diastolic hypertension in young adults. Circulation. 2020;141:1778-1786. https://doi.org/10.1161/circulationaha.119.044838

405. Mancia G, facchetti R, Bombelli M, Grassi G, Sega R. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension. 2006;47(5):846-853. https://doi.org/10.1161/01.HYP.0000215363.69793.bb

406. Beckett N, Peters R, Leonetti G, et al. Subgroup and per-protocol analyses from the Hypertension in the Very Elderly Trial. J Hypertens. 2014;32(7):1478-1487. https://doi.org/10.1097/HJH.0000000000000195

407. Insua JT, Sacks HS, Lau TS, et al. Drug treatment of hypertension in the elderly: a meta-analysis. ann Intern Med. 1994;121(5):355-362. https://doi.org/10.7326/0003-4819-121-5-199409010-00008

408. Blood Pressure Lowering Treatment Trialists' Collaboration, Turnbull f, Neal B, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008;336(7653):1121-1123. https://doi.org/10.1136/bmj.39548.738368.BE

409. Thomopoulos C, Brguljan J, C?fkova R, Persu a, Kreutz R. Mild chronic hypertension in pregnancy: to treat or wait? [formula: see text]. Blood Press 2022;31:121-124. https://doi.org/10.1080/08037051.2022.2077698

410. Laura a Magee, Mark a Brown, David R Hall, Sanjay Gupte, et al. The Hypertensive Disorders of Pregnancy: The 2021 International Society forthe Study of Hypertesion in Pregnancy Classification, Diagnosis & Manage?ment Recommendations for International Practice. Pregnancy Hypertension: an International Journal of Women's Cardiovascular Health (2021), https://doi.org/10.1016/j.preghy.2021.09.008

411. Стрюк Р.И., Бунин Ю.А., Гурьева В.М., Иртюга О.Б., и др. Диагностика и лечение сердечно-сосудистых заболеваний при беременности 2018. Национальные рекомендации. Российский кардиологический журнал. 2018;23(7):156-200. https://doi.org/10.15829/1560-4071-2018-7-156-200

412. Brown Ma, Magee La, Kenny LC, Karumanchi Sa, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens 2018;13:291-310. https://doi.org/10.1016/j.preghy.2018.05.004

413. Преэклампсия. Эклампсия. Отеки, протеинурия и гипертензивные расстройства во время беременности, в родах и послеродовом периоде. Клинические рекомендации РОАГ (протокол лечения), Москва 2021 https://roag-portal.ru/recommendations_obstetrics

414. Duley L, Henderson-Smart D, Meher S. altered dietary salt for preventing pre-eclampsia, and its complications. Cochrane Database Syst Rev. 2005 Oct 19;2005(4):CD005548. https://doi.org/10.1002/14651858.cd005548

415. Webster K, fishburn S, Maresh M, findlay SC, Chappell LC. Guideline Committee. Diagnosis and management of hypertension in pregnancy: summary of updated NICE guidance. BMJ. 2019; 366:l5119. https://doi.org/10.1136/bmj.l5119

416. Garovic VD, Dechend R, Easterling T, Karumanchi Sa, et al. Hypertension in Pregnancy: Diagnosis, Blood Pressure Goals and Pharmacotherapy: a Scientific Statement from the american Heart association. Hypertension. 2022 feb;79(2):e21-e41. https://doi.org/10.1161/HYP.0000000000000208

417. Whelan a, Izewski J, Berkelhammer C, Walloch J, Kay HH. Labetalol-Induced Hepatotoxicity during Pregnancy: a Case Report. aJP Rep. 2020;10:e210-e212. https://doi.org/10.1055/s-0040-1713789

418. Podymow T, august P. Update on the use of antihypertensive drugs in pregnancy. Hypertension (Dallas, Tex: 1979). 2008;51:960-969. https://doi.org/10.1161/hypertensionaha.106.075895

419. Mannisto T, Mendola P, Vaarasmaki M, Jarvelin MR, Hartikainen aL, Pouta a, et al. Elevated blood pressure in pregnancy and subsequent chronic disease risk. Circulation. 2013;127:681-690. https://doi.org/10.1161/circulationaha.112.128751

420. Tepper NK, Curtis KM, Steenland MW, Marchbanks Pa. Blood pressure measurement prior to initiating hormonal contraception: a systematic review. Contraception 2013;87:631-638. https://doi.org/10.1016/j.contraception.2012.08.025

421. Curtis KM, Jatlaoui TC, Tepper NK, Zapata LB, Horton LG, Jamieson DJ, et al. US Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Recomm Rep. 2016; 65:1-66. https://doi.org/10.15585/mmwr.rr6504a1

422. Mosca L, Benjamin EJ, Berra K, Bezanson JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women – 2011 update: a guideline from the american heart association. Circulation. 2011;123:1243-1262. https://doi.org/10.1161/cir.0b013e31820faaf8

423. academic Committee of the Korean Society of Menopause; Lee SR, Cho MK, Cho YJ, Chun S, Hong SH, Hwang KR, Jeon GH, Joo JK, Kim SK, Lee DO, Lee DY, Lee ES, Song JY, Yi KW, Yun BH, Shin JH, Chae HD, Kim T. The 2020 Menopausal Hormone Therapy Guidelines. J Menopausal Med. 2020 aug;26(2):69-98. PMID: 32893509; PMCID: PMC7475284. https://doi.org/10.6118/jmm.20000

424. Thomopoulos C, Salamalekis G, Kintis K, andrianopoulou I, Michalopoulou H, Skalis G, et al. Risk of hypertensive disorders in pregnancy following assisted reproductive technology: overview and meta-analysis. J Clin Hypertens (Greenwich). 2017;19:173-183. https://doi.org/10.1111/jch.12945

425. Okunogbe a, Nugent R, Spencer G, Powis J, Ralston J, Wilding J. Economic impacts of overweight and obesity: current and future estimates for 161 countries. BMJ Glob Health. 2022 Sep;7(9):e009773. PMID: 36130777; PMCID: PMC9494015. https://doi.org/10.1136/bmjgh-2022-009773

426. Шальнова С.А., Деев А.Д., Баланова Ю.А., и др. Двадцатилетние тренды ожирения и артериальной гипертонии и их ассоциации в России. Кардиоваскулярная терапия и профилактика. 2017;16(4):4-10. https://doi.org/10.15829/1728-8800-2017-4-4-10

427. Баланова Ю.А., Шальнова С.А., Деев А.Д., Имаева А.Э., и соавт. Ожирение в российской популяции – распространенность и ассоциации с факторами риска хронических неинфекционных заболеваний. Российский кардиологический журнал. 2018;(6):123-130. https://doi.org/10.15829/1560-4071-2018-6-123-130

428. Palatini P, Saladini f, Mos L, Benetti E, Bortolazzi a, Cozzio S, Casiglia E. Obesity is a strong determinant of hypertensive target organ damage in young-to-middle-age patients. Int J Obes (Lond). 2013 feb;37(2):224-9. Epub 2012 Mar 6. PMID: 22391882. https://doi.org/10.1038/ijo.2012.32

429. Lipski D, Marzy?ska D, Sytek P, Rzeso? P, Rabiza a, ?urek S, Radziemski a, Stryczy?ski ?, Tykarski a, Uruski P. Obesity in Hypertensive Patients Is Characterized by a Dawn Phenomenon in Systolic Blood Pressure Values and Variability. Journal of Clinical Medicine. 2024;13(2):371. https://doi.org/10.3390/jcm13020371

430. McMurray JJ, Holman RR, Haffner SM, Bethel Ma, Holzhauer B, Hua Ta, et al. Effect of valsartan on the incidence of diabetes and cardiovascular events. N Engl J Med. 2010;362:1477-1490. https://doi.org/10.1056/nejmoa1001121

431. Bosch J, Yusuf S, Gerstein HC, Pogue J, Sheridan P, Dagenais G, et al. Effect of ramipril on the incidence of diabetes. N Engl J Med. 2006;355:1551-1562. https://doi.org/10.1056/nejmoa065061

432. Sharma aM, Pischon T, Hardt S, Kunz I, Luft fC. Hypothesis: Beta-adrenergic receptor blockers and weight gain: a systematic analysis. Hypertension (Dallas, Tex: 1979). 2001; 37:250-254. https://doi.org/10.1161/01.hyp.37.2.250

433. Bakris GL, fonseca V, Katholi RE, McGill JB, Messerli fH, Phillips Ra, et al. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. JaMa. 2004;292:2227-2236. https://doi.org/10.1001/jama.292.18.2227

434. Agabiti Rosei E, Rizzoni D. Metabolic profile of nebivolol, a beta-adrenoceptor antagonist with unique characteristics. Drugs 2007;67:1097-1107. https://doi.org/10.2165/00003495-200767080-00001

435. Reisin E, Graves J, Yamal JM, Barzilay JI, Pressel S, Einhorn PT, et al. Blood pressure control and cardiovascular outcomes in normal, overweight, and obese hypertensives treated with three different anti-hypertensives in aLLHaT. J Hypertens. 2014;32:1503-1513. https://doi.org/10.1097/hjh.0000000000000204

436. Rocchini aP, Key J, Bondie D, Chico R, Moorehead C, Katch V, et al. The effect of weight loss on the sensitivity of blood pressure to sodium in obese adolescents. N Engl J Med. 1989;321:580-585. https://doi.org/10.1056/nejm198908313210905

437. Grassi G, Seravalle G, Dell’Oro R, Turri C, Bolla GB, Mancia G. adrenergic and reflex abnormalities in obesityrelated hypertension. Hypertension (Dallas, Tex: 1979) 2000;36:538-542. https://doi.org/10.1161/01.hyp.36.4.538

438. Weber Ma, Jamerson K, Bakris GL, Weir MR, Zappe D, Zhang Y, et al. Effects of body size and hypertension treatments on cardiovascular event rates: subanalysis of the aCCOMPLISH randomised controlled trial. Lancet. 2013;381:537-545. https://doi.org/10.1016/s0140-6736(12)61343-9

439. Jordan J, Engeli S, Boye SW, Le Breton S, Keefe DL. Direct Renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension (Dallas, Tex: 1979) 2007;49:1047-1055. https://doi.org/10.1161/hypertensionaha.106.084301

440. Jordan J, Stinkens R, Jax T, Engeli S, Blaak EE, May M, et al. Improved Insulin Sensitivity With angiotensin Receptor Neprilysin Inhibition in Individuals With Obesity and Hypertension. Clin Pharmacol Ther. 2017;101:254-263. https://doi.org/10.1002/cpt.455

441. Клинические рекомендации – Ожирение – 2020 (17.02.2021).

442. Российское медицинское общество по артериальной гипертонии. Рекомендации по ведению больных артериальной гипертонией с метаболическими нарушениями и сахарным диабетом 2-го типа. Системные гипертензии. 2020;17(1):7-45. https://doi.org/10.26442/2075082X.2020.1.200051

443. Zomer E, Gurusamy K, Leach R, Trimmer C, Lobstein T, Morris S, et al. Interventions that cause weight loss and the impact on cardiovascular risk factors: a systematic review and meta-analysis. Obes Rev. 2016;17:1001-1011. https://doi.org/10.1111/obr.12433

444. Siebenhofer a, Winterholer S, Jeitler K, Horvath K, et al. Long-term effects of weight-reducing drugs in people with hypertension. Cochrane Database Syst Rev. 2021;1:Cd007654. https://doi.org/10.1002/14651858.cd007654.pub5

445. Maloney a, Rosenstock J, fonseca V. a model-based meta-analysis of 24 antihyperglycemic drugs for type 2 diabetes: comparison of treatment effects at therapeutic doses. Clin Pharmacol Ther. 2019;105:1213-1223. https://doi.org/10.1002/cpt.1307

446. Knowler WC, Barrett-Connor E, fowler SE, Hamman Rf, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403. https://doi.org/10.1056/nejmoa012512

447. Sjostrom L, Peltonen M, Jacobson P, Sjostrom CD, et al. Bariatric surgery and long-term cardiovascular events. JaMa. 2012;307:56-65. https://doi.org/10.1001/jama.2011.1914

448. Wiggins T, Guidozzi N, Welbourn R, ahmed aR, Markar SR. association of bariatric surgery with all-cause mortality and incidence of obesity-related disease at a population level: a systematic review and metaanalysis. PLoS Med 2020;17:e1003206. https://doi.org/10.1371/journal.pmed.1003206

449. Schiavon Ca, Bhatt DL, Ikeoka D, Santucci EV, et al. Three-Year Outcomes of Bariatric Surgery in Patients With Obesity and Hypertension: a Randomized Clinical Trial. ann Intern Med 2020;173:685-693. https://doi.org/10.7326/m19-3781

450. Sj?str?m L, Lindroos aK, Peltonen M, Torgerson J, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004;351:2683-2693. https://doi.org/10.1056/nejmoa035622

451. Sun H, Saeedi P, Karuranga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDf Diabetes atlas: global, regional and country-level diabetes prevalence estimates for2021 and projections for 2045. Diabetes Res Clin Pract 2022;183:109119. https://doi.org/10.1016/j.diabres.2021.109119

452. Жернакова Ю.В., Азимова М.О., Железнова Е.А., и др. Оценка распространенности поражения органов-мишеней на различных этапах кардиометаболического континуума. По данным исследования ЭССЕ РФ. Системные гипертензии. 2022;19(3):31-39. https://doi.org/10.38109/2075-082X-2022-3-31-39

453. Жернакова Ю.В., Чазова И.Е., Ощепкова Е.В. и др. Распространенность сахарного диабета в популяции больных артериальной гипертонией. По данным исследования ЭССЕ-РФ. Системные гипертензии. 2018;15(1):56-62. https://doi.org/10.26442/2075-082X_15.1.56-62

454. Grassi G, Biffi a, Dell’Oro R, Quarti Trevano f, Seravalle G, Corrao G, et al. Sympathetic neural abnormalities in type 1 and type 2 diabetes: a systematic review and meta-analysis. J Hypertens. 2020;38:1436-1442. https://doi.org/10.1097/hjh.0000000000002431

455. Jia G, Sowers JR. Hypertension in diabetes: an update of basic mechanisms and clinical disease. Hypertension (Dallas, Tex: 1979) 2021;78:1197-1205. https://doi.org/10.1161/hypertensionaha.121.17981

456. Olivares-Reyes Ja, arellano-Plancarte a, Castillo-Hernandez JR. angiotensin II and the development of insulin resistance: implications for diabetes. Mol Cell Endocrinol. 2009 apr 29;302(2):128-39. Epub 2008 Dec 25. PMID: 19150387. https://doi.org/10.1016/j.mce.2008.12.011

457. Defronzo Ra, ferrannini E, Groop L, Henry RR, Herman WH, Holst JJ, et al. Type 2 diabetes mellitus. Nat Rev Dis Primers 2015;1:15019. https://doi.org/10.1038/nrdp.2015.19

458. Narkiewicz K, Kjeldsen SE, Egan BM, Kreutz R, Burnier M. Masked hypertension in type 2 diabetes: never take normotension for granted and always assess out-of-office blood pressure. Blood Press 2022;31:207-209. https://doi.org/10.1080/08037051.2022.2107483

459. Sarwar N, Gao P, Seshasai SR. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375(9733):2215-22. https://doi.org/10.1016/s0140-6736(10)60484-9

460. Sur G, Sur M, Kudor-Szabadi L et al. arterial hypertension – prevalence of risk factors and morbid associations that increase cardiovascular risk. Maedica (Buchar). 2010;5(1):34-40. PMID: 21977116 PMCID: PMC3150077.

461. Joseph JJ, Deedwania P, acharya T, aguilar D, Bhatt DL, Chyun Da, et al. Comprehensive Management of Cardiovascular Risk factors for adults With Type 2 Diabetes: a Scientific Statement from the american Heart association. Circulation. 2022;145:e722-e759. https://doi.org/10.1161/cir.0000000000001040

462. Brunstrom M, Carlberg B. Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ. 2016;352:i717. https://doi.org/10.1136/bmj.i717

463. Thomopoulos C, Parati G, Zanchetti a. Effects of blood-pressure-lowering treatment on outcome incidence in hypertension: 10 – Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials.J Hypertens. 2017;35:922-944. https://doi.org/10.1097/hjh.0000000000001276

464. Niskanen L, Hedner T, Hansson L, Lanke J, Niklason a; CaPPP Study Group. Reduced cardiovascular morbidity and mortality in hypertensive diabetic patients on first-line therapy with an aCE inhibitor compared with a diuretic/?-blocker–based treatment regimen: a subanalysis of the Captopril Prevention Project. Diabetes Care 2001;24:2091-2096. https://doi.org/10.2337/diacare.24.12.2091

465. Emdin Ca, Rahimi K, Neal B, Callender T, Perkovic V, Patel a. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JaMa. 2015;313:603-615. https://doi.org/10.1001/jama.2014.18574

466. Margolis KL, O’Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the aCCORD randomized trial. Diabetes Care 2014;37:1721-1728. https://doi.org/10.2337/dc13-2334

467. Buckley Lf, Dixon DL, Wohlford Gft, Wijesinghe DS, Baker WL, Van Tassell BW. Intensive Versus Standard Blood Pressure Control in SPRINTEligible Participants of aCCORD-BP. Diabetes Care 2017;40:1733-1738. https://doi.org/10.2337/dc17-1366

468. Olsen E, Holzhauer B, Julius S, Kjeldsen SE, Larstorp aCK, Mancia G, et al. Cardiovascular outcomes at recommended blood pressure targets in middle-aged and elderly patients with type 2 diabetes mellitus and hypertension. Blood Press 2021;30:82-89. https://doi.org/10.1080/08037051.2020.1855968

469. Holman RR, Paul SK, Bethel Ma, Neil Ha, Matthews DR. Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med. 2008 Oct 9;359(15):1565-76. Epub 2008 Sep 10. PMID:18784091. https://doi.org/10.1056/NEJMoa0806359

470. Lindholm LH, Ibsen H, Dahl?f B, Devereux RB, Beevers G, de faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention for Endpoint reduction in hypertension study (LIfE): a randomised trial against atenolol. Lancet. 2002;359:1004-1010. https://doi.org/10.1016/S0140-6736(02)08090-X

471. ?stergren J, Poulter NR, Sever PS, Dahl?f B, Wedel H, Beevers G, et al. The anglo-Scandinavian Cardiac Outcomes Trial: blood pressure-lowering limb: effects in patients with type II diabetes. J Hypertension 2008;26:2103-2111. https://doi.org/10.1097/HJH.0b013e328310e0d9

472. Weber Ma, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, et al. Cardiovascular events during differing hypertension therapies in patients with diabetes. J am College Cardiol 2010;56:77-85. https://doi.org/10.1016/j.jacc.2010.02.046

473. Shen J, Huang YM, Song XN, Hong XZ, Wang M, Ling W, et al. Protection against death and renal failure by renin-angiotensin system blockers in patients with diabetes and kidney disease. J Renin angiotensin aldosterone Syst. 2016 Jul 3;17(3):1470320316656481. https://doi.org/10.1177/1470320316656481

474. Caruso I, Cignarelli a, Sorice GP, Natalicchio a, Perrini S, Laviola L, et al. Cardiovascular and Renal Effectiveness of GLP-1 Receptor agonists vs. Other Glucose-Lowering Drugs in Type 2 Diabetes: a Systematic Review and Meta- analysis of Real-World Studies. Metabolites. 2022 feb 15;12(2):183. https://doi.org/10.3390/metabo12020183

475. Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788-1801. https://doi.org/10.1016/S0140-6736(22)02074-8

476. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. The New England Journal of Medicine 2017;377:644-657. https://doi.org/10.1056/nejmoa1611925

477. Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. The New England Journal of Medicine 2019;380:2295-2306. https://doi.org/10.1056/nejmoa1811744

478. O’Seaghdha CM, Perkovic V, Lam TH, McGinn S, Barzi f, Gu Df, et al. Blood pressure is a major risk factor for renal death. Hypertension. 2009;54:509-515. https://doi.org/10.1161/hypertensionaha.108.128413

479. Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S. Blood pressure predicts risk of developing endstage renal disease in men and women. Hypertension 2003;41:1341-1345. https://doi.org/10.1161/01.hyp.0000069699.92349.8c

480. Cheung aK, Chang TI, Cushman WC, furth SL, Hou ff, Ix JH, et al. KDIGO 2021 Clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2021;99:S1-S87. https://doi.org/10.1016/j.kint.2020.11.003

481. Чазова И.Е., Кисляк О.А., Подзолков В.И., Брагина А.Е., Сивакова О.А., Солнцева Т.Д., Елфимова Е.М., Валиева З.С., Фомин В.В., Миронова О.Ю. Артериальная гипертензия и хроническая болезнь почек: консенсус по ведению пациентов. Системные гипертензии. 2023;20(1):5-19. https://doi.org/10.38109/2075-082X-2023-1-5-19

482. Cheung aK, Rahman M, Reboussin DM, Craven TE, Greene T, Kimmel PL, et al. Effects of intensive BP control in CKD. J am Soc Nephrol. 2017;28:2812-23. https://doi.org/10.1681/asn.2017020148

483. Tomson CR, Cheung aK, Mann Jf, Chang TI, Cushman WC, furth SL, et al. Management of blood pressure in patients with chronic kidney disease not receiving dialysis: synopsis of the 2021 KDIGO clinical practice guideline. ann Intern Med. 2021;174:1270-81. https://doi.org/10.7326/m21-0834

484. Hung SC, Kuo KL, Peng CH, Wu CH, Lien YC, Wang YC, et al. Volume overload correlates with cardiovascular risk factors in patients with chronic kidney disease. Kidney Int 2014;85:703-709. https://doi.org/10.1038/ki.2013.336

485. McMahon EJ, Bauer JD, Hawley CM, Isbel NM, Stowasser M, Johnson DW, et al. a randomized trial of dietary sodium restriction in CKD. J am Soc Nephrol 2013;24:2096-2103. https://doi.org/10.1681/asn.2013030285

486. Stevens, P.E., ahmed, S.B., Carrero, J.J., foster, B., francis, a., Hall, R.K., Herrington, W.G., Hill, G., Inker, L.a., Kazanc?o?lu, R. and Lamb, E. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney international. 2024 apr;105(4S):S117-S314. https://doi.org/10.1016/j.kint.2023.10.018

487. Sarafidis Pa, Persu a, agarwal R, Burnier M, de Leeuw P, ferro CJ, et al. Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECa-m) working group of the European Renal association–European Dialysis and Transplant association (ERa-EDTa) and the hypertension and the kidney working group of the European Society of Hypertension (ESH). Nephrol Dial Transplant. 2017;32:620-640. https://doi.org/10.1093/ndt/gfw433

488. Sarafidis Pa, Blacklock R, Wood E, Rumjon a, Simmonds S, fletcher-Rogers J, et al. Prevalence and factors associated with hyperkalemia in predialysis patients followed in a low-clearance clinic. Clinical journal of the american Society of Nephrology: CJaSN. 2012;7:1234-1241. https://doi.org/10.2215/cjn.01150112

489. Einhorn LM, Zhan M, Hsu VD, Walker LD, Moen Mf, Seliger SL, et al. The frequency of hyperkalemia and its significance in chronic kidney disease. archives of Internal Medicine. 2009;169:1156-1162. https://doi.org/10.1001/archinternmed.2009.132

490. Yildirim T, arici M, Piskinpasa S, aybal-Kutlugun a, Yilmaz R, altun B, et al. Major barriers against reninangiotensin-aldosterone system blocker use in chronic kidney disease stages 3-5 in clinical practice: a safety concern? Ren fail. 2012;34:1095-1099. https://doi.org/10.3109/0886022x.2012.717478

491. Walther CP, Winkelmayer WC, Richardson Pa, Virani SS, Navaneethan SD. Renin-angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease. Nephrol Dial Transplant. 2021;36:1893-1899. https://doi.org/10.1093/ndt/gfaa300

492. Yang a, Shi M, Lau ESH, Wu H, Zhang X, fan B, et al. Clinical outcomes following discontinuation of reninangiotensin-system inhibitors in patients with type 2 diabetes and advanced chronic kidney disease: a prospective cohort study. EClinicalMedicine. 2023;55:101751. https://doi.org/10.1016/j.eclinm.2022.101751

493. Bakris GL, Pitt B, Weir MR, freeman MW, Mayo MR, Garza D, et al. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The aMETHYST-DN Randomized Clinical Trial. JaMa. 2015;314:151-161. https://doi.org/10.1001/jama.2015.7446

494. Roger SD, Spinowitz BS, Lerma EV, Singh B, Packham DK, al-Shurbaji a, et al. Efficacy and Safety of Sodium Zirconium Cyclosilicate for Treatment of Hyperkalemia: an 11-Month Open-Label Extension of HaRMONIZE. am J Nephrol. 2019;50:473-480. https://doi.org/10.1159/000504078

495. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl Ma, Lewis JB, et al. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. The New England Journal of Medicine 2001;345:851-860. https://doi.org/10.1056/nejmoa011303

496. adler aI, Stratton IM, Neil Ha, Yudkin JS, Matthews DR, Cull Ca, et al. association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. (Clinical research ed) 2000;321:412-419. https://doi.org/10.1136/bmj.321.7258.412

497. Bakris GL, Sarafidis Pa, Weir MR, Dahlof B, Pitt B, Jamerson K, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (aCCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet. 2010;375:1173-1181. https://doi.org/10.1016/s0140-6736(09)62100-0

498. Imprialos KP, Sarafidis Pa, Karagiannis aI. Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class? Journal of Hypertension. 2015;33:2185-2197. https://doi.org/10.1097/hjh.0000000000000719

499. Ruilope LM, agarwal R, anker SD, filippatos G, Pitt B, Rossing P, et al. Blood Pressure and Cardiorenal Outcomes With finerenone in Chronic Kidney Disease in Type 2 Diabetes. Hypertension (Dallas, Tex: 1979). 2022;79:2685- 2695. https://doi.org/10.1161/hypertensionaha.122.19744

500. Bakris GL, agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JaMa. 2015;314:884-894. https://doi.org/10.1001/jama.2015.10081

501. Rossing P, filippatos G, agarwal R, anker SD, Pitt B, Ruilope LM, Chan JC, Kooy a, McCafferty K, Schernthaner G, Wanner C. finerenone in predominantly advanced CKD and type 2 diabetes with or without sodium- glucose cotransporter-2 inhibitor therapy. Kidney international reports. 2022 Jan 1;7(1):36-45. https://doi.org/10.1016/j.ekir.2021.10.008

502. Ruilope LM, Pitt B, anker SD, Rossing P, Kovesdy CP, Pecoits-filho R, Pergola P, Joseph a, Lage a, Mentenich N, Scheerer Mf. Kidney outcomes with finerenone: an analysis from the fIGaRO-DKD study. Nephrology Dialysis Transplantation. 2023 feb;38(2):372-83. https://doi.org/10.1093/ndt/gfac157

503. Filippatos G, anker SD, august P, Coats aJS, Januzzi JL, Mankovsky B, et al. finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a fIDELITY analysis. Eur Heart J Cardiovasc Pharmacother 2023;9:183-191. https://doi.org/10.1093/ehjcvp/pvad001

504. Чазова И.Е., Жернакова Ю.В., Кисляк О.А., и соавт. Консенсус по ведению пациентов с гиперурикемией и высоким сердечно-сосудистым риском: 2022. Системные гипертензии. 2022;19(1):5-22. https://doi.org/10.38109/2075-082X-2022-1-5-22

505. Hansildaar R, Vedder D, Baniaamam M, et al. Cardiovascular risk in inflammatory arthritis: rheumatoid arthritis and gout. Lancet. Rheumatol. 2021;3(1):e58-e70. https://doi.org/10.1016/S2665-9913(20)30221-6

506. Миронова О.Ю. Гиперурикемия и поражение почек у пациентов с сердечно-сосудистыми заболеваниями. Терапевтический архив. 2022;94(12):1426-1430. https://doi.org/10.26442/00403660.2022.12.201999

507. Миронова О.Ю., Лакотка П.Г., Фомин В.В. Гиперурикемия как фактор риска контраст-индуцированного острого повреждения почек. Consilium Medicum. 2021;23(1):25-27. https://doi.org/10.26442/20751753.2021.1.200572.

508. Bombelli M, Ronchi I, Volpe M, et al. Prognostic value of serum uric acid: new-onset in and out-of-office hypertension and long-term mortality. J Hypertens. 2014;32(6):1237-1244. https://doi.org/10.1097/HJH.0000000000000161

509. Cicero af, Salvi P, D'addato S, et al.; Brisighella Heart Study group. association between serum uric acid, hypertension, vascular stiffness and subclinical atherosclerosis: data from the Brisighella Heart Study. J Hypertens. 2014;32(1):57-64. https://doi.org/10.1097/HJH.0b013e328365b916

510. Ndrepepa G. Uric acid and cardiovascular disease. Clin Chim acta. 2018;484:150-163. https://doi.org/10.1016/j.cca.2018.05.046

511. Niskanen LK, Laaksonen DE, Nyyss?nen K, et al. Uric acid level as a risk factor for cardiovascular and all-cause mortality in middle-aged men: a prospective cohort study. arch Intern Med. 2004;164(14):1546-1551. https://doi.org/10.1001/archinte.164.14.1546

512. Drosos GC, Vedder D, Houben E, et al. EULaR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. ann Rheum Dis. 2022;81(6):768-779. https://doi.org/10.1136/annrheumdis-2021-221733

513. Agarwal V, Hans N, Messerli fH. Effect of allopurinol on blood pressure: a systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2013;15(6):435-442. https://doi.org/10.1111/j.1751-7176.2012.00701.x

514. Gill D, Cameron aC, Burgess S, et al. Urate, Blood Pressure, and Cardiovascular Disease: Evidence from Mendelian Randomization and Meta-analysis of Clinical Trials. Hypertension. 2021;77(2):383-392. https://doi.org/10.1161/HYPERTENSIONaHa.120.16547

515. Cebollada J, Buisan C. Therapeutic role of colchicine in reducing cardiovascular risk associated with inflammation. Endocrinol Diabetes Nutr (Engl Ed). 2022;69(8):551-553. https://doi.org/10.1016/j.endien.2022.09.001

516. Deftereos SG, Beerkens fJ, Shah B, et al. Colchicine in Cardiovascular Disease: In-Depth Review. Circulation. 2022;145(1):61-78. https://doi.org/10.1161/CIRCULaTIONaHa.121.056171

517. Borghi C, agabiti-Rosei E, Johnson RJ, et al. Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease. Eur J Intern Med. 2020;80:1-11. https://doi.org/10.1016/j.ejim.2020.07.006

518. Choi HK, Soriano LC, Zhang Y, et al. antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ. 2012 Jan 12;344:d8190. https://doi.org/10.1136/bmj.d8190

519. H?ieggen a, alderman MH, Kjeldsen SE, et al. The impact of serum uric acid on cardiovascular outcomes in the LIfE study. Kidney Int. 2004;65(3):1041-1049. https://doi.org/10.1111/j.1523-1755.2004.00484.x

520. Чазова И.Е., Солнцева Т.Д., Сивакова О.А., и соавт. Консенсус экспертов Российского медицинского общества по артериальной гипертонии. Артериальная гипертония и приверженность к антигипертензивной терапии. Системные гипертензии. 2024;21(2):7-17. https://doi.org/10.38109/2075-082X-2024-2-5-15

521. Чазова И.Е., Невзорова В.А., Амбатьелло Л.Г. с соавт. Клинические рекомендации по диагностике и лечению пациентов с артериальной гипертонией и хронической обструктивной болезнью легких. Системные гипертензии. 2020;17(3):7-34. https://doi.org/10.26442/2075082X.2020.3.200294

522. Christiansen SC, Zuraw BL. Treatment of Hypertension in Patients with asthma. N Engl J Med. 2019;381:1046- 1057. https://doi.org/10.1056/NEJMra1800345

523. Ferguson S, Teodorescu MC, Gangnon RE et al. factors associated with systemic hypertension in asthma. Lung. 2014;192:675-683. https://doi.org/10.1007/s00408-014-9600-y

524. Климова АА, Амбатьелло ЛГ, Смолякова ЕВ с соавт. Частота выявления сочетанной бронхообструктивной патологии у пациентов с артериальной гипертонией, поступающих в специализированный кардиологический стационар. Системные гипертензии. 2023;20(1):35-43. https://doi.org/10.38109/2075-082X-2023-1-35-43

525. Верткин А.Л., Скотников А.С., Тихоновская Е.Ю. с соавт. Коморбидность при ХОБЛ: роль хронического системного воспаления. РМЖ. Медицинское обозрение. 2014;22(11):811-816.

526. Ryan S, Taylor CT, McNicholas WT. Systemic inflammation: a key factor in the pathogenesis of cardiovascular complications in obstructive sleep apnoea syndrome? Thorax. 2009;64:631-636. https://doi.org/10.1136/thx.2008.105577

527. 8. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised. 2019. http://www.goldcopd.com

528. Divo M, Cote C, de Torres JP et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. am J Respir Crit Care Med 2012;186(2):155-61. https://doi.org/10.1164/rccm.201201-0034oc

529. Finks SW, Rumbak MJ, Self TH. Treating Hypertension in Chronic Obstructive Pulmonary Disease. N Engl J Med. 2020;382:353-363. https://doi.org/10.1056/nejmra1805377

530. Чазова И.Е., Лазарева Н.В., Ощепкова Е.В. Артериальная гипертония и хроническая обструктивная болезнь легких: клиническая характеристика и эффективность лечения (по данным национального регистра артериальной гипертонии). 2019;91(3):4-10. https://doi.org/10.26442/00403660.2019.03.000110

531. Клинические рекомендации – Хроническая обструктивная болезнь легких (ХОБЛ) – 2021-2022-2023 (23.06.2021) – Утверждены Минздравом РФ.

532. Чучалин А.Г., Авдеев С.Н., Айсанов З.Р. и соавт. Бронхиальная астма: федеральные клинические рекомендации по диагностике и лечению. Пульмонология. 2022;32(3):393-447. https://doi.org/10.18093/0869-0189-2022-32-3-393-447

533. Singh D, agusti a, anzueto a, et al. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: the GOLD science committee report 2019. Eur Respir J. 2019 May 18;53(5):1900164. PMID: 30846476. https://doi.org/10.1183/13993003.00164-2019

534. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. a review of the literature and pathophysiology. ann Intern Med. 1992;117(3):234-42. https://doi.org/10.7326/0003-4819-117-3-234

535. Brooks TW, Creekmore fM, Young DC et al. Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers. Pharmacotherapy. 2007;27:684-690 https://doi.org/10.1592/phco.27.5.684

536. Mortensen EM, Copeland La, Pugh MJV, et al. Impact of statins and aCE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45. https://doi.org/10.1186/1465-9921-10-45

537. Kanazawa H, Hirata K, Yoshikawa J. Effects of captopril administration on pulmonary haemodynamics and tissue oxygenation during exercise in aCE gene subtypes in patients with COPD: a preliminary study. Thorax. 2003;58(7):629-31 https://doi.org/10.1136/thorax.58.7.629

538. Mancini GB, Etminan M, Zhang B et al. Reduction of morbidity and mortality by statins, angiotensinconverting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J am Coll Cardiol. 2006;47(12):2554-60. https://doi.org/10.1016/j.jacc.2006.04.039

539. Gali? N, McLaughlin VV, Rubin LJ, Simonneau G. an overview of the 6th World Symposium on Pulmonary Hypertension. Eur Respir J. 2019 Jan 24;53(1):1802148. https://doi.org/10.1183/13993003.02148-2018

540. Yilmaz E, Canberk a, Ero?lu L. Nifedipine alters serum theophylline levels in asthmatic patients with hypertension. fund Clin Pharmacol. 1991;5(4):341-5. https://doi.org/10.1111/j.1472-8206.1991.tb00728.x

541. Bear R, Goldstein M, Phillipson E et al. Effect of metabolic alkalosis on respiratory function in patients with chronic obstructive lung disease. Can Med assoc J. 1977 Oct 22;117(8):900-3. PMID: 21028. PMCID: PMC1880127.

542. Yang YL, Xiang ZJ, Yang JH, Wang WJ, Xu ZC, Xiang RL. association of b-blocker use with survival and pulmonary function in patients with chronic obstructive pulmonary and cardiovascular disease: a systematic review and meta-analysis. Eur Heart J 2020;41:4415-4422. https://doi.org/10.1093/eurheartj/ehaa793

543. 26. Sharafkhaneh a, Majid H, Gross NJ. Safety and tolerability of inhalational anticholinergics in COPD. Drug Healthc Patient Saf. 2013;5:49-55. https://doi.org/10.2147/DHPS.S7771

544. Yang Ia, Clarke MS, Sim EHa, fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2012;7:CD002 https://doi.org/10.1002/14651858.CD002991.pub3

545. Faessel H, Ravva P, Williams K. Pharmacokinetics, safety, and tolerability of varenicline in healthy adolescent smokers: a multicenter, randomized, double-blind, placebocontrolled, parallel-group study. Clin Ther. 2009;31:177-89. https://doi.org/10.1016/j.clinthera.2009.01.003

546. Bennett M, Chang CL, Tatley M et al. The safety of cardioselective b(1)-blockers in asthma: literature review and search of global pharmacovigilance safety reports. ERJ. Open Res 2021;7(1):00801-2020. https://doi.org/10.1183/23120541.00801-2020

547. O’Driscoll BR, Kay Ea, Taylor RJ et al. a long-term prospective assessment of home nebulizer treatment. Respir Med. 1992;86:317-25. https://doi.org/10.1016/s0954-6111(06)80031-4

548. Приказ Министерства здравоохранения РФ от 29.03.2019 №173н «Об утверждении порядка проведения диспансерного наблюдения за взрослыми». https://www.garant.ru/products/ipo/prime/doc/72132764/

549. Razo C, Welgan Ca, Johnson CO, et al. Effects of elevated systolic blood pressure on ischemic heart disease: a Burden of Proof study. Nat Med. 2022;28(10):2056-2065. https://doi.org/10.1038/s41591-022-01974-1

550. Danaei G, Ding EL, Mozaffarian D, et al. The preventable causes of death in the United States: comparative risk assessment of dietary, lifestyle, and metabolic risk factors [published correction appears in PLoS Med. 2011 Jan;8(1). https://doi.org/10.1371/annotation/0ef47acd-9dcc-4296-a897-872d182cde57]. PLoS Med. 2009;6(4):e1000058. https://doi.org/10.1371/journal.pmed.1000058

551. Lewington S, Clarke R, Qizilbash N, et al. Prospective Studies Collaboration. age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies [published correction appears in Lancet. 2003 Mar 22;361(9362):1060]. Lancet. 2002;360(9349):1903- 1913. https://doi.org/10.1016/s0140-6736(02)11911-8

552. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335(8692):765-774. https://doi.org/10.1016/0140-6736(90)90878-9

553. Vidal-Petiot E, ford I, Greenlaw N, et al. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet. 2016;388(10056):2142-2152. https://doi.org/10.1016/S0140-6736(16)31326-5

554. Thomopoulos C, Parati G, Zanchetti a. Effects of blood-pressure-lowering treatment on outcome incidence. 12. Effects in individuals with high-normal and normal blood pressure: overview and meta-analyses of randomized trials. J Hypertens. 2017;35(11):2150-2160. https://doi.org/10.1097/HJH.0000000000001547

555. Kjeldsen SE, Berge E, Bangalore S, et al. No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VaLUE trial. Blood Press. 2016;25(2):83-92. https://doi.org/10.3109/080370 51.2015.1106750

556. Карпов Ю.А., Барбараш О.Л., Бощенко А.А., Кашталап В.В., Кухарчук В.В., Миронов В.М., Панченко Е.П., Руда М.М., Самко А.Н., Соболева Г.Н., Ширяев А.А. Евразийские клинические рекомендации по диагностике и лечению стабильной ишемической болезни сердца (2020-2021). Евразийский Кардиологический Журнал. 2021;(3):54-93. https://doi.org/10.38109/2225-1685-2021-3-54-93

557. B?hm M, Schumacher H, Teo KK, et al. achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTaRGET and TRaNSCEND trials. Eur Heart J. 2018;39(33):3105-3114. https://doi.org/10.1093/eurheartj/ehy287

558. Bangalore S, Messerli fH, Wun CC, et al. J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. Eur Heart J. 2010;31(23):2897-2908. https://doi.org/10.1093/eurheartj/ehq328

559. Okin PM, Hille Da, Kjeldsen SE, Dahl?f B, Devereux RB. Impact of lower achieved blood pressure on outcomes in hypertensive patients. J Hypertens. 2012;30(4):802-810. https://doi.org/10.1097/HJH.0b013e3283516499

560. Polese a, De Cesare N, Montorsi P, et al. Upward shift of the lower range of coronary flow autoregulation in hypertensive patients with hypertrophy of the left ventricle. Circulation. 1991;83(3):845-853. https://doi.org/10.1161/01.cir.83.3.845

561. Hwang D, Lee JM, Kim HK, et al. Prognostic Impact of ?-Blocker Dose after acute Myocardial Infarction. Circ J. 2019;83(2):410-417. https://doi.org/10.1253/circj.CJ-18-0662

562. Manolis aJ, Boden WE, Collins P, et al. State of the art approach to managing angina and ischemia: tailoring treatment to the evidence. Eur J Intern Med. 2021;92:40-47. https://doi.org/10.1016/j.ejim.2021.08.003

563. Kolloch R, Legler Uf, Champion a, et al. Impact of resting heart rate on outcomes in hypertensive patients with coronary artery disease: findings from the INternational VErapamil-SR/trandolapril STudy (INVEST). Eur Heart J. 2008;29(10):1327-1334. https://doi.org/10.1093/eurheartj/ehn123

564. Ho JE, Bittner V, Demicco Da, et al. Usefulness of heart rate at rest as a predictor of mortality, hospitalization for heart failure, myocardial infarction, and stroke in patients with stable coronary heart disease (Data from the Treating to New Targets [TNT] trial). am J Cardiol. 2010;105(7):905-911. https://doi.org/10.1016/j.amjcard.2009.11.035

565. Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, et al. Effects of an angiotensin- converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients [published correction appears in 2000 May 4;342(18):1376] [published correction appears in N Engl J Med. 2000 Mar 9;342(10):748]. N Engl J Med. 2000;342(3):145-153. https://doi.org/10.1056/NEJM200001203420301

566. Fox KM; EURopean trial On reduction of cardiac events with Perindopril in stable coronary artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPa study). Lancet. 2003;362(9386):782-788. https://doi.org/10.1016/s0140-6736(03)14286-9

567. Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. https://doi.org/10.15829/1560-4071-2020-4083

568. Терещенко С.Н., Жиров И.В., Ускач Т.М. и соавт. Клинические рекомендации Евразийской Ассоциации Кардиологов (ЕАК)/ Национального общества по изучению сердечной недостаточности и заболеваний миокарда (НОИСН) по диагностике и лечению хронической сердечной недостаточности (2024). Евразийский кардиологический журнал. Май 2024;(2):6-76. https://doi.org/10.38109/2225-1685-2024-2-6-76

569. Bozkurt B, Coats aJS, Tsutsui H, et al. Universal definition and classification of heart failure: a report of the Heart failure Society of america, Heart failure association of the European Society of Cardiology, Japanese Heart failure Society and Writing Committee of the Universal Definition of Heart failure: Endorsed by the Canadian Heart failure Society, Heart failure association of India, Cardiac Society of australia and New Zealand, and Chinese Heart failure association. Eur J Heart fail. 2021;23(3):352-380. https://doi.org/10.1002/ejhf.2115

570. Haider aW, Larson MG, franklin SS, Levy D; framingham Heart Study. Systolic blood pressure, diastolic blood pressure, and pulse pressure as predictors of risk for congestive heart failure in the framingham Heart Study. ann Intern Med. 2003;138(1):10-16. https://doi.org/10.7326/0003-4819-138-1-200301070-00006

571. McMurray JJ, Packer M, Desai aS, et al. angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004. https://doi.org/10.1056/NEJMoa1409077

572. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to congestive heart failure. JaMa. 1996;275(20):1557-62

573. Ситникова М.Ю., Лясникова Е.А., Юрченко А.В. и соавт. Результаты Российского госпитального регистра хронической сердечной недостаточности в 3 субъектах Российской Федерации. Кардиология 2015;10:5- 13. https://doi.org/10.18565/cardio.2015.10.5-13

574. Moser M, Hebert PR. Prevention of disease progression, left ventricular hypertrophy and congestive heart failure in hypertension treatment trials. J am Coll Cardiol. 1996;27(5):1214-1218. https://doi.org/10.1016/0735-1097(95)00606-0

575. Dahl?f B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering arm (aSCOT-BPLa): a multicentre randomised controlled trial. Lancet. 2005;366(9489):895-906. https://doi.org/10.1016/S0140-6736(05)67185-1

576. Adamo M, Gardner RS, McDonagh Ta, Metra M. The 'Ten Commandments' of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2022;43(6):440-441. https://doi.org/10.1093/eurheartj/ehab853

577. McMurray JJV, Jackson aM, Lam CSP, et al. Effects of Sacubitril-Valsartan Versus Valsartan in Women Compared With Men With Heart failure and Preserved Ejection fraction: Insights from PaRaGON-Hf. Circulation. 2020;141(5):338-351. https://doi.org/10.1161/CIRCULaTIONaHa.119.044491

578. Santema BT, Ouwerkerk W, Tromp J, et al. Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study. Lancet. 2019;394(10205):1254-1263. https://doi.org/10.1016/S0140-6736(19)31792-1

579. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in Patients with Heart failure and Reduced Ejection fraction. N Engl J Med. 2019;381(21):1995-2008. https://doi.org/10.1056/NEJMoa1911303

580. Packer M, anker SD, Butler J, et al. Cardiovascular and Renal Outcomes with Empagliflozin in Heart failure. N Engl J Med. 2020;383(15):1413-1424. https://doi.org/10.1056/NEJMoa2022190

581. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on aCE Inhibitor Trials [published correction appears in JaMa. 1995 aug 9;274(6):462]. JaMa. 1995;273(18):1450-1456. PMID: 7654275.

582. Schmieder RE, Rockstroh JK. Efficacy and tolerance of low-dose loop diuretics in hypertension. Cardiology. 1994;84 Suppl 2:36-42. https://doi.org/10.1159/000176455

583. Packer M, Carson P, Elkayam U, et al. Effect of amlodipine on the survival of patients with severe chronic heart failure due to a nonischemic cardiomyopathy: results of the PRaISE-2 study (prospective randomized amlodipine survival evaluation 2). JaCC Heart fail. 2013;1(4):308-314. https://doi.org/10.1016/j.jchf.2013.04.004

584. Cohn JN, Ziesche S, Smith R, et al. Effect of the calcium antagonist felodipine as supplementary vasodilator therapy in patients with chronic heart failure treated with enalapril: V-HefT III. Vasodilator-Heart failure Trial (V-HefT) Study Group. Circulation. 1997;96(3):856-863. https://doi.org/10.1161/01.cir.96.3.856

585. Kasiakogias a, Rosei Ea, Camafort M, et al. Hypertension and heart failure with preserved ejection fraction: position paper by the European Society of Hypertension. J Hypertens. 2021;39(8):1522-1545. https://doi.org/10.1097/HJH.0000000000002910

586. Kjeldsen SE, von Lueder TG, Smiseth Oa, et al. Medical Therapies for Heart failure With Preserved Ejection fraction. Hypertension. 2020;75(1):23-32. https://doi.org/10.1161/HYPERTENSIONaHa.119.14057

587. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in Heart failure with Mildly Reduced or Preserved Ejection fraction. N Engl J Med. 2022;387(12):1089-1098. https://doi.org/10.1056/NEJMoa2206286

588. Anker SD, Butler J, filippatos G, et al. Empagliflozin in Heart failure with a Preserved Ejection fraction. N Engl J Med. 2021;385(16):1451-1461. https://doi.org/10.1056/NEJMoa2107038

589. Heidenreich Pa, Bozkurt B, aguilar D, et al. 2022 aHa/aCC/HfSa Guideline for the Management of Heart failure: a Report of the american College of Cardiology/american Heart association Joint Committee on Clinical Practice Guidelines [published correction appears in Circulation. 2022 May 3;145(18):e1033. https://doi.org/10.1161/CIR.0000000000001073] [published correction appears in Circulation. 2022 Sep 27;146(13):e185. https://doi.org/10.1161/CIR.0000000000001097] [published correction appears in Circulation. 2023 apr 4;147(14):e674. https://doi.org/10.1161/CIR.0000000000001142]. Circulation. 2022;145(18):e895-e1032. https://doi.org/10.1161/CIR.0000000000001063

590. Pitt B, Pfeffer Ma, assmann Sf, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370(15):1383-1392. https://doi.org/10.1056/NEJMoa1313731

591. Taylor RS, Sagar Va, Davies EJ, et al. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev. 2014 apr 27;2014(4):CD003331. https://doi.org/10.1002/14651858.CD003331.pub4

592. January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC Jr, et al. 2019 aHa/aCC/HRS focused Update of the 2014 aHa/aCC/HRS Guideline for the Management of Patients With atrial fibrillation: a Report of the american College of Cardiology/american Heart association Task force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019;140:e125-e151. https://doi.org/10.1161/cir.0000000000000665

593. Hindricks G, Potpara T, Dagres N, arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European association for Cardio-Thoracic Surgery (EaCTS): The Task force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm association (EHRa) of the ESC. Eur Heart J. 2021;42:373-498. https://doi.org/10.1093/eurheartj/ehaa612

594. Benjamin EJ, Levy D, Vaziri SM, D'agostino RB, Belanger aJ, Wolf Pa. Independent risk factors for atrial fibrillation in a population-based cohort. The framingham Heart Study. JaMa. 1994 Mar 16;271(11):840-4. PMID: 8114238. https://doi.org/10.1001/jama.1994.03510350050036

595. Kannel WB, Wolf Pa, Benjamin EJ, Levy D. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. am J Cardiol. 1998 Oct 16;82(8a):2N-9N. https://doi.org/10.1016/s0002-9149(98)00583-9

596. Ezekowitz MD, aikens TH, Nagarakanti R, Shapiro T. atrial fibrillation: outpatient presentation and management. Circulation. 2011 Jul 5;124(1):95-9. PMID: 21730322. https://doi.org/10.1161/CIRCULaTIONaHa.110.967455

597. Shkolnikova Ma, Jdanov Da, Ildarova Ra, Shcherbakova NV, Polyakova EB, Mikhaylov EN, Shalnova Sa, Shkolnikov VM. atrial fibrillation among Russian men and women aged 55 years and older: prevalence, mortality, and associations with biomarkers in a population-based study. J Geriatr Cardiol. 2020 feb;17(2):74- 84. https://doi.org/10.11909/j.issn.1671-5411.2020.02.002

598. Kallistratos MS, Poulimenos LE, Manolis aJ. atrial fibrillation and arterial hypertension. Pharmacological research 2018;128:322-326. https://doi.org/10.1016/j.phrs.2017.10.007

599. Kim D, Yang PS, Kim TH, Jang E, Shin H, Kim HY, et al. Ideal blood pressure in patients with atrial fibrillation. J am Coll Cardiol. 2018;72:1233-1245. https://doi.org/10.1016/j.jacc.2018.05.076

600. Kollias a, Kyriakoulis KG, Stambolliu E, Stergiou GS. Prognostic value of office blood pressure measurement in patients with atrial fibrillation on anticoagulation therapy: systematic review and meta-analysis. J Hypertens. 2020;38:13-20. https://doi.org/10.1097/hjh.0000000000002244

601. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, Ezekowitz MD, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955-962. https://doi.org/10.1016/s0140-6736(13)62343-0

602. Stergiou GS, Kyriakoulis KG, Stambolliu E, Destounis a, Karpettas N, Kalogeropoulos P, et al. Blood pressure measurement in atrial fibrillation: review and meta-analysis of evidence on accuracy and clinical relevance. J Hypertens. 2019;37:2430-2441. https://doi.org/10.1097/hjh.0000000000002201

603. Чазова И.Е., Голицын С.П., Жернакова Ю.В., Железнова Е.А., и соавт. Ведение пациентов с артериальной гипертонией и фибрилляцией предсердий. Системные гипертензии. 2021;18(3):105-128. https://doi.org/10.26442/2075082X.2021.3.201077

604. Kario K, Hasebe N, Okumura K, Yamashita T, akao M, atarashi H, et al. Home Blood Pressure Can Predict the Risk for Stroke/Bleeding Events in Elderly Patients With Nonvalvular atrial fibrillation from the aNafIE Registry. Hypertension (Dallas, Tex: 1979). 2022 Dec;79(12):2696-2705. https://doi.org/10.1161/hypertensionaha.122.19810

605. Kollias a, Destounis a, Kalogeropoulos P, Kyriakoulis KG, Ntineri a, Stergiou GS. atrial fibrillation detection during 24-hour ambulatory blood pressure monitoring: comparison with 24-hour electrocardiography. Hypertension (Dallas, Tex: 1979). 2018;72(1):110-115. http://dx.doi.org/10.1161/HYPERTENSIONaHa.117.10797

606. Halfon M, Wuerzner G, Marques-Vidal P, Taffe P, Vaucher J, Waeber B, et al. Use of oscillometric devices in atrial fibrillation: a comparison of three devices and invasive blood pressure measurement. Blood Press. 2018;27:48- 55. https://doi.org/10.1080/08037051.2017.1383852

607. Verberk WJ, Omboni S, Kollias a, Stergiou GS. Screening for atrial fibrillation with automated blood pressure measurement: Research evidence and practice recommendations. Int J Cardiol. 2016;203:465-473. https://doi.org/10.1016/j.ijcard.2015.10.182

608. Tang EWL, Yip BHK, Yu CP, Wong SYS, Lee EKP. Sensitivity and specificity of automated blood pressure devices to detect atrial fibrillation: a systematic review and meta-analysis of diagnostic accuracy. front Cardiovasc Med. 2022;9:956542. https://doi.org/10.3389/fcvm.2022.956542

609. Lowe a, Oh TH, Stewart R. Screening for atrial fibrillation During automatic Blood Pressure Measurements. IEEE J Transl Eng Health Med. 2018;6:4400307. https://doi.org/10.1109/jtehm.2018.2869609

610. Brandes a, Stavrakis S, freedman B, antoniou S, Boriani G, Camm aJ, et al. Consumer-Led Screening for atrial fibrillation: frontier Review of the afSCREEN International Collaboration. Circulation. 2022;146:1461-1474. https://doi.org/10.1161/circulationaha.121.058911

611. Van Gelder IC, Rienstra M, Crijns HJ, Olshansky B. Rate control in atrial fibrillation. Lancet. 2016;388:818-828. https://doi.org/10.1016/s0140-6736(16)31258-2

612. Washam JB, Hellkamp aS, Lokhnygina Y, Piccini JP, Berkowitz SD, Nessel CC, et al. Efficacy and Safety of Rivaroxaban Versus Warfarin in Patients Taking Nondihydropyridine Calcium Channel Blockers for atrial fibrillation (from the ROCKET af Trial). am J Cardiol. 2017;120:588-594. https://doi.org/10.1016/j.amjcard.2017.05.026

613. Hanigan S, Das J, Pogue K, Barnes GD, Dorsch MP. The real world use of combined P-glycoprotein and moderate CYP3a4 inhibitors with rivaroxaban or apixaban increases bleeding. Journal of thrombosis and thrombolysis 2020;49:636-643. https://doi.org/10.1007/s11239-020-02037-3

614. Lafuente-Lafuente C, Valembois L, Bergmann Jf, Belmin J. antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation.Cochrane Database Syst Rev. 2015;Cd005049. https://doi.org/10.1002/14651858.cd005049.pub4

615. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahl€of B, et al. angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention for End Point Reduction in Hypertension (LIfE) study. J am Coll Cardiol. 2005;45:712-719. https://doi.org/10.1016/j.jacc.2004.10.068

616. Ducharme a, Swedberg K, Pfeffer Ma, Cohen-Solal a, Granger CB, Maggioni aP, et al. Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: assessment of Reduction in Mortality and morbidity (CHaRM) program. american heart journal. 2006;152:86-92. PMID: 16838426.

617. Schneider MP, Hua Ta, Bohm M, Wachtell K, Kjeldsen SE, Schmieder RE. Prevention of atrial fibrillation by Renin-angiotensin system inhibition ameta-analysis. J am Coll Cardiol. 2010;55:2299-2307. https://doi.org/10.1016/j.jacc.2010.01.043

618. Cikes M, Claggett B, Shah aM, Desai aS, Lewis Ef, Shah SJ, et al. atrial fibrillation in Heart failure With Preserved Ejection fraction: The TOPCaT Trial. JaCC Heart fail. 2018;6:689-697. https://doi.org/10.1016/j.jchf.2018.05.005

619. Tveit a, Grundvold I, Olufsen M, Seljeflot I, abdelnoor M, arnesen H, et al. Candesartan in the prevention of relapsing atrial fibrillation. Int J Cardiol. 2007;120:85-91. https://doi.org/10.1016/j.ijcard.2006.08.086

620. Swedberg K, Zannad f, McMurray JJ, Krum H, van Veldhuisen DJ, Shi H, et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHaSIS-Hf (Eplerenone in Mild Patients Hospitalization and SurvIval Study in Heart failure) study. J am Coll Cardiol. 2012;59:1598-1603. https://doi.org/10.1016/j.jacc.2011.11.063

621. Zheng RJ, Wang Y, Tang JN, Duan JY, Yuan MY, Zhang JY. association of SGLT2 Inhibitors With Risk of atrial fibrillation and Stroke in Patients With and Without Type 2 Diabetes: a Systemic Review and Meta-analysis of Randomized Controlled Trials. J Cardiovasc Pharmacol. 2022;79:e145-e152. https://doi.org/10.1097/fjc.0000000000001183

622. Pandey aK, Okaj I, Kaur H, Belley-Cote EP, Wang J, Oraii a, et al. Sodium-Glucose Co-Transporter Inhibitors and atrial fibrillation: a Systematic Review and Meta-analysis of Randomized Controlled Trials. J am Heart assoc. 2021;10:e022222. https://doi.org/10.1161/jaha.121.022222

623. Zhuo M, D’andrea E, Paik JM, Wexler DJ, Everett BM, Glynn RJ, et al. association of Sodium-Glucose Cotransporter-2 Inhibitors With Incident atrial fibrillation in Older adults With Type 2 Diabetes. JaMa. Network Open 2022;5:e2235995-e2235995. https://doi.org/10.1001/jamanetworkopen.2022.35995

624. Ma L, Hu X, Song L, Chen X, Ouyang M, Billot L, et al. The third Intensive Care Bundle with Blood Pressure Reduction in acute Cerebral Haemorrhage Trial (INTERaCT3): an international, stepped wedge cluster randomised controlled trial. Lancet. 2023;402:27-40. https://doi.org/10.1016/s0140-6736(23)00806-1

625. Arima H, Chalmers J. PROGRESS: Prevention of Recurrent Stroke. J Clin Hypertens (Greenwich) 2011;13:693-702. https://doi.org/10.1111/j.1751-7176.2011.00530.x

626. Lip GY, frison L, Grind M. Effect of hypertension on anticoagulated patients with atrial fibrillation. Eur Heart J 2007;28:752-759. https://doi.org/10.1093/eurheartj/ehl504

627. Rao MP, Halvorsen S, Wojdyla D, Thomas L, alexander JH, Hylek EM, et al. Blood Pressure Control and Risk of Stroke or Systemic Embolism in Patients With atrial fibrillation: Results from the apixaban for Reduction in Stroke and Other Thromboembolic Events in atrial fibrillation (aRISTOTLE) Trial. J am Heart assoc. 2015 Dec 1;4(12):e002015. https://doi.org/10.1161/jaha.115.002015

628. Крылов В.В., Дашьян В.Г., Буров А.С., Петриков С.С. Хирургия геморрагического инсульта. – М.: Медици- на, 2012. – 336 с. ISBN 978-5-225-10003-2.

629. Rodriguez-Luna D, Pi?eiro S, Rubiera M, et al. Impact of blood pressure changes and course on hematoma growth in acute intracerebral hemorrhage. Eur J Neurol. 2013;20(9):1277-1283. https://doi.org/10.1111/ene.12180

630. Sakamoto Y, Koga M, Yamagami H, et al. Systolic blood pressure after intravenous antihypertensive treatment and clinical outcomes in hyperacute intracerebral hemorrhage: the stroke acute management with urgent risk-factor assessment and improvement-intracerebral hemorrhage study. Stroke. 2013;44(7):1846-1851. https://doi.org/10.1161/STROKEaHa.113.001212

631. Anderson CS, Heeley E, Huang Y, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368(25):2355-2365. https://doi.org/10.1056/NEJMoa1214609

632. Qureshi aI, Palesch YY, Barsan WG, et al. Intensive Blood-Pressure Lowering in Patients with acute Cerebral Hemorrhage. N Engl J Med. 2016;375(11):1033-1043. https://doi.org/10.1056/NEJMoa1603460

633. Клинические рекомендации – Геморрагический инсульт – 2022-2023-2024 (15.12.2022) – Утверждены Минздравом РФ

634. Sandset EC, anderson CS, Bath PM, et al. European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage [retracted in: Eur Stroke J. 2022 Mar;7(1):NP1. https://doi.org/10.1177/23969873211059425]. Eur Stroke J. 2021;6(2):II. https://doi.org/10.1177/23969873211026998

635. Wang X, Di Tanna GL, Moullaali TJ, et al. J-shape relation of blood pressure reduction and outcome in acute intracerebral hemorrhage: a pooled analysis of INTERaCT2 and aTaCH-II individual participant data. Int J Stroke. 2022;17(10):1129-1136. https://doi.org/10.1177/17474930211064076

636. Tsivgoulis G, Katsanos aH, Butcher KS, et al. Intensive blood pressure reduction in acute intracerebral hemorrhage: a meta-analysis [published correction appears in Neurology. 2015 Jun 16;84(24):2466. https:// doi.org/10.1212/WNL.0000000000001695]. Neurology. 2014;83(17):1523-1529. https://doi.org/10.1212/WNL.0000000000000917

637. Qureshi aI, Huang W, Lobanova I, et al. Outcomes of Intensive Systolic Blood Pressure Reduction in Patients With Intracerebral Hemorrhage and Excessively High Initial Systolic Blood Pressure: Post Hoc analysis of a Randomized Clinical Trial. JaMa. Neurol. 2020;77(11):1355-1365. https://doi.org/10.1001/jamaneurol.2020.3075

638. Moullaali TJ, Wang X, Sandset EC, et al. Early lowering of blood pressure after acute intracerebral haemorrhage: a systematic review and meta-analysis of individual patient data. J Neurol Neurosurg Psychiatry. 2022;93(1):6- 13. https://doi.org/10.1136/jnnp-2021-327195

639. Ascanio LC, Enriquez-Marulanda a, Maragkos Ga, et al. Effect of Blood Pressure Variability During the acute Period of Subarachnoid Hemorrhage on functional Outcomes. Neurosurgery. 2020;87(4):779-787. https://doi.org/10.1093/neuros/nyaa019

640. Tang C, Zhang TS, Zhou Lf. Risk factors for rebleeding of aneurysmal subarachnoid hemorrhage: a meta- analysis. PLoS One. 2014 Jun 9;9(6):e99536. https://doi.org/10.1371/journal.pone.0099536

641. Connolly ES Jr, Rabinstein aa, Carhuapoma JR, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the american Heart association/ american Stroke association. Stroke. 2012;43(6):1711-1737. https://doi.org/10.1161/STR.0b013e3182587839

642. Steiner T, Juvela S, Unterberg a, et al. European Stroke Organization guidelines for the management of intracranial aneurysms and subarachnoid haemorrhage. Cerebrovasc Dis. 2013;35(2):93-112. https://doi.org/10.1159/000346087

643. Britton M, Carlsson a, de faire U. Blood pressure course in patients with acute stroke and matched controls. Stroke. 1986;17(5):861-864. https://doi.org/10.1161/01.str.17.5.861

644. Lee M, Ovbiagele B, Hong KS, et al. Effect of Blood Pressure Lowering in Early Ischemic Stroke: Meta-analysis. Stroke. 2015;46(7):1883-1889. https://doi.org/10.1161/STROKEaHa.115.009552

645. Zhao R, Liu fD, Wang S, et al. Blood Pressure Reduction in the acute Phase of an Ischemic Stroke Does Not Improve Short- or Long-Term Dependency or Mortality: a Meta-analysis of Current Literature. Medicine (Baltimore). 2015;94(23):e896. https://doi.org/10.1097/MD.0000000000000896

646. G?secki D, Coca a, Cunha P, et al. Blood pressure in acute ischemic stroke: challenges in trial interpretation and clinical management: position of the ESH Working Group on Hypertension and the Brain. J Hypertens. 2018;36(6):1212-1221. https://doi.org/10.1097/HJH.0000000000001704

647. Ahmed N, Wahlgren N, Brainin M, et al. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from Safe Implementation of Thrombolysis in Stroke-International Stroke Thrombolysis Register (SITS-ISTR). Stroke. 2009;40(7):2442-2449. https://doi.org/10.1161/STROKEaHa.109.548602

648. Wu W, Huo X, Zhao X, et al. Relationship between Blood Pressure and Outcomes in acute Ischemic Stroke Patients administered Lytic Medication in the TIMS-China Study. PLoS One. 2016 feb 1;11(2):e0144260. https://doi.org/10.1371/journal.pone.0144260

649. Berge E, Whiteley W, audebert H, et al. European Stroke Organisation (ESO) guidelines on intravenous thrombolysis for acute ischaemic stroke. Eur Stroke J. 2021;6(1):I-LXII. https://doi.org/10.1177/2396987321989865

650. Katsanos aH, Malhotra K, ahmed N, et al. Blood Pressure after Endovascular Thrombectomy and Outcomes in Patients With acute Ischemic Stroke: an Individual Patient Data Meta-analysis. Neurology. 2022;98(3):e291-e301. https://doi.org/10.1212/WNL.0000000000013049

651. Yang P, Song L, Zhang Y, et al. Intensive blood pressure control after endovascular thrombectomy for acute ischaemic stroke (ENCHaNTED2/MT): a multicentre, open-label, blinded-endpoint, randomised controlled trial [published correction appears in Lancet. 2022 Dec 3;400(10367):1926. https://doi.org/10.1016/S0140-6736(22)02427-8]. Lancet. 2022;400(10363):1585-1596. https://doi.org/10.1016/S0140-6736(22)01882-7

652. Mazighi M, Richard S, Lapergue B, et al. Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TaRGET): a multicentre, open-label, randomised controlled trial. Lancet. Neurol. 2021;20(4):265-274. https://doi.org/10.1016/S1474-4422(20)30483-X

653. Sandset EC, Bath PM, Boysen G, et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCaST): a randomised, placebo-controlled, double-blind trial. Lancet. 2011;377(9767):741-750. https://doi.org/10.1016/S0140-6736(11)60104-9

654. Sandset EC, Murray GD, Bath PM, et al.; Scandinavian Candesartan acute Stroke Trial (SCaST) Study Group. Relation between change in blood pressure in acute stroke and risk of early adverse events and poor outcome. Stroke. 2012;43(8):2108-2114. https://doi.org/10.1161/STROKEaHa.111.647362

655. ENOS Trial Investigators. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial [published correction appears in Lancet. 2015 feb 14;385(9968):606]. Lancet. 2015;385(9968):617-628. https://doi.org/10.1016/S0140-6736(14)61121-1

656. Robinson TG, Potter Jf, ford Ga, et al. Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke antihypertensives Collaborative Study (COSSaCS): a prospective, randomised, open, blinded-endpoint trial. Lancet. Neurol. 2010;9(8):767-775. https://doi.org/10.1016/S1474-4422(10)70163-0

657. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack [published correction appears in Lancet. 2001 Nov 3;358(9292):1556] [published correction appears in Lancet. 2002 Jun 15;359(9323):2120]. Lancet. 2001;358(9287):1033-1041. https://doi.org/10.1016/S0140-6736(01)06178-5

658. PaTS Collaborating Group. Post-stroke antihypertensive treatment study. a preliminary result. Chin Med J (Engl). 1995 Sep;108(9):710-7. PMID: 8575241.

659. Powers WJ, Rabinstein aa, ackerson T, et al. Guidelines for the Early Management of Patients With acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of acute Ischemic Stroke: a Guideline for Healthcare Professionals from the american Heart association/american Stroke association [published correction appears in Stroke. 2019 Dec;50(12):e440-e441. https://doi.org/10.1161/STR.0000000000000215]. Stroke. 2019;50(12):e344-e418. https://doi.org/10.1161/STR.0000000000000211

660. Mant J, McManus RJ, Roalfe a, et al. Different systolic blood pressure targets for people with history of stroke or transient ischaemic attack: PaST-BP (Prevention after Stroke--Blood Pressure) randomised controlled trial. BMJ. 2016 feb 24;352:i708. https://doi.org/10.1136/bmj.i708

661. Odden MC, McClure La, Sawaya BP, et al. achieved Blood Pressure and Outcomes in the Secondary Prevention of Small Subcortical Strokes Trial. Hypertension. 2016;67(1):63-69. https://doi.org/10.1161/HYPERTENSIONaHa.115.06480

662. Bath PM, Scutt P, Blackburn DJ, et al. Intensive versus Guideline Blood Pressure and Lipid Lowering in Patients with Previous Stroke: Main Results from the Pilot 'Prevention of Decline in Cognition after Stroke Trial' (PODCaST) Randomised Controlled Trial. PLoS One. 2017 Jan 17;12(1):e0164608. https://doi.org/10.1371/journal.pone.0164608

663. Kitagawa K, Yamamoto Y, arima H, et al. Effect of Standard vs Intensive Blood Pressure Control on the Risk of Recurrent Stroke: a Randomized Clinical Trial and Meta-analysis. JaMa. Neurol. 2019;76(11):1309-1318. https://doi.org/10.1001/jamaneurol.2019.2167

664. Katsanos aH, filippatou a, Manios E, et al. Blood Pressure Reduction and Secondary Stroke Prevention: a Systematic Review and Metaregression analysis of Randomized Clinical Trials. Hypertension. 2017;69(1):171- 179. https://doi.org/10.1161/HYPERTENSIONaHa.116.08485

665. Dawson J, B?jot Y, Christensen LM, et al. European Stroke Organisation (ESO) guideline on pharmacological interventions for long-term secondary prevention after ischaemic stroke or transient ischaemic attack. Eur Stroke J. 2022;7(3):I-II. https://doi.org/10.1177/23969873221100032

666. Wang WT, You LK, Chiang CE, et al. Comparative Effectiveness of Blood Pressure-lowering Drugs in Patients who have already Suffered from Stroke: Traditional and Bayesian Network Meta-analysis of Randomized Trials. Medicine (Baltimore). 2016;95(15):e3302. https://doi.org/10.1097/MD.0000000000003302

667. Dahl?f B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint reduction in hypertension study (LIfE): a randomised trial against atenolol. Lancet. 2002;359(9311):995-1003. https://doi.org/10.1016/S0140-6736(02)08089-3

668. Collier DJ, Poulter NR, Dahl?f B, et al; aSCOT Investigators. Impact of amlodipine-based therapy among older and younger patients in the anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering arm (aSCOT- BPLa). J Hypertens. 2011 Mar;29(3):583-91. https://doi.org/10.1097/HJH.0b013e328342c845

669. Thomopoulos C, Bazoukis G, Tsioufis C, Mancia G. Beta-blockers in hypertension: overview and meta- analysis of randomized outcome trials. J Hypertens. 2020;38(9):1669-1681. https://doi.org/10.1097/HJH.0000000000002523

670. GBD 2016 Dementia Collaborators. Global, regional, and national burden of alzheimer's disease and other dementias, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. Neurol. 2019;18(1):88-106. https://doi.org/10.1016/S1474-4422(18)30403-4

671. GBD 2019 Dementia forecasting Collaborators. Estimation of the global prevalence of dementia in 2019 and forecasted prevalence in 2050: an analysis for the Global Burden of Disease Study 2019. Lancet. Public Health. 2022;7(2):e105-e125. https://doi.org/10.1016/S2468-2667(21)00249-8

672. Li C, Zhu Y, Ma Y, Hua R, Zhong B, Xie W. association of Cumulative Blood Pressure With Cognitive Decline, Dementia, and Mortality. J am Coll Cardiol. 2022;79(14):1321-1335. https://doi.org/10.1016/j.jacc.2022.01.045

673. Emdin Ca, Rothwell PM, Salimi-Khorshidi G, et al. Blood Pressure and Risk of Vascular Dementia: Evidence from a Primary Care Registry and a Cohort Study of Transient Ischemic attack and Stroke. Stroke. 2016;47(6):1429- 1435. https://doi.org/10.1161/STROKEaHa.116.012658

674. Клинические рекомендации: Когнитивные расстройства у лиц пожилого и старческого возраста МЗ 2020

675. Peters R, Xu Y, fitzgerald O, et al. Blood pressure lowering and prevention of dementia: an individual patient data meta-analysis. Eur Heart J. 2022;43(48):4980-4990. https://doi.org/10.1093/eurheartj/ehac584

676. SPRINT MIND Investigators for the SPRINT Research Group, Williamson JD, Pajewski NM, et al. Effect of Intensive vs Standard Blood Pressure Control on Probable Dementia: a Randomized Clinical Trial. JaMa. 2019;321(6):553- 561. https://doi.org/10.1001/jama.2018.21442

677. Verhaaren Bf, Vernooij MW, de Boer R, et al. High blood pressure and cerebral white matter lesion progression in the general population. Hypertension. 2013;61(6):1354-1359. https://doi.org/10.1161/HYPERTENSIONaHa.111.00430

678. Chiu WC, Ho WC, Lin MH, et al. angiotension receptor blockers reduce the risk of dementia. J Hypertens. 2014;32(4):938-947. https://doi.org/10.1097/HJH.0000000000000086

679. van Middelaar T, van Vught La, Moll van Charante EP, et al. Lower dementia risk with different classes of antihypertensive medication in older patients. J Hypertens. 2017;35(10):2095-2101. https://doi.org/10.1097/HJH.0000000000001411

680. van Dalen JW, Marcum Za, Gray SL, et al. association of angiotensin II-Stimulating antihypertensive Use and Dementia Risk: Post Hoc analysis of the PreDIVa Trial. Neurology. 2021;96(1):e67-e80. https://doi.org/10.1212/WNL.0000000000010996

681. Marcum Za, Cohen JB, Zhang C, et al. association of antihypertensives That Stimulate vs Inhibit Types 2 and 4 angiotensin II Receptors With Cognitive Impairment. JaMa. Netw Open. 2022 Jan 4.;5(1):e2145319. https://doi.org/10.1001/jamanetworkopen.2021.45319

682. Roberts WC, Ko JM. frequency by decades of unicuspid, bicuspid, and tricuspid aortic valves in adults having isolated aortic valve replacement for aortic stenosis, with or without associated aortic regurgitation. Circulation. 2005;111(7):920-925. https://doi.org/10.1161/01.CIR.0000155623.48408.C5

683. Rosseb aB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med. 2008;359(13):1343-1356. https://doi.org/10.1056/NEJMoa0804602

684. Mancusi C, de Simone G, Brguljan Hitij J, et al. Management of patients with combined arterial hypertension and aortic valve stenosis: a consensus document from the Council on Hypertension and Council on Valvular Heart Disease of the European Society of Cardiology, the European association of Cardiovascular Imaging (EaCVI), and the European association of Percutaneous Cardiovascular Interventions (EaPCI). Eur Heart J Cardiovasc Pharmacother. 2021;7(3):242-250. https://doi.org/10.1093/ehjcvp/pvaa040

685. Sen J, Chung E, Neil C, Marwick T. antihypertensive therapies in moderate or severe aortic stenosis: a systematic review and meta-analysis. BMJ. Open. 2020 Oct 5;10(10):e036960. https://doi.org/10.1136/bmjopen-2020-036960

686. Vahanian a, Beyersdorf f, Praz f, et al. 2021 ESC/EaCTS Guidelines for the management of valvular heart disease [published correction appears in Eur Heart J. 2022 Jun 1;43(21):2022. https://doi.org/10.1093/eurheartj/ehac051]. Eur Heart J. 2022;43(7):561-632. https://doi.org/10.1093/eurheartj/ehab395

687. Scognamiglio R, Rahimtoola SH, fasoli G, et al. Nifedipine in asymptomatic patients with severe aortic regurgitation and normal left ventricular function. N Engl J Med. 1994;331(11):689-694. https://doi.org/10.1056/NEJM199409153311101

688. Rahimi K, Mohseni H, Otto CM, et al. Elevated blood pressure and risk of mitral regurgitation: a longitudinal cohort study of 5.5 million United Kingdom adults. PLoS Med. 2017 Oct 17;14(10):e1002404. https://doi.org/10.1371/journal.pmed.1002404

689. Mazzolai L, Teixido-Tura G, Lanzi S, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases. Eur Heart J. 2024;45(36):3538-3700. https://doi.org/10.1093/eurheartj/ehae179

690. Zanchetti a, Hennig M, Hollweck R, et al. Baseline values but not treatment-induced changes in carotid intima-media thickness predict incident cardiovascular events in treated hypertensive patients: findings in the European Lacidipine Study on atherosclerosis (ELSa). Circulation. 2009;120(12):1084-1090. https://doi.org/10.1161/CIRCULaTIONaHa.108.773119

691. Zanchetti a, Crepaldi G, Bond MG, et al. Different effects of antihypertensive regimens based on fosinopril or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal results of PHYLLIS--a randomized double-blind trial. Stroke. 2004;35(12):2807-2812. https://doi.org/10.1161/01.STR.0000147041.00840.59

692. Emdin Ca, anderson SG, Callender T, et al. Usual blood pressure, peripheral arterial disease, and vascular risk: cohort study of 4.2 million adults. BMJ. 2015 Sep 29;351:h4865. https://doi.org/10.1136/bmj.h4865

693. Thomas Manapurathe D, Krishna SM, Dewdney B, et al. Effect of blood pressure lowering medications on leg ischemia in peripheral artery disease patients: a meta-analysis of randomised controlled trials. PLoS One. 2017 Jun 2;12(6):e0178713. https://doi.org/10.1371/journal.pone.0178713

694. Itoga NK, Tawfik DS, Lee CK, et al. association of Blood Pressure Measurements With Peripheral artery Disease Events. Circulation. 2018;138(17):1805-1814. https://doi.org/10.1161/CIRCULaTIONaHa.118.033348

695. Paravastu SC, Mendonca Da, da Silva a. Beta blockers for peripheral arterial disease. Eur J Vasc Endovasc Surg. 2009;38(1):66-70. https://doi.org/10.1016/j.ejvs.2009.02.019

696. Espinola-Klein C, Weisser G, Jagodzinski a, et al. ?-Blockers in patients with intermittent claudication and arterial hypertension: results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension. 2011;58(2):148-154. https://doi.org/10.1161/HYPERTENSIONaHa.110.169169

697. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009 May 19;338:b1665. https://doi.org/10.1136/bmj.b1665

698. Nieto fJ, Young TB, Lind BK, et al. association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study [published correction appears in JaMa. 2002 Oct 23- 30;288(16):1985]. JaMa. 2000;283(14):1829-1836. https://doi.org/10.1001/jama.283.14.1829

699. Tadic M, Cuspidi C, Grassi G, Mancia G. Isolated Nocturnal Hypertension: What Do We Know and What Can We Do? Integr Blood Press Control. 2020 apr 21;13:63-69. https://doi.org/10.2147/IBPC.S223336

700. Crinion SJ, Kleinerova J, Kent B, et al. Non-dipping nocturnal blood pressure correlates with obstructive sleep apnoea severity in normotensive subjects and may reverse with therapy. ERJ Open Res. 2021 aug 16;7(3):00338-2021. https://doi.org/10.1183/23120541.00338-2021

701. Hedner J, Bengtsson-Bostr?m K, Peker Y, et al. Hypertension prevalence in obstructive sleep apnoea and sex: a population-based case-control study. Eur Respir J. 2006;27(3):564-570. https://doi.org/10.1183/09031936.06.00042105

702. Sateia MJ. International classification of sleep disorders-third edition: highlights and modifications. Chest. 2014;146(5):1387-1394. https://doi.org/10.1378/chest.14-0970

703. Sleep-related breathing disorders in adults: recommendations for syndrome definition and measurement techniques in clinical research. The Report of an american academy of Sleep Medicine Task force. Sleep. 1999;22(5):667-689. PMID: 10450601.

704. Young T, Palta M, Dempsey J, et al. Burden of sleep apnea: rationale, design, and major findings of the Wisconsin Sleep Cohort study. WMJ. 2009;108(5):246-249. 704 Young T, Palta M, Dempsey J, et al. Burden of sleep apnea: rationale, design, and major findings of the Wisconsin Sleep Cohort study. WMJ. 2009;108(5):246- 249. PMID: 19743755. PMCID: PMC2858234.

705. Pedrosa RP, Drager Lf, Gonzaga CC, et al. Obstructive sleep apnea: the most common secondary cause of hypertension associated with resistant hypertension. Hypertension. 2011;58(5):811-817. https://doi.org/10.1161/HYPERTENSIONaHa.111.179788

706. Florczak E, Prejbisz a, Szwench-Pietrasz E, et al. Clinical characteristics of patients with resistant hypertension: the RESIST-POL study. J Hum Hypertens. 2013;27(11):678-685. https://doi.org/10.1038/jhh.2013.32

707. Muxfeldt ES, Margallo VS, Guimar?es GM, Salles Gf. Prevalence and associated factors of obstructive sleep apnea in patients with resistant hypertension. am J Hypertens. 2014;27(8):1069-1078. https://doi.org/10.1093/ajh/hpu023

708. Бочкарев М.В., Коростовцева Л.С., Фильченко И.А., и соавт. Жалобы на нарушения дыхания во сне и фак- торы риска сердечно-сосудистых заболеваний в регионах России: данные исследования ЭССЕ-РФ. Российский кардиологический журнал. 2018;(6):152-158. https://doi.org/10.15829/1560-4071-2018-6-152-158

709. Kapur VK, auckley DH, Chowdhuri S, et al. Clinical Practice Guideline for Diagnostic Testing for adult Obstructive Sleep apnea: an american academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2017 Mar 15.;13(3):479-504. https://doi.org/10.5664/jcsm.6506

710. Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive Sleep apnea and Cardiovascular Disease: a Scientific Statement from the american Heart association [published correction appears in Circulation. 2022 Mar 22;145(12):e775. https://doi.org/10.1161/CIR.0000000000001043]. Circulation. 2021;144(3):e56-e67. https://doi.org/10.1161/CIR.0000000000000988

711. Min HJ, Cho YJ, Kim CH, et al. Clinical features of Obstructive Sleep apnea That Determine Its High Prevalence in Resistant Hypertension. Yonsei Med J. 2015;56(5):1258-1265. https://doi.org/10.3349/ymj.2015.56.5.1258

712. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000;342(19):1378-1384. https://doi.org/10.1056/NEJM200005113421901

713. Marin JM, agusti a, Villar I, et al. association between treated and untreated obstructive sleep apnea and risk of hypertension. JaMa. 2012;307(20):2169-2176. https://doi.org/10.1001/jama.2012.3418

714. Hudgel DW, Patel SR, ahasic aM, et al. The Role of Weight Management in the Treatment of adult Obstructive Sleep apnea. an Official american Thoracic Society Clinical Practice Guideline. am J Respir Crit Care Med. 2018;198(6):e70-e87. https://doi.org/10.1164/rccm.201807-1326ST

715. Jordan aS, McSharry DG, Malhotra a. adult obstructive sleep apnoea. Lancet. 2014;383(9918):736-747. https:// doi.org/10.1016/S0140-6736(13)60734-5

716. Giles TL, Lasserson TJ, Smith BJ, White J, Wright J, Cates CJ. Continuous positive airways pressure for obstructive sleep apnoea in adults. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD001106. https://doi.org/10.1002/14651858.CD001106.pub2

717. Walia HK, Thompson NR, Pascoe M, et al. Effect of Positive airway Pressure Therapy on Drowsy Driving in a Large Clinic-Based Obstructive Sleep apnea Cohort. J Clin Sleep Med. 2019;15(11):1613-1620. https://doi.org/10.5664/jcsm.8024

718. Pengo Mf, Soranna D, Giontella a, et al. Obstructive sleep apnoea treatment and blood pressure: which phenotypes predict a response? a systematic review and meta-analysis. Eur Respir J. 2020 May 7;55(5):1901945. https://doi.org/10.1183/13993003.01945-2019

719. Muxfeldt ES, Margallo V, Costa LM, et al. Effects of continuous positive airway pressure treatment on clinic and ambulatory blood pressures in patients with obstructive sleep apnea and resistant hypertension: a randomized controlled trial. Hypertension. 2015;65(4):736-742. https://doi.org/10.1161/HYPERTENSIONaHa.114.04852

720. Iftikhar IH, Valentine CW, Bittencourt LR, et al. Effects of continuous positive airway pressure on blood pressure in patients with resistant hypertension and obstructive sleep apnea: a meta-analysis. J Hypertens. 2014;32(12):2341-2350. https://doi.org/10.1097/HJH.0000000000000372

721. Mart?nez-Garc?a Ma, Capote f, Campos-Rodr?guez f, et al. Effect of CPaP on blood pressure in patients with obstructive sleep apnea and resistant hypertension: the HIPaRCO randomized clinical trial. JaMa. 2013;310(22):2407-2415. https://doi.org/10.1001/jama.2013.281250

722. Montesi SB, Edwards Ba, Malhotra a, Bakker JP. The effect of continuous positive airway pressure treatment on blood pressure: a systematic review and meta-analysis of randomized controlled trials. J Clin Sleep Med. 2012 Oct 15;8(5):587-596. https://doi.org/10.5664/jcsm.2170

723. Litvin aY, Sukmarova ZN, Elfimova EM, et al. Effects of CPaP on «vascular» risk factors in patients with obstructive sleep apnea and arterial hypertension. Vasc Health Risk Manag. 2013;9:229-235. https://doi.org/10.2147/VHRM.S40231

724. Patil SP, ayappa Ia, Caples SM, et al. Treatment of adult Obstructive Sleep apnea with Positive airway Pressure: an american academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med. 2019 feb 15;15(2):335- 343. https://doi.org/10.5664/jcsm.7640

725. Kou C, Zhao X, Lin X, fan X, Wang Q, Yu J. Effect of different treatments for obstructive sleep apnoea on blood pressure. J Hypertens. 2022;40(6):1071-1084. https://doi.org/10.1097/HJH.0000000000003131

726. Bokarica P. Re: K. Hatzimouratidis, I. Eardley, f. Giuliano, I. Moncada, a. Salonia. Guidelines on male sexual dysfunction: erectile dysfunction and premature ejaculation. European association of Urology Web site. http://uroweb.org/guideline/male-sexual-dysfunction/. Updated 2015. Eur Urol. 2015;68(4):e77. https://doi.org/10.1016/j.eururo.2015.06.013

727. Doumas M, Douma S. Sexual dysfunction in essential hypertension: myth or reality? J Clin Hypertens (Greenwich). 2006;8(4):269-274. https://doi.org/10.1111/j.1524-6175.2006.04708.x

728. Zhao B, Hong Z, Wei Y, Yu D, Xu J, Zhang W. Erectile Dysfunction Predicts Cardiovascular Events as an Independent Risk factor: a Systematic Review and Meta-analysis. J Sex Med. 2019;16(7):1005-1017. https://doi.org/10.1016/j.jsxm.2019.04.004

729. Gratzke C, angulo J, Chitaley K, et al. anatomy, physiology, and pathophysiology of erectile dysfunction [published correction appears in J Sex Med. 2010 Mar;7(3):1316]. J Sex Med. 2010;7(1 Pt 2):445-475. https://doi.org/10.1111/j.1743-6109.2009.01624.x

730. Алексеева Т.А., Литвин А.Ю., Елфимова Е.М., и соавт. Консенсус экспертов Российского медицинского общества по артериальной гипертонии. Артериальная гипертония и эректильная дисфункция. Системные гипертензии. 2021;18(2):69-79. https://doi.org/10.26442/2075082X.2021.2.200836

731. Клинические рекомендации – Эректильная дисфункция – 2021-2022-2023 (21.12.2021) – Утверждены Минздравом РФ. http://disuria.ru/_ld/11/1133_kr21f52N48p4MZ.pdf

732. B?hm M, Baumh?kel M, Teo K, et al. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized assessmeNt Study in aCE iNtolerant subjects with cardiovascular Disease (ONTaRGET/TRaNSCEND) Trials. Circulation. 2010;121(12):1439-1446. https://doi.org/10.1161/CIRCULaTIONaHa.109.864199

733. Lou IX, Chen J, ali K, Chen Q. Relationship Between Hypertension, antihypertensive Drugs and Sexual Dysfunction in Men and Women: a Literature Review. Vasc Health Risk Manag. 2023 Nov 3;19:691-705. https://doi.org/10.2147/VHRM.S439334

734. Cordero a., Bertomeu-Martinez V., Mazon P. et al. Erectile dysfunction in high-risk hypertensive patients treated with beta-blockers agents. Cardiovasc Ther 2010;28:15-22. https://doi.org/10.1111/j.1755-5922.2009.00123.x

735. Kloner Ra, Sadovsky R, Johnson EG, et al. Efficacy of tadalafil in the treatment of erectile dysfunction in hypertensive men on concomitant thiazide diuretic therapy. Int J Impot Res. 2005;17(5):450-454. https://doi.org/10.1038/sj.ijir.3901360

736. Oni Oa, Dehkordi SHH, Jazayeri Ma, et al. Relation of Testosterone Normalization to Mortality and Myocardial Infarction in Men With Previous Myocardial Infarction. am J Cardiol. 2019;124(8):1171-1178. https://doi.org/10.1016/j.amjcard.2019.07.019

737. Ikdahl E, Wibetoe G, Rollefstad S, et al. Guideline recommended treatment to targets of cardiovascular risk is inadequate in patients with inflammatory joint diseases. Int J Cardiol. 2019;274:311-318. https://doi.org/10.1016/j.ijcard.2018.06.111

738. Panoulas Vf, Metsios GS, Pace aV, et al. Hypertension in rheumatoid arthritis. Rheumatology (Oxford) 2008;47:1286–1298. https://doi.org/10.1093/rheumatology/ken159

739. Jagpal a, Navarro-Mill?n I. Cardiovascular co-morbidity in patients with rheumatoid arthritis: a narrative review of risk factors, cardiovascular risk assessment and treatment. BMC Rheumatol. 2018 apr 11;2:10. https://doi.org/10.1186/s41927-018-0014-y

740. Dijkshoorn B, Raadsen R, Nurmohamed MT. Cardiovascular Disease Risk in Rheumatoid arthritis anno 2022. J Clin Med. 2022 May 11;11(10):2704. https://doi.org/10.3390/jcm11102704

741. McEntegart a, Capell Ha, Creran D, Rumley a, Woodward M, Lowe GD. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford). 2001;40(6):640-644. https://doi.org/10.1093/rheumatology/40.6.640

742. Johnson aG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? a meta- analysis. ann Intern Med. 1994;121(4):289-300. https://doi.org/10.7326/0003-4819-121-4-199408150-00011

743. Гордеев А.В., Галушко Е.А., Савушкина Н.М. Роль ангиотензинов в патогенезе воспалительных заболеваний суставов.Терапевтический архив. 2021;93(5):635-639. https://doi.org/10.26442/00403660.2021.05.200796

744. Landgren aJ, Dehlin M, Jacobsson L, et al. Cardiovascular risk factors in gout, psoriatic arthritis, rheumatoid arthritis and ankylosing spondylitis: a cross-sectional survey of patients in Western Sweden. RMD Open. 2021;7(2):e001568. https://doi.org/10.1136/rmdopen-2021-001568

745. Mehta NN, Yu Y, Pinnelas R, et al. attributable risk estimate of severe psoriasis on major cardiovascular events. am J Med. 2011;124(8):775.e1-775.e7756. https://doi.org/10.1016/j.amjmed.2011.03.028

746. Azzouz B, De Guizelin a, Lambert a, et al. Psoriasis risk after beta-blocker exposure: Description of a pharmacovigilance signal. Br J Clin Pharmacol. 2022;88(8):3813-3818. https://doi.org/10.1111/bcp.15330

747. Hidayat K, Du X, Zou SY, Shi BM. Blood pressure and kidney cancer risk: meta-analysis of prospective studies. J Hypertens. 2017;35(7):1333-1344. https://doi.org/10.1097/HJH.0000000000001286

748. Christakoudi S, Kakourou a, Markozannes G, et al. Blood pressure and risk of cancer in the European Prospective Investigation into Cancer and Nutrition. Int J Cancer. 2020;146(10):2680-2693. https://doi.org/10.1002/ijc.32576

749. Cohen JB, Brown NJ, Brown Sa, Dent S, van Dorst DCH, Herrmann SM, et al. Cancer therapy-related hypertension: a scientific statement from the american Heart association. Hypertension (Dallas, Tex: 1979). 2023;80:e46-e57. https://doi.org/10.1161/hyp.0000000000000224

750. Чазова И.Е., Агеев Ф.Т., Аксенова А.В., и соавт. Евразийские клинические рекомендации по диагностике, профилактике и лечению сердечно-сосудистых осложнений при противоопухолевой терапии (2022). Евразийский кардиологический журнал. 2022;(1):6-79, https://doi.org/10.38109/2225-1685-2022-1-6-79

751. Mir O, Coriat R, Ropert S, et al. Treatment of bevacizumab-induced hypertension by amlodipine. Invest New Drugs. 2012;30(2):702-707. https://doi.org/10.1007/s10637-010-9549-5

752. Nazer B, Humphreys BD, Moslehi J. Effects of novel angiogenesis inhibitors for the treatment of cancer on the cardiovascular system: focus on hypertension. Circulation. 2011;124(15):1687-1691. https://doi.org/10.1161/CIRCULaTIONaHa.110.992230

753. McKay RR, Rodriguez GE, Lin X, et al. angiotensin system inhibitors and survival outcomes in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2015;21(11):2471-2479. CCR-14-2332. https://doi.org/10.1158/1078-0432

754. Ara?jo Wf, Naves Ma, Ravanini JN, Schor N, Teixeira VP. Renin-angiotensin system (RaS) blockade attenuates growth and metastatic potential of renal cell carcinoma in mice. Urol Oncol. 2015;33(9):389.e1-389.e3897. https://doi.org/10.1016/j.urolonc.2014.11.022

755. Khairy Y, Naghibi D, Moosavi a, Sardareh M, azami-aghdash S. Prevalence of hypertension and associated risks in hospitalized patients with COVID-19: a meta-analysis of meta-analyses with 1468 studies and 1,281,510 patients. Syst Rev 2022; 11:242. https://doi.org/10.1186/s13643-022-02111-2

756. Чазова И.Е., Блинова Н.В., Невзорова В.А. и соавт. Консенсус экспертов Российского медицинского общества по артериальной гипертонии: артериальная гипертония и COVID-19. Системные гипертензии. 2020;17(3):35-41. https://doi.org/10.26442/2075082X.2020.3.200362

757. Kreutz R, algharably EaE, azizi M, Dobrowolski P, Guzik T, Januszewicz a, et al. Hypertension, the reninangiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovasc Res 2020;116:1688-1699. https://doi.org/10.1093/cvr/cvaa097

758. Mancia G, Rea f, Ludergnani M, apolone G, Corrao G. Renin-angiotensin-aldosterone System Blockers and the Risk of Covid-19. N Engl J Med. 2020;382:2431-2440. https://doi.org/10.1056/nejmoa2006923

759. Reynolds HR, adhikari S, Pulgarin C, Troxel aB, Iturrate E, Johnson SB, et al. Renin-angiotensin-aldosterone System Inhibitors and Risk of Covid-19.N Engl J Med. 2020;382:2441-2448. https://doi.org/10.1056/nejmoa2008975

760. Bavishi C, Whelton PK, Mancia G, Corrao G, Messerli fH. Renin-angiotensin-system inhibitors and all-cause mortality in patients with COVID-19: a systematic review and meta-analysis of observational studies. J Hypertens. 2021;39:784-794. https://doi.org/10.1097/hjh.0000000000002784

761. Loader J, Taylor fC, Lampa E, Sundstr?m J. Renin-angiotensin aldosterone System Inhibitors and COVID-19: a Systematic Review and Meta-analysis Revealing Critical Bias across a Body of Observational Research. J am Heart assoc. 2022;11:e025289. https://doi.org/10.1161/jaha.122.025289

762. Kreutz R, Dobrowolski P, Prejbisz a, et al. European Society of Hypertension COVID-19 Task force Review. Lifestyle, psychological, socioeconomic and environmental factors and their impact on hypertension during the coronavirus disease 2019 pandemic. J Hypertens. 2021;39(6):1077-89. https://doi.org/10.1097/HJH.0000000000002770

763. Ротарь О. П., Ерина А. М., Бояринова М. А., и соавт. Контроль артериальной гипертензии в период пандемии коронавирусной инфекции: результаты российской акции скрининга МММ2021. Российский кардиологический журнал. 2022;27(4):5014. EDN aVGCIE. https://doi.org/10.15829/1560-4071-2022-5014

764. Laffin LJ, Kaufman HW, Chen Z, Niles JK, arellano aR, Bare La, et al. Rise in Blood Pressure Observed among US adults During the COVID-19 Pandemic. Circulation. 2022; 145:235–237.

765. Shah NP, Clare RM, Chiswell K, Navar aM, Shah BR, Peterson ED. Trends of blood pressure control in the U.S. during the COVID-19 pandemic.american heart journal. 2022;247:15-23. https://doi.org/10.1016/j.ahj.2021.11.017

766. Kim YE, Huh K, Park YJ, Peck KR, Jung J. association Between Vaccination and acute Myocardial Infarction and Ischemic Stroke after COVID-19 Infection. JaMa. 2022;328:887-889. https://doi.org/10.1001/jama.2022.12992

767. Buso G, agabiti-Rosei C, Muiesan ML. The relationship between COVID-19 vaccines and increased blood pressure: a word of caution. Eur J Intern Med. 2023. 2023 May:111:27-29. https://doi.org/10.1016/j.ejim.2023.03.002

768. Angeli f, Reboldi G, Trapasso M, Santilli G, Zappa M, Verdecchia P. Blood pressure increase following COVID-19 vaccination: a systematic overview and meta-analysis. J Cardiovasc Dev Dis. 2022 May 9;9(5):150. https://doi.org/10.3390/jcdd9050150

769. Чазова И.Е., Блинова Н.В., Жернакова Ю.В., и соавт. Консенсус экспертов Российского медицинского общества по артериальной гипертонии: артериальная гипертония и постковидный синдром. Системные гипертензии. 2022;19(3):5-13. https://doi.org/10.38109/2075-082X-2022-3-5-13

770. Crook H, Raza S, Nowell J, Young M, Edison P. Long covid-mechanisms, risk factors, and management. BMJ. 2021;374:n1648. https://doi.org/10.1136/bmj.n1648

771. van den Born BJ, Lip GYH, Brguljan-Hitij J, et al. ESC Council on hypertension position document on the management of hypertensive emergencies. Eur Heart J Cardiovasc Pharmacother. 2019 Jan 1;5(1):37-46. https://doi.org/10.1093/ehjcvp/pvy032

772. Vaughan CJ, Delanty N. Hypertensive emergencies. Lancet. 2000;356:411-417. https://doi.org/10.1016/s0140-6736(00)02539-3

773. Saladini f, Mancusi C, Bertacchini f, Spannella f, Maloberti a, Giavarini a, et al. Diagnosis and treatment of hypertensive emergencies and urgencies among Italian emergency and intensive care departments. Results from an Italian survey: Progetto GEaR (Gestione dell’Emergenza e urgenza in area critica). Eur J Intern Med 2020;71:50-56. https://doi.org/10.1016/j.ejim.2019.10.004

774. van den Born BJ, Lowenberg EC, van der Hoeven NV, de Laat B, Meijers JC, Levi M, et al. Endothelial dysfunction, platelet activation, thrombogenesis and fibrinolysis in patients with hypertensive crisis. J Hypertens. 2011;29:922-927. https://doi.org/10.1097/hjh.0b013e328345023d

775. Amraoui f, Van Der Hoeven NV, Van Valkengoed IG, Vogt L, Van Den Born BJ. Mortality and cardiovascular risk in patients with a history of malignant hypertension: a case-control study. J Clin Hypertens (Greenwich). 2014;16:122-126. https://doi.org/10.1111/jch.12243

776. Shantsila a, Lip GYH. Malignant Hypertension Revisited-Does This Still Exist? am J Hypertens. 2017;30:543-549. https://doi.org/10.1093/ajh/hpx008

777. Kulkarni S, Glover M, Kapil V, abrams SML, Partridge S, McCormack T, Sever P, Delles C, Wilkinson IB. Management of hypertensive crisis: British and Irish Hypertension Society Position document. J Hum Hypertens. 2023 Oct;37(10):863-879. Epub 2022 Nov 22. PMID: 36418425; PMCID: PMC10539169. https://doi.org/10.1038/s41371-022-00776-9

778. van den Born BJ, Koopmans RP, Groeneveld JO, van Montfrans Ga. Ethnic disparities in the incidence, presentation and complications of malignant hypertension. J Hypertens. 2006;24:2299–2304. https://doi.org/10.1097/01.hjh.0000249710.21146.38

779. Cremer a, amraoui f, Lip GY, et al. from malignant hypertension to hypertension – MOD: a modern definition for an old but still dangerous emergency. J Hum Hypertens. 2016;30:463-466. https://doi.org/10.1038/jhh.2015.112

780. Pinna G, Pascale C, fornengo P, et al. Hospital admissions for hypertensive crisis in the emergency departments: a large multicenter Italian study. PLoS One 2014;9:e93542. https://doi.org/10.1371/journal.pone.0093542

781. Rodriguez M.a., Kumar S.K., De Caro M. Hypertensive crisis. Cardiol. Rev. 2010;18(2):102-7. https://doi.org/10.1097/CRD.0b013e3181c307b7

782. Miller JB, Hrabec D, Krishnamoorthy V, Kinni H, Brook RD. Evaluation and management of hypertensive emergency. BMJ. 2024 Jul 26;386:e077205. PMID: 39059997. https://doi.org/10.1136/bmj-2023-077205.

783. Born B., Lip G., Brguljan-Hitij J., Cremer a., Segura J., Morales E. et al. ESC Council on hуpertension position document on the management of hypertensive emergencies. Eur. Heart J. Cardiovasc. Pharmacother. 2019;5(1):37-46. https://doi.org/10.1093/ehjcvp/pvy032

784. Perez MI, Musini VM. Pharmacological interventions for hypertensive emergencies: a Cochrane systematic review. J Hum Hypertens. 2008;22:596-607. https://doi.org/10.1038/jhh.2008.25

785. Patel KK, Young L, Howell EH, et al. Characteristics and outcomes of patients presenting with hypertensive urgency in the office setting. JaMa. Intern Med 2016;176:981-8. https://doi.org/10.1001/jamainternmed.2016.1509

786. Nistor C., Badila E., Weiss E., Japie C. Daniela Bartos 2, 3, ana-Maria Balahura. The gray zone in severe hypertension – from uncontrolled to hypertensive emergencies: where one stops and the other begins. J Hypertens. Res. 2022;8(1):22-30.

787. Peixoto aJ. acute severe hypertension. N Engl J Med. 2019;381(19):1843-1852. https://doi.org/10.1056/nejmcp1901117

788. Park SK, Lee DY, Kim WJ, et al. Comparing the clinical efficacy of resting and antihypertensive medication in patients of hypertensive urgency: a randomized, control trial. J Hypertens. 2017;35:1474-80. https://doi.org/10.1097/HJH.0000000000001340

789. Pa?trovi? f, Ok?tajner PK, Vodanovi? M, et al. The role of anxiolytics in hypertensive urgency management. Psychiatr Danub 2020;32(Suppl 4):593-6. PMID: 33212468.

790. Терещенко С.Н., Джаниани Н.А., Морозова М.Н. Сравнительная эффективность карведилола и капотена при лечении неосложненного гипертонического криза. Терапевтический архив. 2006;8:26-30.

791. Терещенко С.Н., Гапонова Н.И., Абдарахманов В.Р. Рандомизированное многоцентровое сравнительное исследование эффективности моксонидина у больных с неосложненным гипертоническим кризом (АВЕС). Артериальная гипертензия. 2011;4:316-324.

792. Chaudri Na. adherence to long-term therapies evidence for action World Health Organization (WHO). ann Saudi Med 2004;24:221-2. https://doi.org/10.5144/0256-4947.2004.221

793. Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J, et al. High rates of non-adherence to antihypertensive treatment revealed by highperformance liquid chromatography-tandem mass spectrometry (HP LC-MS/MS) urine analysis. Heart 2014;100:855-861. https://doi.org/10.1136/heartjnl-2013-305063

794. Burnier M, Egan BM. adherence in Hypertension. Circ Res 2019;124:1124-1140. https://doi.org/10.1161/circresaha.118.313220

795. Pareja-Martinez E, Esquivel-Prados E, Martinez-Martinez f, Garcia-Corpas JP. Questionnaires on adherence to antihypertensive treatment: a systematic review of published questionnaires and their psychometric properties. Int J Clin Pharm 2020;42:355-365. https://doi.org/10.1007/s11096-020-00981-x

796. Vrijens B, Vincze G, Kristanto P, Urquhart J, Burnier M. adherence to prescribed antihypertensive drug treatments: longitudinal study of electronically compiled dosing histories. BMJ. 2008;336:1114-1117. https://doi.org/10.1136/bmj.39553.670231.25

797. Unger T, Borghi C, Charchar f, Khan Na, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension (Dallas, Tex: 1979). 2020; 75:1334-1357. https://doi.org/10.1161/hypertensionaha.120.15026

798. Агеев ФТ, Смирнова МД, Фофанова ТВ. Повышение приверженности к терапии: «дело техники»? Сердечная недостаточность. 2011;4:238-43.

799. Чазова ИЕ, Агеев ФТ, Фофанова ТВ, Чихладзе НМ, Кузнецова МБ, Смирнова МД, и др. Обучение и самообразование пациента – важный шаг на пути повышения приверженности пациента лечению. Системные гипертензии. 2014;3:7-10. https://doi.org/10.26442/SG29023

800. Johnson Ra, Huntley a, Hughes Ra, et al. Interventions to support shared decision making for hypertension: a systematic review of controlled studies. Health Expect. 2018;21(6):1191-1207. https://doi.org/10.1111/hex.12826

801. King CC, Bartels CM, Magnan EM, fink JT, Smith Ma, Johnson HM. The importance of frequent return visits and hypertension control among US young adults: a multidisciplinary group practice observational study. J Clin Hypertens (Greenwich). 2017;19(12):1288-1297. https://doi.org/10.1111/jch.13096

802. van der Wardt V, Harrison JK, Welsh T, Conroy S, Gladman J. Withdrawal of antihypertensive medication: a systematic review. J Hypertens. 2017;35(9):1742-1749. https://doi.org/10.1097/HJH.0000000000001405

803. Cook NR, Cutler Ja, Obarzanek E, et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ. 2007;334(7599):885- 888. https://doi.org/10.1136/bmj.39147.604896.55

804. Khan Na, Stergiou GS, Omboni S, et al. Virtual management of hypertension: lessons from the COVID-19 pandemic-International Society of Hypertension position paper endorsed by the World Hypertension League and European Society of Hypertension. J Hypertens. 2022;40(8):1435-1448. https://doi.org/10.1097/HJH.0000000000003205

805. Johansson M, Guyatt G, Montori V. Guidelines should consider clinicians' time needed to treat. BMJ. 2023 Jan 3;380:e072953. https://doi.org/10.1136/bmj-2022-072953

806. Li Q, Li R, Zhang S, et al. Occupational Physical activity and New-Onset Hypertension: a Nationwide Cohort Study in China [published correction appears in Hypertension. 2022 Jun;79(6):e109. https://doi.org/10.1161/HYP.0000000000000213]. Hypertension. 2021;78(1):220-229. https://doi.org/10.1161/HYPERTENSIONaHa.121.17281

807. Manohar S, Thongprayoon C, Cheungpasitporn W, Mao Ma, Herrmann SM. associations of rotational shift work and night shift status with hypertension: a systematic review and meta-analysis. J Hypertens. 2017;35(10):1929-1937. https://doi.org/10.1097/HJH.0000000000001442

808. Lecours a, Major M?, Lederer V, Vincent C, Lamontagne M?, Drolet aa. Integrative Prevention at Work: a Concept analysis and Meta-Narrative Review. J Occup Rehabil. 2023;33(2):301-315. https://doi.org/10.1007/s10926-022-10073-4

809. Muntner P, Einhorn PT, Cushman WC, et al. Blood Pressure assessment in adults in Clinical Practice and Clinic- Based Research: JaCC Scientific Expert Panel. J am Coll Cardiol. 2019;73(3):317-335. https://doi.org/10.1016/j.jacc.2018.10.069

810. McEvoy JW, McCarthy CP, Bruno RM, et al. 2024 ESC Guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912-4018. https://doi.org/10.1093/eurheartj/ehae178